This may include, but is not limite d to, redaction of the following: 
ï‚·ï‚·
â€¢Title: A Phase 1/2 Study of brentuximab vedotin (SGN-35) in Pediatric Patients With Relapsed or 
Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Study ID: [REMOVED]
Protocol Approve Date: 12 June 2014
Certain information  within this protocol has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable 
information 
or company confidential information. 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal
information, or to otherwise protect the integrity of the clinical study.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO &/,1,&$/678'<[ZIP_CODE]&2/&$0(1'0(17
%UHQWX[LPDEYHGRWLQ6*1
$3KDVH6WXG\RIEUHQWX[LPDEYHGRWLQ 6*1LQ3HGLDWULF3D WLHQWV:LWK5HODSVHG
RU5HIUDFWRU\6\VWHPLF$QDSODVWLF/DUJH&HOO/\PSKRPDRU+RGJNL Q/\PSKRPD
3URWRFRO1XPEHU &
,QGLFDWLRQ6\VWHPLF$QDSODVWLF/DUJH&HOO/\PSKRPDRU+RGJNLQ
/\PSKRPD
3KDVH 
6SRQVRU 0LOOHQQLXP3KDUPDFHXWLFDOV,QF
(XGUD&71XPEHU 
7KHUDSHXWLF$UHD 2QFRORJ\
3URWRFRO+LVWRU\
2ULJLQDO -XQH
$PHQGPHQW  -XO\
$PHQGPHQW)UDQFHVSHFLILF 2FWREHU
$PHQGPHQW )HEUXDU\
$PHQGPHQW -XQH
0LOOHQQLXP3KDUPDFHXWLFDOV,QF
/DQGVGRZQH6WUHHW
&DPEULGJH0$86$
7HOHSKRQH
$SSURYHGE\1RWH,IWKLVGRFXPHQWZDVDSSURYHGHOHFWURQLFDOO\WKHHOHFWU RQLFDSSURYDOVLJQDWXUHVPD\
EHIRXQGDWWKHHQGRIWKHGRFXPHQW
6LJQDWXUH
'DWH''0RQWK<<<<
6LJQDWXUH 'DWH''0RQWK<<<<
&RQILGHQWLDOLW\6WDWHPHQW
7KHLQIRUPDWLRQFRQWDLQHGKHUHLQLVFRQILGHQWLDODQGWKHSURSUL HWDU\SURSHUW\RI0LOOHQQLXP
3KDUPDFHXWLFDOVDQGDQ\XQDXWKRUL]HGXVHRUGLVFORVXUHRIVXFK LQIRUPDWLRQZLWKRXWWKHSULRU
ZULWWHQDXWKRUL]DWLRQRI0LOOHQQLXP3KDUPDFHXWLFDOVLVH[SUHVVO \SURKLELWHG[COMPANY_003]
[COMPANY_003]
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 2Rationale for Amendment 4
The length of the follow -up period has been changed to align with the content of the 
pediatric investigation plan ( PIP).  The PIP states that patients will be followed for safet y 
and survivalfor [ADDRESS_577567] 
been revised to state that patients will be followed for progression- free surviva l and overall 
survival (OS) every  12 weeks for 12 months after the E nd of Treatment ( EOT)visit.  
Thereafter, assessment for OS will continue every  [ADDRESS_577568] overall response rate (ORR)(which waspreviously  written as ORR) .  
The following changes have been made to the inclusion/exclusion criteria : The inclusion 
criterion for total bilirubin has been revised to include patients with total serum bilirubin â‰¤ 3 
times the upper limit of thenormal range (ULN) if the abnormal value is due to indirect 
hyperbilirubinemia due to Gilbertâ€™s disease.  P atients with elevated alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) values [ADDRESS_577569] dose of study  drug, 
respectivel y.  These changesmake it possible for patients to receive treatment s oonerbut 
with a sufficient amount of time for posttransplant recovery. This amendment also includes 
a change to the exclusion criterion for cytochrome P450 ( CYP) 3A4 inhibitors to exclude
both strong and listed moderate inhibitors of CYP3A4 within [ADDRESS_577570] been added to the Risks in Children section to align with 
updates to the safet y profile of brentuximab vedotin : Stevens-Johnson sy ndrome (SJS), 
pancreatitis , hepatotoxicity  (elevated AST and ALT). 
The amendment also updates the protocol to align with the current Millennium protocol 
standards, and clarifies the collection and reporting requirements for serious adverse e vents 
(SAEs) that are considered to be drug related to alignwith the current guidelines of the 
Millennium Department of Pharmacovigilance .  
Purposes for Amendment4
The purpose sof this amendment are to:
MajorContent Changes
ï‚·Revisethe length of the follow-up period to align with the PI P
ï‚·Clarify that the primary  endpoint of the phase [ADDRESS_577571] ORR
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 3ï‚·Add safet y language regarding the potential risk of SJS 
ï‚·Add safet y language regarding the potential risk of pancreatitis
ï‚·Add safet y language regarding the potential risk of hepatotoxicity
ï‚·Revise the total bilirubin inclusion criterion to include patients with abnormal values 
due to indirect hyperbilirubinemia due to Gilbertâ€™s disease
ï‚·Revisestudy eligibility  criterion regarding elevated ALTand ASTvaluesdue to the 
presence of metastatic disease in the liver
ï‚·Revise the washout period for s ystemic corticosteroid treatment in theexclusion 
criteria
ï‚·Revise the required minimum time between previous allogeneic or autologous stem 
cell transplantation and the first dose of stud y drug
ï‚·Add totheexclusion criteria any history of progressive multifocal 
leukoencephalopath y
ï‚·Revise the CYP3A4 exclusion criterion to excludelisted moderate inhibitors of 
CYP3A4
Minor Content Changes
ï‚·Modify the contraception language regarding abstinence to align with company  
standards
ï‚·Reviselanguage regarding dose adjus tments for a â‰¥ 10% weight change; add language 
for patients weighing more than 100 kg
ï‚·Correct the unit sof measurement for platelet count, absolute neutrophil count, a nd 
white blood cell count
ï‚·Remove the restriction on the use of pol yethylene infusion bags for dilution of 
brentuximab vedotin, as previously  described in Administrative L etter2
ï‚·Update packaging and labeling instructions for brentuximab vedotin
ï‚·Revise the timing for the development assessment and Tanner Scale
ï‚·Permit occasional changes in the timing of tests and procedures without permission 
from the project clinician
ï‚·Revise language regarding premedication for infusion- related reactions to allow the use 
ofcorticosteroids
ï‚·Addanassessment for immune reconstitution at the EOT visit, as previously  described 
in Administrative L etter1, and add awindow to perform immune reconstitution
ï‚·Revisethesection on Immune Reconstitution; revise thesection heading an d add 
separate sections for Immunogenicit y Assessment and Tumor Specimen Measurements
ï‚·Add language regarding reporting requirements for SAEs
ï‚·Delete redundant SAE reporting language ,update the period for reporting SAEs to 
Millennium from [ADDRESS_577572] 
information
ï‚·Add language regarding the collection of events of peripheral neuropath y
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO ï‚·5HGHILQHWKHSRSXODWLRQIRUDQDO\VLVRIWKHSKDVHH[SORUDWRU\ HQGSRLQWDVWKH 

ï‚·8SGDWHDGYHUVHHYHQW$(HYDOXDWLRQDQGDQDO\VLVODQJXDJH
ï‚·5HPRYHWH[WUHJDUGLQJWKHVWDUWRIDQWLQHRSODVWLFRUDQWLFDQFHU WKHUDS\DVLWUHODWHVWR
IROORZXSRI$(V
ï‚·8SGDWHFRQWDFWLQIRUPDWLRQIRUUHSRUWLQJSURGXFWFRPSODLQWVDQG PHGLFDWLRQHUURUV
7H[W&ODULILFDWLRQV
ï‚·&ODULI\WKHVDPSOHVL]HIRUWKHSKDVHDQGSKDVHSRUWLRQVRIW KHVWXG\
ï‚·5HYLVHODQJXDJHLQWKH6 WXG\'HVLJQVHFWLRQRIWKH3URWRFRO6XP PDU\WRDOLJQZLWK
SUHYLRXVXSGDWHVPDGHWRWKHSURWRFROERG\ WH[W
ï‚·&ODULI\WKHSODQQHGVWXG\SURFHGXUHVIRUSDWLHQWVZKRUHPDLQRQ WUHDWPHQWDIWHU& \FOH
DVSUHYLRXVO\RXWOLQHGLQ$GPLQLVWUDWLYH/HWWHU
ï‚·6SHFLI\WKDWVHUXPRUXULQHSUHJQDQF\WHVWVDUHDFFHSWDEOHDWV FUHHQLQJDQGEHIRUH
GRVLQJRQ'D\DQGDGGDVWDWHPHQWUHJDUGLQJWKHVFKHGXOLQJRI SUHJQDQF\WHVWV
ï‚·&ODULI\WKDWWKHWLPHIUDPHIRUFROOHFWLQJFOLQLFDOODERUDWRU\Y DOXHVDWVFUHHQLQJLV
ZLWKLQGD\VEHIRUHWKHILUVWGRVHRIWKHVWXG\GUXJ
ï‚·&ODULI\WKDWSDWLHQWVVKRXOGEHREVHUYHGIRUDQDSK\OD[LVDIWHUH DFKLQIXVLRQRI
EUHQWX[LPDEYHGRWLQ
ï‚·&ODULI\WKDW*UDGHQHXWURSHQLDODVWLQJPRUHWKDQGD\VLVFR QVLGHUHGDGRVHOLPLWLQJ
WR[LFLW\
ï‚·&ODULI\WKDWXQDFFHSWDEOHVWXG\GUXJUHODWHGWR[LFLW\RUGLVHDV HSURJUHVVLRQZLOOUHVXOW
LQPDQGDWRU\SHUPDQHQWGLVFRQWLQXDWLRQRIWKHVWXG\GUXJ
ï‚·&ODULI\WKDWLQLWLDWLRQRIKHPDWRSRLHWLFVWHPFHOOWUDQVSODQWDW LRQLVDUHDVRQIRUVWXG\
GUXJGLVFRQWLQXDWLRQ
ï‚·&ODULI\WKDWGHYHORSPHQWDVVHVVPHQWVLQFOXGHZHLJKWIRUDJHDQGV WDWXUHIRUDJH
SHUFHQWLOHV
ï‚·&ODULI\SURFHGXUHVIRUFOLQLFDOODERUDWRU\HYDOXDWLRQV
ï‚·&ODULI\WKHWLPLQJIRUFROOHFWLRQRIEORRGVDPSOHVIRUSKDUPDFR NLQHWLFDVVHVVPHQWVDQG
UHPRYHUHIHUHQFHWRWRWDOEORRGYROXPHVWREHFROOHFWHGIRUWKH VHDVVHVVPHQWV
ï‚·&ODULI\WKHGHVFULSWLRQVRI&RPSOHWLRQRI7UHDWPHQWDQG&RPSOHWLR QRI6WXG\DQG
FODULI\ODQJXDJHIRUSRVWWUHDWPHQWDVVHVVPHQWV
ï‚·&ODULI\HIILFDF\DQDO\VLVODQJXDJHWRVSHFLI\ WKDWWKH.DSODQ0HL HUPHWKRGZLOOEH
XVHGWRDQDO\]HHIILFDF\SDUDPHWHUVDQGVSHFLI\WKHSHUFHQWLOHV WREHSURYLGHG
ï‚·&ODULI\WKDWDVVHVVPHQWVWREHSHUIRUPHGDWWKH(27YLVLWDUHOL VWHGLQWKH 6FKHGXOHRI
(YHQWV
ï‚·&ODULI\WKDWWKHIUHTXHQF\RIUDGLRORJLFDOHYDOXDWLRQVIRUSDWL HQWVZKRUHFHLYH
WUHDWPHQWSDVW&\FOHLVRXWOLQHGLQWKH 6FKHGXOHRI(YHQWV
ï‚·&ODULI\UHDVRQVIRUVWXG\ZLWKGUDZDOCCI
CCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 5Adminstrative and Editorial Changes 
ï‚·Remove Section 14.4 ,Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors ( the list of 
prohibited CYP3A4 inhibitors is located in the Study  Manual)
ï‚·Replace references to [COMPANY_003]I with Millennium Department of Pharmacovigilance o r
designee
ï‚·Add abbreviations to table footnotes in theSchedule of Events
ï‚·Add bone marrow (BM) and [LOCATION_002] Pharmacopeia (USP) to theList of 
Abbreviations and Glossary  of Terms
ï‚·Updatethe name [CONTACT_17008] G roupHead on the titlepage
ï‚·Replace references to medical monitor or study monitor with project clinician
ï‚·Correct typographical errors, punctuation, grammar, and formatting
For specific examples of changes in text and where t he changes are located, see 
Section14.7.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO [ZIP_CODE]&2/6800$5<
6WXG\7LWOH $3KDVH6WXG\RIEUHQWX[LPDEYHGRWLQ6*1LQ3HGLDWULF 3DWLHQWV:LWK
5HODSVHGRU5HIUDFWRU\6\VWHPLF$QDSODVWLF/DUJH&HOO/\PSKRPD RU+RGJNLQ/\PSKRPD
1XPEHURI3DWLHQWV $SSUR[LPDWHO\HYDOXDEOHSDWLHQWVDVIROORZV
ï‚·3KDVHGRVHHVFDODWLRQDWOHDVWSDWLHQWVZLWKDQ\UHODSVHGRU UHIUDFWRU\&'SRVLWLYH
&'KHPDWRORJLFPDOLJQDQF\
ï‚·3KDVHUHODSVHGRUUHIUDFWRU\V\VWHPLFDQDSODVWLFODUJHFHOOO\ PSKRPDV$/&/DWOHDVW
HYDOXDEOHSDWLHQWVLQFOXGLQJSDWLHQWVWUHDWHGDWWKHUHFRPPH QGHGSKDVHGRVH>53'@
GXULQJSKDVHRIZKRPDWOHDVWSDWLHQWVDUHLQILUVWUHODSVH
ï‚·3KDVHUHODSVHGRUUHIUDFWRU\+RGJNLQO\PSKRPD+/DWOHDVW HYDOXDEOHSDWLHQWV
LQFOXGLQJSDWLHQWVWUHDWHGDWWKH53'GXULQJSKDVH
3KDVH6WXG\2EMHFWLYHV
3KDVH3ULPDU\
ï‚·7RDVVHVVWKHVDIHW\SURILOHDQGGHWHUPLQHWKHSHGLDWULFPD[LPX PWROHUDWHGGRVH07'
DQGRUUHFRPPHQGHGSKDVHGRVHRIEUHQWX[LPDEYHGRWLQ
ï‚·7RDVVHVVWKHSKDUPDFRNLQHWLFV3.RIEUHQWX[LPDEYHGRWLQ
3KDVH6HFRQGDU\
ï‚·7RGHWHUPLQHWKHLPPXQRJHQLFLW\RIEUHQWX[LPDEYHGRWLQ
ï‚·7RGHWHUPLQHWKHEHVWRYHUDOOUHVSRQVHUDWHFRPSOHWHUHPLVVLRQ SDUWLDOUHPLVVLRQZLWK
EUHQWX[LPDEYHGRWLQ
ï‚·7RGHWHUPLQHWKHWLPHWRSURJUHVVLRQWLPHWRUHVSRQVHGXUDWLRQ RIUHVSRQVHDQGHYHQW IUHH
SURJUHVVLRQIUHHDQGRYHUDOOVXUYLYDOZLWKEUHQWX[LPDEYHGRWLQ
3KDVH([SORUDWRU\
3KDVH6WXG\2EMHFWLYHV
3KDVH3ULPDU\
ï‚·7RGHWHUPLQHWKHEHVWRYHUDOOUHVSRQVHUDWHFRPSOHWHUHPLVVLRQ SDUWLDOUHPLVVLRQZLWK
EUHQWX[LPDEYHGRWLQDWWKHUHFRPPHQGHGSKDVHGRVH
3KDVH6HFRQGDU\
ï‚·7RGHWHUPLQHWKHWLPHWRSURJUHVVLRQWLPHWRUHVSRQVHGXUDWLRQ RIUHVSRQVHDQGHYHQW IUHH
SURJUHVVLRQIUHHDQGRYHUDOOVXUYLYDOZLWKEUHQWX[LPDEYHGRWLQ
ï‚·7RDVVHVVWKH3.DQGVDIHW\SURILOHRIEUHQWX[LPDEYHGRWLQ
ï‚·7RGHWHUPLQHWKHLPPXQRJHQLFLW\RIEUHQWX[LPDEYHGRWLQ
3KDVH([SORUDWRU\
ï‚·CCI
CCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 7Overview of Study Design:   This is a phase 1/2, open-label, single -agent, multicenter, 
dose-escalation study of brentuximab vedotin in pediatric patients with relapsed or refractory sALCL 
or HLfor which standard, curative, life -prolonging, or palliative treatment does not exist or is no 
longer effective .  Patients with primary mediastinal B cell lymphoma will be eligible during phase 1.  
The primary objectives of the study are to assess the safety and pharmacokinetics, and determine the 
pediatric MTD and/or RP2Dof brentuximab vedotin in pediatric patients .  In addition, the 
immunogenicity and antitumor activity of brentuximab vedotin will be evaluated in eligible patients.
Overall response will be evaluated beginning after 2cycles of therapy .  
Objective response over the 
course of th e study will be assessed by [CONTACT_223225] (IRF) according to the 
International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma .(1)
Patients, including those who achieve a CR, PR, or stable disease may receive brentuximab vedotin
for up to 16 cycles.  Treatment with brentuximab vedotin beyond 16 cycles may be permitted at the 
joint discretion of the sponsor and the investigato r for those patients experiencing continued clinical 
benefit.  Following administration of the final dose of brentuximab vedotin, patients will be 
monitored for adverse events for a minimum of 30 days.  Patients will be followed for progression -
free surviv al (PFS)and overall survival (OS) every 12 weeks for 12 months after the end of 
treatment (EOT) visit.  Thereafter, assessment for OS will continue every [ADDRESS_577573] patient. Patients who
remain on treatment after Cycle 16 will be followed according to the above schedule or until study 
closure.
Sample Size Determination:   Approximately 42evaluable patients will be enrolled in this study .  In 
the phase1 portion o f the study, at least12patients with relapsed or refractory CD30+ malignancies 
will be enrolled in 2 planned dose cohorts (3-6patients per cohort), according to the standard 3 +3 
dose escalation scheme.
Once the pediatric MTDand/or RP2D havebeen reac hed, patients will be enrol led by [CONTACT_452959]2 study arms: relapsedor refractory sALCL or relapsed or refractory HL.  A sufficient 
number of patients will be enrolled in the phase2portion of the study to have 
at least 15evaluable 
patients with sALCL (including patients treated at the RP2D during phase 1), of whom at least 
10patients are in first relapse, and at least 15evaluable patients with HL (including patients treated 
at RP2D during phase 1).
The sample size is not based on statist ical consideration.  Based on the exact binomial confidence 
interval (CI) calculation, 10 responses observed from 15evaluable patients (overall response rate of 
66.7%)will provide 95% CI (38%, 88%) .
Study Population:   The study will enroll m ale or fema le patients aged 2 to <18 years, with relapsed 
or refractory sALCL or HL (5 to <18 years for HL), and radiographically or clinically evaluable 
tumor per the IWG revised response criteria(patients diagnosed with any relapsed or refractory 
CD30+ hematological malignancy may be included in phase 1 of the study) .  Anaplastic lymphoma 
kinase (ALK) status must be documented for patients with sALCL.  
Patients with HL must have 
failed systemic chemotherapy, either as induction therapy for advanced -stage disease or salvage 
therapy after initial radiotherapy for early stage disease, and be ineligible for, re fused, or previously 
received a stem cell transplant .  Patients with sALCL must be beyond first remission or refractory to 
front-line chemotherapy
.
Patients with a current diagnosis of primary cutaneous ALCL, or who received any of the following:
allogeneic stem cell transplant < 3monthsbeforethe first dose of study medication, systemic therapy 
for chronic graft versus host disease, immu nosuppressive therapy, any anti -CD30 antibody, 
therapeutic monoclonal antibodies ( mAbs)within the longer of 6 weeks or 5 plasma half -lives, local 
palliative radiation therapy within 14 days,or radiation therapy to more than 25% of bone 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577574] dose, or prior autologous hematopoietic stem 
cell infusion <4weeks prior to first study dose will be excluded from the study .  Patients with 
symptomatic cardiac disease, history of another primary malignancy not in remission for at least 
3years (excluding nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous 
intraepi[INVESTIGATOR_451367]), or known cerebral/meningeal disease, including signs or 
symptoms or any history of PML,will be excluded.
Duration of Study:   Following a screening period to determine eligibility, patients may receive up 
to 16 cycles (21 days per cycle) of treatment with brentuximab vedotin.  Patients will be foll owed for 
at least 2 years from enrollment, until the sooner of death or study clo sure.  Extended brentuximab 
vedotin therapy, beyond 16 cycles, may be permitted at the joint discretion of the sponsor and 
investigator for those patients experiencing continued clinical benefit.  The overall expected study 
duration is approximately 5 years.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 9Phase1 Study Schema â€“Dose Escalation
Enter 3 additional
patients at
1.4 mg/kg dose
> 1 DLT in
6 patients1 DLT in
6 pat ientsEnter 3 patients
SGN -35 1.4 mg/kg
Enter 3 pat ients
1.8 mg/kg
Reduce dose
to 0.9 mg/kg
0 or 1 DLT
Enter 3 additional
patients at
1.8 mg/kg dose
0 or 1 DLT in 6 patients
MTD/RP2D=
1.8 mg/kg>1 DLT
MTD/RP2D =
1.4 mg/kg0 DLT 1 DLT 2-3 DLTs
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 10Phase2 Study Overview Diagram
Within 28 
days of 
enrollm entCycles 1 & 2
21 days each
Infusion  of 
brent uximab
vedot in
on Day 1Subseq uent 
courses up to 
16 cycles
Repeat  
disease  
evaluation at 
end of
Cycles 4, 7, 
10, 13, 16, and 
at EOTCR, PR, or SD
YES
CR, PR, or SD
NODisease  
evaluation at 
end of Cycle 2
30 ï‚±7days 
from last 
dose of 
brentuximab
vedot inDisease 
evalu ationE
N
D
O
F
T
R
E
A
T
M
E
N
T
V
I
S
I
TP
O
S
T
T
R
E
A
T
M
E
N
T
F
O
L
L
O
W
-
U
PS
C
R
E
E
N
I
N
GE
N
R
O
L
L
M
E
N
T
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 11Schedule of Events
ScreeningEnrollment 
(date of 
first dose)Cycles1â€“16 Cycle17 and 
Beyond (for 
patients who 
continue 
beyond 
16cycles)EOTaPFSFUP/
OSFUPbEach 21-Day CycleAdditional 
Assessments 
at Cycles 2, 
4, 7, 10, 13, 
and 16 only
Day (D) D1cD2 D3 D5 D14D15-[ADDRESS_577575] 
doseq 12wks for 
12 months/
q 6 months 
thereafter
Visit Window -28 to D1 ï‚±7days ï‚±7daysScreening/ BaselineInformed consent X
EnrollmentInclusion/exclusion X
Tumor specimen CD30 
expressiondX
Demographics X
Medical history XSafety 
AssessmentsHeight XeXe
Weight XeXeX
Pregnancy testfX X X
Vital signs X Xg
Physical exam including 
focused lymphoma 
assessment X XhX
Lansky/Karnofsky ScaleiX X X
Hematology/serum 
chemistryjX XjX
12-lead ECGkX X X
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 12ScreeningEnrollment 
(date of 
first dose)Cycles1â€“16 Cycle17 and 
Beyond (for 
patients who 
continue 
beyond 
16cycles)EOTaPFSFUP/
OSFUPbEach 21-Day CycleAdditional 
Assessments 
at Cycles 2, 
4, 7, 10, 13, 
and 16 only
Day (D) D1cD2 D3 D5 D14D15-[ADDRESS_577576] 
doseq 12wks for 
12 months/
q 6 months 
thereafter
Visit Window -28 to D1 ï‚±7days ï‚±7daysDisease 
AssessmentDevelopment assessment 
and Tanner ScalelX XlX
Dedicated CT of chest  X X XmXnXo
MRI of  neck, abdomen, 
pelvis X X XmXnXo
B symptom assessment X X X
PET X Xp
Bone marrow  aspi[INVESTIGATOR_452931] X
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 6FUHHQLQJ(QUROOPHQW
GDWHRI
ILUVWGRVH&\FOHVÂ± &\FOHDQG
%H\RQGIRU
SDWLHQWVZKR
FRQWLQXH
EH\RQG
F\FOHV(27D3)6)83
26)83E(DFK'D\&\FOH$GGLWLRQDO
$VVHVVPHQWV
DW&\FOHV

DQGRQO\
'D\' 'F' ' ' ''RI
&\FOH 'F'
RI
&\FOHGD\V
SRVWODVW
GRVHTZNVIRU
PRQWKV
TPRQWKV
WKHUHDIWHU
9LVLW:LQGRZ WR' ï‚±ï‚±GD\V ï‚±GD\V7UHDWPHQW6*1DGPLQLVWUDWLRQV;;
0RQLWRULQJRI
FRQFRPLWDQWPHGLFDWLRQV
DQGSURFHGXUHV5HFRUGHGIURPVLJQLQJLQIRUPHGFRQVHQWIRUPWKURXJKGD\VDIWH UWKHODVWGRVHRIVWXG\GUXJ
$GYHUVHHYHQWUHSRUWLQJ5HFRUGHGIURPILUVWGRVHRIVWXG\GUXJWKURXJKGD\VDIWHUWKH ODVWGRVHRIVWXG\GUXJ
$OOHYHQWVUHODWHGWR31UHJDUGOHVVRIVHULRXVQHVVZLOOEHIR OORZHGIRUDOOFKDQJHVLQVHYHULW\
XQWLOUHVROXWLRQWREDVHOLQHRUVWXG\FORVXUHZKLFKHYHURFFXUV ILUVWDQGUHFRUGHGLQWKHH&5)
6HULRXVDGYHUVHHYHQWV6HULRXVDGYHUVHHYHQWVWZLOOEHFROOHFWHGIURPVLJQLQJRIWKHLQIRUPHGFRQVHQWWKURXJK GD\VDIWHUWKHODVW
GRVHRIVWXG\GUXJ6DPSOHV3.6DPSOH ;X;X;X;X;X
,PPXQRJHQLFLW\ ; ;Y;
$EEUHYLDWLRQV$( DGYHUVHHYHQW%0 ERQHPDUURZ%0$ ERQHPDUU RZDVSLUDWH&7 FRPSXWHGWRPRJUDSK\' GD\(&* HOHFWURFDUGLR JUDP(27 HQGRI
WUHDWPHQW05, PDJQHWLFUHVRQDQFHLPDJLQJ26)83 2YHUDOOVXUYLY DO)ROORZXS3(7 SRVLWURQHPLVVLRQWRPRJUDSK\3)6)83 3URJUHVV LRQIUHHVXUYLYDO
)ROORZXS3. SKDUPDFRNLQHWLFV3' SKDUPDFRG\QDPLFVT HYHU\
7HVWVDQGSURFHGXUHVVKRXOGEHSHUIRUPHGRQVFKHGXOHEXWRFFDV LRQDOFKDQJHVDUHDOORZDEOHÂ“GD\VIRUKROLGD\VYDFDWLRQVDQ GRWKHUDGPLQLVWUDWLYHUHDVRQVXQOHVV
RWKHUZLVHLQGLFDWHG ,IH[WHQXDWLQJFLUFXPVWDQFHVSUHYHQWDSDWLHQWIURPEHJLQQLQJW UHDWPHQWRUFRPSOHWLQJDVFKHGXOHGSURFHGXUHRUDVVHVVPHQWZLWK LQWKLV
WLPHWKHSDWLHQWPD\FRQWLQXHWKHVWXG\RQO\ZLWKWKHZULWWHQ SHUPLVVLRQRIWKHSURMHFWFOLQLFLDQRUGHVLJQHH
D (27HYDOXDWLRQVKRXOGEHREWDLQHGEHIRUHLQLWLDWLRQRIQRQSURW RFROWKHUDS\,I(27HYDOXDWLRQVDUHFRPSOHWHGEHIRUHGD\VD IWHUWKHODVWWUHDWPHQWWKHVLWHZLOO
FRQGXFWDSKRQHVFUHHQGD\VIROORZLQJWKHSDWLHQWÂ¶VODVWW UHDWPHQWWRHQVXUHWKDWQRFKDQJHVLQDGYHUVHHYHQWSURILOHKDY HRFFXUUHG
E 3DWLHQWVZLOOEHIROORZ HGIRU3)6DQG26HYHU\ZHHNVIRUP RQWKVDIWHUWKH(27YLVLW7KHUHDIWHUDVVHVVPHQWIRU26ZLOOF RQWLQXHHYHU\PRQWKVXQWLOWKH
VRRQHURIGHDWKRUVWXG\FORVXUHRUDPD[LPXPRI\HDUVDIWHU HQUROOPHQWRIWKHODVWSDWLHQW3DWLHQWVZKRUHPDLQRQWUHDWPHQ WDIWHU&\FOHZLOOEHIROORZHGCCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 14ScreeningEnrollment 
(date of 
first dose)Cycles1â€“16 Cycle17 and 
Beyond (for 
patients who 
continue 
beyond 
16cycles)EOTaPFSFUP/
OSFUPbEach 21-Day CycleAdditional 
Assessments 
at Cycles 2, 
4, 7, 10, 13, 
and 16 only
Day (D) D1cD2 D3 D5 D14D15-[ADDRESS_577577] 
doseq 12wks for 
12 months/
q 6 months 
thereafter
Visit Window -28 to D1 ï‚±7days ï‚±7days
according to the above schedule or until study closure .  
cAll procedures performed on Day 1 of each cycle should be performed prior to dosing unless otherwise specified.
dTumor tissue collected at the time of original diagnosis or subsequent procedures (unstained) will be sent to central lab or affiliate for testing.
eScreening assessment must be performed within [ADDRESS_577578] will be performed for female patients of childbearing potential during screening , prior to dosing on Day 1 during Cycles 1 â€“16, and at 
EOT.  If the screening test was per formed within [ADDRESS_577579] should be performed per institutional gu idelines; any samples collected during 
Cycle [ADDRESS_577580] of the IEC/IRB, or if required by [CONTACT_427].
g On Cycle 1, Day1 only, also perform vital signs measurements at 1 hour(Â±10minutes) postdose.
hThe Cycle 1, Day1 physical examination (including height and w eight) isnot required on Day [ADDRESS_577581] (Cycle 1, Day1) dose of study drug.
iThe Lansky Scale will be used for patie nts â‰¤16years of age; the Karnofsky Sc ale will be used for patient s >16years of age.  See Section 14.1for Lansky Play -
Performance Scale information; see Section 14.2for Karnofsky Performance Scale information.
jA blood sample fo r hematology and serum chemistry will be obtained at screening , prior to dosing onDay1during Cycles 1 â€“16, and at EOT .  The hematology and 
chemistry blood samples for Cycle 1, Day1 mustbe collected w ithin 4days prior to dosing to ensure patient eligib ility on Cycle 1 Day1.  If screening clinical 
laboratory testing was performed within 4 days before the Cycle 1, Day1 dose, it need not be repeated on Cycle 1, Day1.  See Section 7.4.12 for a listing of the 
required hematology and serum chemistry parame ters.  During Cycle 17 and beyond, h ematology and s erum chemistry tests should be performed per institutional 
guidelines at the local laboratory; samples should not be sent to the central laboratory and data shou ld not be captured in the eCRF, unless the l aboratory result is 
assessed to contribute to an AE .
kA 12-lead ECG will be obtained at screening, Cycle1, Day1; and end of treatment only, unless clinically indicated.  If the screening ECG is obtained w ithin 4days of 
study drug administration on Cyc le1, Day 1, the ECG assessment need not be repeated.  ECG assessments are to be performed with the patient supi[INVESTIGATOR_452932] r 
5minutes and before any closely timed PK blood collection.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 15ScreeningEnrollment 
(date of 
first dose)Cycles1â€“16 Cycle17 and 
Beyond (for 
patients who 
continue 
beyond 
16cycles)EOTaPFSFUP/
OSFUPbEach 21-Day CycleAdditional 
Assessments 
at Cycles 2, 
4, 7, 10, 13, 
and 16 only
Day (D) D1cD2 D3 D5 D14D15-[ADDRESS_577582] 
doseq 12wks for 
12 months/
q 6 months 
thereafter
Visit Window -28 to D1 ï‚±7days ï‚±7days
lDevelopment assessment and Tanner Scale to be performed on Day 1 ofCycles 2, 4, 7, 10, 13, and 16 only.  Development assessment to include weight-for-age and 
stature-for-age percentiles ; see Section 14.3for Tanner Scale information.
mDisease assessment, according to IWG R evised Response Criteria for Malignant Lymphoma, should be performed on Day 15-[ADDRESS_577583] dose of brentuximab vedotin.  If a positive bone marrow  aspi[INVESTIGATOR_337] (BMA) and biopsy was taken more than [ADDRESS_577584] dose and the patient has not received treatment in the interim, these do not need to be repeated.
rBMA and biopsy required to confirm response if BM positive at baseline.  BMA/biopsy should be obtained within [ADDRESS_577585] 10% from the 
most recent dose calculation ;otherwise ,institutional practice should be followed .
tIncluding serious pretreatment events; see Section9.3of the study protocol.
uPK blood samples willbe obtained at the following times:   
ï‚·All Cycles : Day1: within 4 hoursbefore the start of the brentuximab vedotin infusion and 5 minutes (Â±1 minute) after the end of the brentuximab ve dotin infusion .
ï‚·Cycles1 and 8:  
oDay2: 24hours (Â±4 hours) from the start of the Day 1 brentuximab vedotin infusion.
oDay3: 48hours (Â±4 hours) from the start of the Day 1 brentuximab vedotin infusion.
oDay5: 96hours (Â±24 hours) from the start of the Day1 brentuximab vedotin infusion.
oDay14: 312hours (Â±48 hours) from the start of the Day 1 brentuximab vedotin infusion.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 6FUHHQLQJ(QUROOPHQW
GDWHRI
ILUVWGRVH&\FOHVÂ± &\FOHDQG
%H\RQGIRU
SDWLHQWVZKR
FRQWLQXH
EH\RQG
F\FOHV(27D3)6)83
26)83E(DFK'D\&\FOH$GGLWLRQDO
$VVHVVPHQWV
DW&\FOHV

DQGRQO\
'D\' 'F' ' ' ''RI
&\FOH 'F'
RI
&\FOHGD\V
SRVWODVW
GRVHTZNVIRU
PRQWKV
TPRQWKV
WKHUHDIWHU
9LVLW:LQGRZ WR' ï‚±ï‚±GD\V ï‚±GD\V
ï‚·&\FOH
o'D\SKDVHRQO\KRXUVÂ“KRXUVIURPWKHVWDUWRIWKH'D\ EUHQWX[LPDEYHGRWLQLQIXVLRQ
o'D\KRXUVÂ“KRXUVIURPWKHVWDUWRIWKH'D\EUHQWX[LPDEY HGRWLQLQIXVLRQ
o'D\ KRXUVÂ“KRXUVIURPWKHVWDUWRIWKH'D\EUHQWX[LPDE YHGRWLQLQIXVLRQ
Y ,PPXQRJHQLFLW\WHVWLQJZLOOEHSHUIRUPHGDWVFUHHQLQJSUHGRVH RQ'D\DW&\FOHDQG&\FOHDQGDW(27
ZCCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577586] Metabolism in Humans................................ ........31
1.2.3 Preclinical Toxicology ................................ ................................ ........................... 32
1.2.4 Immune Function ................................ ................................ ................................ ...32
1.3 Clinical Experience................................ ................................ ................................ .......32
1.3.1 Study  Rationale ................................ ................................ ................................ ......35
1.4 Potential Risks and Benefits ................................ ................................ ......................... 36
1.4.1 Benefit Anal ysis in Hodgkin Ly mphoma................................ .............................. 36
1.4.2 Benefit Anal ysis in Systemic Anaplastic Large Cell Ly mphoma......................... 37
1.4.3 Potential Risks in Children ................................ ................................ .................... 37
2.STUDY OBJECTIVES ................................ ................................ ................................ ......41
2.1 Phase 1 Primary  Objectives ................................ ................................ .......................... 41
2.2 Phase1 Secondary  Objectives ................................ ................................ ...................... 41
2.3 Phase 1 Exploratory  Objectives ................................ ................................ .................... 42
2.4 Phase 2 Primary  Objectives ................................ ................................ .......................... 42
2.5 Phase 2 Secondary  Objectives ................................ ................................ ...................... 42
2.6 Phase 2 Exploratory  Objectives ................................ ................................ .................... 42
3.STUDY ENDPOINTS ................................ ................................ ................................ ........42
3.1 Phase 1 Primary  Endpoints ................................ ................................ ........................... 42
3.2 Phase 1 Secondary  Endpoints ................................ ................................ ....................... 43
3.3 Phase1 Exploratory  Endpoints ................................ ................................ ..................... 43
3.4 Phase 2 Primary  Endpoints ................................ ................................ ........................... 43
3.5 Phase 2 Secondary  Endpoints ................................ ................................ ....................... 44
3.6 Phase 2 Exploratory  Endpoints ................................ ................................ ..................... 44
4.STUDY DESIGN ................................ ................................ ................................ ...............44
4.1 Overview of Study  Design................................ ................................ ........................... 44
4.2 Number of Patients ................................ ................................ ................................ .......46
4.3 Duration of Study ................................ ................................ ................................ .........46
5.STUDY POPUL ATION................................ ................................ ................................ .....47
5.1 Inclusion Criteria ................................ ................................ ................................ ..........47
5.2 Exclusion Criteria ................................ ................................ ................................ .........49
6.STUDY DRUG ................................ ................................ ................................ ................... 51
6.1 Study  Drug Administration ................................ ................................ .......................... 51
6.2 Definit ions of Dose -Limiting Toxicity ................................ ................................ .........52
6.2.1 Toxicity ................................ ................................ ................................ .................. 52
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 186.2.2 Nonhematologic Toxicity ................................ ................................ ...................... 53
6.2.3 Hematologic Toxicity ................................ ................................ ............................ 53
6.2.4 Phase 1:  Dose Modification for an Individual Patient Who Experiences DLT ....53
6.2.5 Phase 1:  Dose Elimination/Holding/Reduction for Patients Who Have Not 
Experienced a DLT ................................ ................................ ......................... 54
6.2.6 Maximum Tolerated Dose or Reco mmended Phase 2 Dose................................ .54
6.3 Dose Escalation Rules................................ ................................ ................................ ..54
6.4 Phase 2 Dose-Modification Guidelines ................................ ................................ ........56
6.4.1 Criteria for Dose Modification ................................ ................................ ..............56
6.4.2 Criteria for Beginning or Delay ing a Subsequent Treatment C ycle...................... 57
6.4.3 Criteria for Discontinuation of Brentuximab vedotin................................ ............58
6.5 Excluded Concomitant Medications and Procedures................................ ................... 59
6.6 Permitted Concomitant Medications and Procedures ................................ ................... 59
6.7 Precautions and Restrictions................................ ................................ ......................... 60
6.8 Management of Clinical Events ................................ ................................ ................... 61
6.8.1 Managem ent of Peripheral Neuropathy ................................ ................................ .61
6.8.2 Management of Progressive Multifocal Leukoencenphalopath y..........................61
6.8.3 Nausea and/or Vomiting ................................ ................................ ........................ [ADDRESS_577587]................................ ................................ ................................ .......65
7.4.8 Concomitant Medications and Procedures ................................ ............................ 66
7.4.9 Adverse Events ................................ ................................ ................................ ......66
7.4.10 Enrollment................................ ................................ ................................ ...........66
7.4.11 Electrocardiogram ................................ ................................ ................................ 66
7.4.12 Clinical L aboratory  Evaluations ................................ ................................ ..........66
7.4.13 Disease Assessment ................................ ................................ ............................. 67
7.4.14 Pharmacokinetic Measurements ................................ ................................ ..........68
7.4.15 Pharmacod ynamic Measurements ................................ ................................ .......69
7.4.16 Immunogenicity................................ ................................ ................................ ...69
7.4.17Tumor Specimen Measurements ................................ ................................ .........70
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 197.5 Completion of Treatment ................................ ................................ .............................. 70
7.6 Completion of Study ................................ ................................ ................................ .....70
7.7 Discontinuation of Treatment With Study  Drug, and Patient Replacement.................70
7.8 Withdrawal of Patients From Study ................................ ................................ .............71
7.9 Study  Compliance ................................ ................................ ................................ .........71
7.10 Posttreatment Follow- up Assessments ................................ ................................ .......71
8.STATISTICAL AND QUANTI TATIVE ANALYSES ................................ ..................... 72
8.1 Statistical Methods ................................ ................................ ................................ .......72
8.1.1 Determination of Sam ple Size................................ ................................ ...............72
8.1.2 Randomization and Stratification ................................ ................................ ..........73
8.1.3 Populations for Analy sis................................ ................................ ........................ 73
8.1.4 Procedures for Handling Missing, Unused, and Spurious Data ............................ 74
8.1.5 Demographic and Baseline Characteristics................................ ........................... 74
8.1.6 Efficacy  Analysis................................ ................................ ................................ ...74
8.1.7 Pharmacokinetics/Pharmacod ynamics................................ ................................ ...[ADDRESS_577588] Retention ................................ ................................ ................................ ......85
11.USE OF INFORMATIO N................................ ................................ ................................ 85
12.INVESTIGATOR AGREEMENT ................................ ................................ ................... 86
13.REFERENCES ................................ ................................ ................................ ................. 87
14.APPENDI CES................................ ................................ ................................ .................. 93
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 2014.1 Lansky Play-Performance Scale ................................ ................................ ................. 93
14.2 Karnofsk y Performance Scale ................................ ................................ .................... 94
14.3 Tanner Scale ................................ ................................ ................................ ...............95
14.4 Amendment 1 Rationale and Purposes ................................ ................................ .......96
14.5 Amendment 2 Rationale and Purposes ([LOCATION_009] -Specific Amendm ent)..................... [ADDRESS_577589] aspartate aminotransferase
ATA anti-therapeutic antibody
BFM Berlin-Frankfurt -Munster
BM bone marrow
BMA bone marrow  aspi[INVESTIGATOR_452933] (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577590] computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP3A4 cytochrome P 4503A4
DLT dose-limiting toxicity
DOR duration of response
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EDC electronic data capture
EFS event-free survival
EOT end of treatment (visit)
EU European Union
FAB French-American -British
GCP Good Clinical Practice
GGT gamma glutamyl transferase
HL Hodgkin lymphoma
H/RS Hodgkin-Reed-Sternberg
HSCT hematopoietic stem cell transplant
IB Investigatorâ€™s Brochure
IC50 concentration producing 50% inhibition
ICF informed consent form
ICH International Conference on Harmonisation
IEC independent ethics committee
IFRT involved field radiotherapy
IRB institutional review board
IRF independent review facility
IV intravenous; intravenously
IWG International Working Group
JCV John Cunningham virus
KD dissociation constant
MedDRA Medical Dictionary for Regulatory Activities
Millennium Millennium Pharmaceuticals, Inc., and its affiliates
MMAE monomethyl auristatin E
MRI magnetic resonance imaging
MTD maximum tolerated dose
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
NHL non-Hodgkin lymphoma
NPM nucleophosmin
ORR overall response rate
OS overall survival
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 22Abbreviation Term
PCR polymerase chain reaction
PD progressive disease (disease progression)
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetic(s)
PMBCL primary mediastinal B -cell lymphoma
PML progressive multifocal leukoencephalopathy
PN peripheral neuropathy
PR partial remis sion
RP2D recommended phase [ADDRESS_577591] upper limit of the normal range
USP [LOCATION_002] Pharmacopeia
WBC white blood cell
WHO World Health Organization
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 231.   BACKGROUND AND STUDY RATIONALE
1.1   Scientific Background
1.1.1   Disease Under Treatment
[IP_ADDRESS]   Hodgkin Lymphoma in Pediatric Pop ulation
Classical Hodgkin l ymphoma (HL)is defined histopathologically  by [CONTACT_452960] -Reed-Sternberg (H/ RS) cells in a background of inflammatory  cells.  
H/RS cells are characterized by  [CONTACT_20376]30, a surface tumor marker a nd cell 
membrane protein belonging to the tumor necrosis factor (TNF) receptor superfamil y.  HL 
occurs in patients in all age groups and presents a bimodal distribution with peaks at 15 to 
35years of age and over the age of 60 .(2)  The median age at diagnosis is [ADDRESS_577592] nonexistent in those under 2 years of age .(3, 4)
Painless cervical l ymphadenopathy  is the most common presenting sign (>70%)in children 
with HL, often with a fluctuating course leading to a delay  in diagnosis .(5)  Mediastinal 
masses are frequent (about 60% of pediatric patients) and sometimes discovered after 
routine chest X-rays.  Patients with mediastinal adenopathy  may present with respi[INVESTIGATOR_452934], chest pain, or cough .  Fewer than 5% present with 
disease limited to the upper cervical l ymph nodes, above the level of the hyoid bone .  
Disseminated ly mphadenopathy  is rare in patients with HL , as is involvement of Waldey erâ€™s 
ring and occipi[INVESTIGATOR_307], epi[INVESTIGATOR_60775], posterior mediastinal, and mesenteric sites .(5, 6)  
Approximately  25% of patie nts will have sy stemic B symptoms at presentation (as defined 
by [CONTACT_452961] s ystem), typi[INVESTIGATOR_452935], fever, weight loss, and night sweats .  Pruritus 
and intermittent fever usually  associated with night sweats are classic s ymptoms of HL .  The 
frequency of these s ymptoms increases with advanced stage of the disease .(5, 6)
Accurate disease staging and classific ation of the histological subty pe determine the most 
favorable treatment options and prognosis.(7, 8, 9)  The stage of the disease is assigned 
according to the Ann Arbor staging s ystem with Cotswold modifications for HL .  All cases 
are subclassified to indicate the absence (A) or presence (B) of the s ystemic symptoms at 
presentation.(8, 10)  Pediatric patients are more likely than adults to present with stage I/II 
disease and less likel y to present with stage IV disease.  Adolescents are more likely  to have 
B symptoms than pediatric patients y ounger than [ADDRESS_577593] a much higher relapse 
rate.(11)
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577594] treatment of pedia tric patients with HL requires a risk- based approach .  This 
ensures that those with good prognosis, low -risk disease can be managed with regimens 
associated with minimal toxicity , while those at high risk of treatment failure can be treated 
more aggressive ly.  Low-risk disease presents favorably  and is usually  defined as localized 
disease (stage I and II), no bulky  disease and absence of B s ymptoms.  Intermediate -risk 
disease has been defined as all stage I and II patients not classified as early stage and 
stageIIIA.  High-risk disease generally  means patients with stage IIIB and IV disease at 
presentation.  Those with favorable risk disease t ypi[INVESTIGATOR_128788] 2 to 4 cycles of 
combination chemotherapy  with low -dose involved field radiotherapy  (IFRT), whereas
those with higher -risk disease receive more intensive chemotherap y before IFRT.  In 
contrast to the treatment of adult patients with HL, IFRT remains an important component of 
the treatment of advanced- stage HL in pediatric patients .(12, 13, 14)
HL is the childhood cancer with the highest cure rates with current OS more than 90% in 
low-stage disease and up to 70% for disseminated disease.(13, 15, 16, 17)  Five-year event-free 
survival in pediatric HL is approximately  80 to 85% .(18)  Pediatric patients less than 10 years 
of age had a significantl y improved freedom from relapse and survival in comparison with 
adolescents and a highly significant improved outcome compared with adults .  Although 
pediatric patients present high cure rates, multi-agent regimens confer a significant 
morbidity , including secondary  malignancies, cardiovascular disease, male infertility , 
pulmonary  diseases,and infections .(19, 20, 21, 22)  Some of the serious sequelae of radiation and 
alkylating chemotherap y are most pronounced in younger patients, in whom growth and 
development are particularly  active when therapy  is administered .  In addition, cardiac 
toxicity appears to be age related, with younger patients at the highest risk .  Secondary  
malignancies represent the leading cause of mortality  in survivor patients with HL.(8, 23)
Approximately  10to 20% of patients presenting with HL  will become refractory  to initial 
therapy or will relapse .  Given the high rate of success of initial treatment for pediatric HL, 
little has been published on the optimal management for relapsed or refractory patients .  
Historical data reveal that children managed initially  with radiation alone and who then 
relapse can achieve cure (as hig h as 85%), whereas those who were initially  treated with 
multi-agent chemotherapy or combined modality therap y have an unfavorable prognosis and 
are much more likel y to subsequently experience treatment failure .(14)  For patients with 
favorable disease at diagnosis, eg, with relapse confined to an area of initial involvement 
after chemotherap y and no radiation, salvage therapy consists of further chemotherap y and 
low-dose IFRT.  Patients w ith an early relapse (between 3-12 months from the end of 
therapy) had a 10 -year event-free survival ( EFS)of 55% and a 5 -year OSof 78%; those with 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 25a late relapse (more than 12 months from the end of therap y) had a 10 -year EFS and OS of 
86% and 90%, r espectively .(24, 25, 26)  For these patients, there is little or no possibility  that 
standard-dose chemotherapy  will prove to be effective .  High-dose chemotherap y plus 
allogeneic stem cell transplant ( alloSCT)is the only  curative option in both pediatric and 
adult patients.(27)
Transplantation -related mortality  rates of more than 20% and even higher relapse rates in 
pediatric and adult series compromise the survival benefit.  Patients who experience relap se 
or progressive HL post -alloSCTfare dismally  and represent a clear unmet need.(28)  A 
pooled anal ysis from 5 international transplant centers of 756 patients who experienced 
relapsed HL after autologous stem cell transplant ( ASCT)revealed a median survival of 
2.4years, with fewer than 10% of patients alive at [ADDRESS_577595] changed dramaticall yto reduce these 
toxicitiesï‚¾high -dose radiation therapy  is no longer utilized ,chemotherap y regimens utilize 
lower doses of alky lating agents, h ybrid regimens allow for lower doses of anthracycline 
and bleomy cinï‚¾minimizing the current late effects in patients receiving modern therap y.  
However, there is still a need to investigate the efficacy  and safety  of these regimens versus
chemotherap y alone in children and adolescents .  Because late effects may  take 10 to 
30years or more to become clinically  apparent, it is too early  to conclude on the long -term 
safety of these treatments .  The proposed pediatric study  has been designed to study  
brentuximab vedotin in patients with relapsed or refractory  HL, where adult data in this 
disease setting are presently  available and where an unmet medical need for new treatments
currently exists.
[IP_ADDRESS]   Anaplastic Large -Cell Lymphoma
Anaplastic large -cell lymphoma (ALCL) accounts for approximately  10% of all childhood 
non-Hodgkin's l ymphomas.  ALCL can occur at any  age, even in infants, and incidence 
increases steadil y with age .  The incidence of non-Hodgkin ly mphoma ( NHL)in the 
pediatric population is much lower than in adults .  The overall rate in pediatric patients is 
approximately  0.7 per 100,000.(29)  The number of cases with NHL in patients 0 to 4years of 
age across European regions was very  low and casesin pediatric patients less than 2 to 
3years of age are extremely  rare.  Patients may  present with isolated ly mphadenopathy  or 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577596], soft tissues, lung, liver, 
and/or bone .  Systemic ALCL (sALCL) behaves similarly  to other diffuse large -cell 
lymphomas and is aggressive but potentially  curable with sy stemic combination 
chemotherap y.(30, 31)
Approximately  50%to 80% of pediatric ALCLcases are associated with a t(2;5)(p23;q35) 
chromosome translocation pr ompting the anaplastic ly mphoma kinase (ALK) gene on 
chromosome 2 to fuse with the nucleophosmin (NPM) gene on chromosome 5 (ALK 
positivity ).  NPM/ALK fusion protein acts as a constitutively  activated t yrosine kinase .(32, 33)  
Inappropriate expression and activation of the fusion kinase in the ly mphoid compartment 
causes the pathogenesis of some forms of ALCL,(34, 35, 36, 37)however, some lymphomas 
positive for ALK lack this translocation .  In these lymphomas, other chromosomal 
rearrangements, such as inv 2 (p23;q35) and t(1;2)(q25;p23), result in ALK expression .(32, 33)  
In general, ALK -positive sAL CL has a superior OSand failure -free survival rate compared 
with ALK-negative sALCL .(38)  ALK positivity  is the most impor tant prognostic indicator in 
adult ALCL but is less helpful in childhood s ALCL where 80% to 95% of sALCL is ALK 
positive, which precludes comparison of treatment results between pediatric and adult 
studies.
Prognostic factors are crucial for selecting an a ppropriate treatment strategy .  Prognosis in 
children and adults is determined b y staging.  Younger age, absence of B symptoms, 
absence of extranodal disease, and good performance status predict a better prognosis .  
Three main clinical factors are associated with an increased risk of failure in childhood 
sALCL:mediastinal involvement, visceral involvement, and skin lesions.(39, 40, 41, 42, 43)  The 
presence of 1 or more of these has been associated with a poor prognosis: 5-year 
progression- free survival (PFS) ranging from 90 to 61% .  Recent studies have associated 
poor prognosis with the presence of minimal disseminated residual disease and a low titerof 
antibodies to the anaplasti c lymphoma kinase (ALK) at diagnosis .  Patients lacking the 
t(2;5) translocation in their tumor cells (ALK -negative AL CL) typi[INVESTIGATOR_452936] a 5 -year survival of approximately  40%, whereas ALK -positive disease 
has a more favorable pr ognosis with 5- year survival as high as 80 to 90%.(39, 40, 41, 42, 43)
In pediatric frontline sALCL, current therapeutic approaches emplo y combination 
chemotherap y.  Significant hema tological toxicity  has been observed.  Improvements in 
first-line therapi[INVESTIGATOR_452937], pediatric patients presenting with 
sALCL have an excellent prognosis.  Event-free-survival (EFS) in pediatric patients 
suffering from s ALCLis up to 100% for earl y stage and 70% in advanced stage .  OShas 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 27been reported to be up to 90% for ea rly stage, and 80% for advanced stage.  Recent trials 
from the Pediatric Oncology  Group, the Childrenâ€™s Cancer Group, and European 
cooperative groups have shown disease -free survival for advanced -stage disease in the range 
of 50%to 80% using chemotherapeutic regimens vary ing in duration and intensity .(39, 41, 44, 
45)
Nonetheless, 25 %to 35% of patients develop recurrent disease .(41)  For recurrent or 
refractory  sALCL, 40% to 60% of patients can achieve long -term survival .  There is no 
standard treatment approach; chemotherap y, ASCT, and alloSCT haveall been employ ed in 
this setting .  Several studies suggest that alloSCTmay result in better outcomes for 
refractory /relapsed sALCL.  The treatment of relapsed sALCL is still a matter of debate .  
Induction therap y followed by [CONTACT_5019] -dose chemotherap y and autologous allogeneic 
hematopoietic stem cell transplant after a second complete remission (CR) is the standard 
treatment for relapsed l ymphoma in children and is currentl y used by [CONTACT_452962] -
line treatment for relapsed sALCL.  Vinblastine is acti ve as a single agent in 
recurrent/refractory  sALCL, in 1study inducing CR in 25 of 30 evaluable patients (83%) 
with acceptable toxicity .  Nine of the 25 patients experiencing a CR with vinblastine 
monotherap y remained in CR with median follow- up of 7years since the end of 
treatment .(42)
The choice of salvage therap y for sALCL patients in first relapse is largely  driven by  
[CONTACT_452963] -line therapy .  
AlloSCTis effective and has acceptable toxicity  as rescue therap y for high-risk sALCL
relapse.  It even offers a cure for patients who are refractory  to chemotherapy , suggesting a 
graft-versus-ALCL effect .  The Berlin -Frankfurt -MÃ¼nster group reported outcomes for 
20children and adolescents with high -risk relapsed or refractory  sALCLwho underwent 
alloSCT.  Nine patients received alloSCTafter their first relapse and 11 patients were 
transplanted after multiple relapses.  Event -free survi val at 3years after allo geneic transplant
was 75%ï‚±10%.  There was no influence of donor ty pe or conditioning regimen on outcome .  
Two of [ADDRESS_577597] relapse after frontline therapy .(46)  Patients allografted in 
complete remi ssion showed a better PFS and OS.(47)
In our proposed stud y, patients with very  high risk disease, particularl y those who progress 
while receiving standard therap y and are eligible for bone marrow transplantation ( BMT), 
may use brentuximab vedotin to bridge to alloSCT .  This population constitutes ~50 to 60% 
of the high -risk relapsed patients.  Patients who respond to 2 cycles or more of brentuximab 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 28vedotintherapy would be eligible to continue therapy with SCTor BMT.  These patients 
will be transitioned to BMT and may  no longer receive brentuximab vedotin .
[IP_ADDRESS]   Primary Mediastinal B -Cell Lymphoma
In addition to sAL CL, primary mediastinal B -cell lymphoma (PMBCL) is a CD30- positive 
(CD30+)expressing malignancy .  PMBCL is a pathological and clinical subty pe of NHL 
derived from mature th ymic B cells .  In children, PBM CL comprises 1.8% and 3.8% of 
patients registered on the Berlin â€“Frankfurt â€“Munster (BFM) and the 
French-American -British (FAB) LMB96 B -cell NHL studies, respectively .  PMBCL hasthe 
poorest survivals in the pediatric age range, but one of the best among adu lts with large 
B-cell lymphomas.  PMBCL are consistentl y positive for CD19, CD20, and CD45 and often 
for CD79a, CD11c, and CD23 .  CD30 is usually  positive while CD10 and CD21 are 
negative.(48, 49, 50, 51, 52)  The BFM group reported 30 PMBCL cases out of 1,650 B -NHL 
pediatric patients, 28 of whom were treated on BFM B -NHL therap y.(53)  From 1984 to 
2003, 116pediatric patients represented <2% of NHL .  The OSrate was 79% and EFS was 
67%, which were significantly  lower than that in other pediatric B -cell lymphomas, such as 
diffuse large B -cell lymphoma or Burkittâ€™s ly mphoma, and inferi or to the results obtained in 
adult patients with PMLBL who have up to 100% progression- free survival using 
dose-adjusted EPOCH with rituximab.(54)
Table1-1   Summary of Results of Chemotherapy Treatment in Pediatric PMBCL 
Studies
Study Number of patients Event-Free Survival Overall Survival
NHLâ€“BFM 86-90-95(51)28 5 year 75% N/A
FAB/LMB 96(52)43 3 year 66% 3 year 73%
FAB/LMB 96
NHLâ€“BFM 86-90-95
AIEOP LNH 92(53)116 3 year 67.4% 3 year 78.6%
High-dose therapy  followed by [CONTACT_452964].  
Won,et al,reported an estimated 2 -year OSof 62.8Â±9.1% and EFS of 59.1Â±9.3% in 
33pediatric patients with relapsed (n =16) or refractory  (n=17) NHL following high- dose 
therapy and ASCT compared to an EFS of 16.3Â±4.6% in those who received conventional 
chemotherap y.  The European Group for Blood and Marrow Transplantation reported on one 
of the largest series of 89 pediatric patients with poor risk B- cell lymphoma who underwent 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577598].  T hey report a 5 -year EFS of 48.7% 
for patients with chemosensitive relapse but a dismal outcome for patients with primary  
refractory  disease, all of whom died within 1 year posttransplant, with a 5- year EFS of onl y 
8%.(55)
1.1.2   Study Drug
Brentuximab vedotinis a CD30- directed antibody -drug conjugate (ADC) consisting of 
3components: 1) the antibody  cAC10, specific for human CD30, 2) the highl y potent 
antimicrotubule agent monomethy l auristatin E (MMAE), and 3) a protease -cleavable linker 
that covalently attaches MMAE to cAC10 .  The biological act ivity of brentuximab vedotin 
results from a multistep process.  Binding of the ADC to CD30 on the cell surface initi ates 
internalization of the ADC -CD30 complex, which then traffics to the l ysosomal 
compartment .  Within the cell, a single defined active species, MMAE, is released via 
proteolytic cleavage .  Binding of MMAE to tubulin disrupts the microtubule network with in 
the cell, induces M -phase cell cy cle arrest, and results in apoptotic death of the 
CD30-expressing tumor cell.
1.2   Preclinical Experience
1.2.1   In Vitro Activity of Brentuximab v edotin
The chimeric antibody  (cAC10)has a typi[INVESTIGATOR_452938] 1 subclass 
(Figure1-1) and is designed to deliver the cy totoxic agent specificall y to tumor cells .  
Brentuximab vedotin binds to the cell surface protein CD30, which is expressed at high 
concentrations on tumor ce lls in HL and sALCL.  Target antigen specificit y allows 
preferential delivery  of the drug to tumor cells when drug is conjugated to the antibody  as an 
ADC.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 30Figure1-1   Schematic Diagram of B rentuximab vedotin
Brentuximab vedotin binds to CD30+ cells (ALCL cell line Karpas 299) at a dissociation 
constant (K D) of approximately  2nM, similar to that of the unconjugated cAC10 anti -CD30 
antibody.  Cell surface and intracellular localization of brentuximab vedotin was 
demonstrated b y fluorescence micros copy after binding to CD30+ cells (HL cell line 
L540cy).  Within 16 hours of incubation at 37 ï‚°C, brentuximab vedotin was detected inside 
cells and co-localized with intracellular l ysosomes indicating internalization and trafficking 
to lysosomes.  Monomethy l auristatin E (MMAE) was released from brentuximab vedotin
intracellularl y by [CONTACT_398]30+ human HL (L540cy  and L428) and ALCL (Karpas 299) cell lines 
as determined b y liquid chromatography  with tandem mass spectrom etryanalysis of cell 
culture medium .  In addition, studies demonstrating release of MMAE from brentuximab 
vedotinby [CONTACT_452965] B and l ysosome-enriched tumor cell extracts were performed 
supporting the concept of release of MMAE via the conditionally  labile linker ( Figure1-1).  
Free MMAE inhibited microtubule poly merization in vitr o and tumor cells (CD30+
embryonal carcinoma Tera -2 cells) treated with MMAE or brentuximab vedotin displayed a 
rounded morphology  and disrupted micotubule network.
The primary  pharmacod ynamic effect of brentuximab vedotin was to induce cell cy cle arrest 
in the G2/M phase of the cell cy cle.  An increase in the percent of cells in G2/M phase was 
observed over t ime in cultures of CD30+ cells (HL cell line L 540cy and ALCL  cell line 
Karpas 299) treated with brentuximab vedotin .  Brentuximab vedotin selectively killed 
CD30+HL and ALCL cell lines (I C50 of 0.089 and 0.031 nM, respectivel y), but not 
CD30-negative cells (WSU -NHL) at concentrat ions of approximately  100-fold higher .  
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 6LPLODUO\00$(NLOOHGWKH&'FHOOVDWORZQ0FRQFHQWUDWLRQV DQGQ0
UHVSHFWLYHO\
%UHQWX[LPDEYHGRWLQGHPRQVWUDWHGDQWLWXPRUDFWLYLW\LQ[HQRJUDIW PRGHOVGHULYHGIURP
KXPDQ+/DQG$/&/WXPRUFHOOOLQHV$GGLWLRQDOGHWDLOVPD\EH IRXQGLQWKHEUHQWX[LPDE
YHGRWLQ,QYHVWLJDWRU%URFKXUH,% 
 3KDUPDFRNLQHWLFVDQG3URGXFW0HWDEROLVPLQ+XPDQV
3KDUPDFRNLQHWLFSDUDPHWHUVIRULQGLYLGXDOSDWLHQWVZHUHGHWHUPL QHGLQ6WXG\6*
XVLQJFRQFHQWUDWLRQVRIVHUXPEUHQWX[LPDEYHGRWLQ$'&SODVPD00 $(DQGVHUXPWRWDO
DQWLERG\%UHQWX[LPDEYHGRWLQ$'&SKDUPDFRNLQHWLFVGHPRQVWUDWHG WKDWLQFUHDVHVLQ
H[SRVXUHZHUHDSSUR[LPDWHO\GRVHSURSRUWLRQDO7KHJHRPHWULFP HDQWHUPLQDOKDOIOLIHZDV
DSSUR[LPDWHO\WRGD\VIRUWKHPJNJGRVHOHYHO7KHILUVW WLPHWRPD[LPXP
FRQFHQWUDWLRQW\SLFDOO\RFFXUUHGLPPHGLDWHO\DIWHUWKHHQGRIL QIXVLRQ6WHDG\VWDWHZDV
DFKLHYHGE\&\FOHFRQVLVWHQWZLWKWKHKDOIOLIHHVWLPDWH$F FXPXODWLRQZDVVOLJKW
00$(SKDUPDFRNLQHWLFVGHPRQVWUDWHGWKDWLQFUHDVHVLQH[SRVXUHZH UHDSSUR[LPDWHO\GRVH
SURSRUWLRQDO7KHDSSDUHQWWHUPLQDOKDOIOLIHZDVDSSUR[LPDWHO \GD\VIRUWKHPJNJ
GRVHOHYHO
$OWKRXJKWKHUHODWLYHH[SUHVVLRQRI&'LQSHGLDWULFSDWLHQWV ZLWKV$/&/DQG+/
FRPSDUHGWRDGXOWSDWLHQWVZLWKV$/&/DQG+/KDVQRWEHHQTXDQWLI LHGLQYLWURF\WRWR[LFLW\
H[SHULPHQWVVXJJHVWWKDWEUHQWX[LPDEYHGRWLQZLOOKDYHDFWLYLW\ DFURVVDODUJHUDQJHRI
&'H[SUHVVLRQ7KHUHIRUHLWLVDQWLFLSDWHGWKDWEUHQWX[LPDE YHGRWLQZRXOGVXFFHVVIXOO\
WDUJHW&'VLPLODUO\LQSHGLDWULF+/V$/&/DQGRWKHUUDUHO\P SKRPDH[SUHVVLQJ&'
DVREVHUYHGLQDGXOWVDQGEDVHGXSRQWKHFOLQLFDOGDWDLQDGXOW V$/&/
)URPDSKDUPDFRNLQHWLFSHUVSHFWLYHDJHUHODWHGFKDQJHVLQWKH GLVSRVLWLRQRIPRQRFORQDO
DQWLERGLHVDUHQRWRIWHQREVHUYHG7KHWR[LQSRUWLRQRIEUHQWX[LPDEYHGRWLQ00$(
LVPHWDEROL]HGWRVHYHUDOLQDFWLYHPHWDEROLWHVYLD&<3$([S UHVVLRQRIWKLVLVRIRUPLV
DSSUR[LPDWHO\RIDGXOWOHYHOVLQSHGLDWULFSDWLHQWVEHWZHHQ DQGPRQWKVRIDJH
DQGLVVLPLODULQSHGLDWULFSDWLHQWVÂ•\HDUROGDQGDGXOWSDWLH QWV 



CCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577599] been conducted with brentuximab vedotin in vitro and in vivo 
(monkeys and rats) .  Overall brentuximab vedotin demonstrated an acceptable safet y profile 
in nonclinical studies.  H ypocellularity  of the bone marrow and l ymphoid depletion of the 
thymus were observed in both rats and monkey s.  In addition, lesions w ere seen in the 
kidneys, liver, and spleen in monkey s and in the liver and testes in rats.  Reversibility  of 
toxicity was demonstrated for all of the findings with the exception of the testicular changes 
in rats.  At the recovery  sacrifice [ADDRESS_577600] dose of brentuximab vedotin
(10mg/kg), testicular changes (diffuse seminiferous tubule degeneration) were still evident .  
Further details are provided in the brentuximab vedotin IB.
1.2.4   Immune Function
Detailed information rega rding the nonclinical pharmacology  and toxicology  of brentuximab 
vedotinmay be found in the brentuximab vedotin IB.
1.3   Clinical Experience
The safety and efficacy  of brentuximab vedotin has been evaluated in more than 
300patients with H L, sALCL, and other CD30+ hematologic malignancies in [ADDRESS_577601] been collected from 2completed phase1 dose escalation studies 
(SG035-0001 and SG035- 0002), a pi[INVESTIGATOR_30338] [ADDRESS_577602] (SG 035-0003),a pi[INVESTIGATOR_30338] 2 study in relapsed or refractory  sALCL 
(SG035-0004) , and a phase 1,drug-drug interaction study  (SG035-008A).  Preliminary  and 
final anal yses of safet y data indicate that brentuximab vedotin has a tolerable and 
manageable safety profile in the studied populations .
In StudySG035-0001, a total of 45 patients with CD30+ hematologic malignancies (42 with 
HL, 2 with sAL CL, 1 with angioimmunoblastic T -cell lymphoma) were treated with 
brentuximab vedotin at doselevelsof 0.1 to 3.6mg /kg administered intravenously (IV) 
every 3 weeks.  The primary  objectives of the study  were to establish a maximum tolerated 
dose (MTD) of brentuximab vedotin and to assess the associated toxicity  profile.  The most 
common adverse events were fatigue (36%), pyrexia(33%), and diarrhea, nausea , peripheral 
neuropath y, and neutropenia (22% each) .  Notable serious adverse events considered at least 
possibly related to treatment included anaphy laxis, myocardial infarction, and peripheral 
neuropath y.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 33In StudySG035-0002, 44 patients with CD30+ hematologic malignancies (38with HL, 
5with sALCL, and 1with peripheral T -cell lymphoma) were treated with brentuximab 
vedotinat doselevelsof 0.4 to 1.4 mg/kg administered IVweekly for 3 of 4 weeks.  The 
primary objectives explored in this study  were to establish the safet y profile and MTD of 
weekly brentuximab vedotin monotherapy  in patients with relapsed or refractory  CD30+ 
hematologic malignancies.  Although this weekl y regimen was designed to enable 
combination use with gemcitabine, efficacy  with brentuximab vedotin monotherap y was 
deemed sufficient and the planned brentuximab vedotin /gemcitabine combination was not 
pursued.  The most common adverse event s were peripheral sensory  neuropathy  (66%); 
fatigue (52%); nausea (50%); diarrhea (32%); arthralgia (27%); py rexia (25%); and 
decreased appetite, my algia, and upper respi[INVESTIGATOR_2826] (23% each) .  Treatment 
discontinuations due to adverse event s were observed in 30% of patients .  The most frequent 
AE that le d to dose modification or delay  was peripheral sensory  neuropathy .  Acute 
infusion reaction AEs occurred in a total of 6 patients.  Overall, these acute infusion reaction 
AEs were reported as less than Grade 2 in severity  and resolved .  Overall, 2 patients(14%) 
who had an acute infusion reaction also had antithe rapeutic antibodies at any  postbaseline 
visit.
InSG035-0003, a phase 2,single-arm,open-label studyin patients with relapsed or 
refractory  HL postASCT ,andSG035-0004, a phase 2 studyconducted i n patients with 
relapsed or refractory  sALCL, brentuximab vedotin was administered at a dose of 1.8 mg/kg 
every 3 weeks.  One hundred two patients with relapsed and refractory  HL and 58patients 
with relapsed and refractory  sALCL were exposed for a median duration of approximately  
27weeks (9cycles) and 20 weeks (6 cycles), respectively.  Most p atients (89%) in the two 
phase2 studies were between the ages of 18 and 65 years.  The primary endpoint of both 
studies was overall response rate (ORR) as assessed by [CONTACT_452966] .  
Key secondary endpoints included duration of response, OS, and PFS .  The key efficacy 
results in HL  (SG035-0003) include ORR per IRF (75% [95%CI:  64.9-82.6%]), CR rate
(34% [95%CI:  25.2-44.6%]), B symptom resolution rate (77%), and duration of response 
(DOR, 29weeks).  Key efficacy points in s ALCL (SG035-0004) include ORR (86% [95% 
CI:  74.6-93.9%]), CR rate (53% [95% CI:  39.6-66.7%]), and B symptom resolution rate 
(82%).
Treatment -emergent AEs occurring in â‰¥20% of patients in phase 2 were peripheral sensory  
neuropath y (44%), fatigue (42%), nausea (41%), diarrhea (34%), p yrexia (31%), upper 
respi[INVESTIGATOR_2826] (28%), neutropenia (21%), and vomiting (20%) .  These events 
were primar ily mild to moderate in severity and reversible .  Approximately  half of patients 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577603].  Dose delay  and subsequent 
reduction to 1.2 mg/kg was generally effective in managing peripheral neuropathy .  Grade3 
and Grade4 neutropenia occurred in 13% and 7% of patients, respectivel y; these events 
weretypi[INVESTIGATOR_452939] s with growth factor 
support in some cases.  Infusion-related reactions occurred in approximately 10% of patients 
and were ty pi[INVESTIGATOR_452940] b y dose delay or reduction .  Infusion-related reaction
prophylaxis in subsequent treatment cy cles was instituted at the discretion of the 
investigator .  The clinical laboratory  parameters for which the most patients had new or 
worsening shifts to ï‚³Grade3 were low neutrophils (11%), l ymphocytes (11%), platelets 
(6%), leukocy tes (5%), and high glucose (6%) .  Only 1patient in the phase 2 studies had 
Grade3 increased alanine aminotransferase (ALT)and aspartate aminotransferase ( AST).
In the phase 2 studies, 31% of patients had a serious adverse event , 28% had an SAE of 
Grade3 or higher, and 15% had an SAE that was determine d by [CONTACT_452967].  The most common SAE preferred terms (2%) were 
abdominal pain, disease progression (recurrent sALCL), pulmonary  embolism, and septic 
shock.  A higher proportion of sALCLpatients experienced SAEs, including deaths within 
30days of last dose, relative to patients with HL, likely due to the older age and more 
aggressive nature of the malignancy in this patient population.
A total of 9 deaths were reported within the safety  evaluation period (within 30days of the 
last dose of brentuximab vedotin ) in 357patients across the 6 phase 1 and phase 2 studies 
for which data are available.  Two patient deaths (0.6%) were considered related to study  
treatment .  One patient in S tudySG035-0001 who received 3.6 mg/kg in phase 1 died due to 
febrile neutropenia and presumed septic shock .  A second treatment -related death in 
StudySG035-008A was attributed to pancytopenia, cy tomegalovirus ( CMV)infection, and 
intracranial hemorrhage .  The remaining on -study deaths were primaril y related to disease 
progression in patients with sALCL.
Four pediatric patients (aged 14 -17years) were included in S tudySG035-0004 in sALCL, 
and 1pediatric patient ( aged 15years) was included in S tudySG035-[ADDRESS_577604] 1 event of peripheral neuropath y, ranging from 
Grade1 to Grade3, and 2patients reported events of neutropenia .  One patient experienced 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 35treatment -related G rade3 neutropenia, and 1 patient experienced G rade3 andGrade4 
neutropenia and Grade3 and Grade4 thrombocy topenia that were assessed as not related to 
brentuximab vedotin .  This same patient experienced an SAE of Grade2 viral 
gastroenteritis, which was unrelated to study  drug.  The patient with HL in S tudySG035-
003 achieved a CR and completed treatment .  The patientâ€™s DOR was 50.4 weeks.  Three of 
the 4pediatric patients with sAL CL in StudySG035-004achieved CR and 1 achieved 
partial remission ( PR); 1patient was transitioned to ASCT.
Brentuximab vedotin has been shown to induce durable remissions in patients with HL  both 
pre-and post-ASCT, and in patients with relapsed or refractory  sALCL.  Progression -free 
survivalresults comparing PFS with brentuximab vedotinto PFS from prior sy stemic 
therapy indicate that PFS is significantl y prolonged with brentuximab vedotinfor both HL  
and sALCL.  A substantial number of patients with HL  and sALCLand B symptoms at 
baseline saw these s ymptoms resolve during treatment with brentuximab vedotin .  In 
addition, the la rge majority  of patients with sALCL presenting with cutaneous lesions at 
baseline experienced resolution of these sy mptoms after receiving brentuximab vedotin .
Further details on clinical studies with brentuximab vedotin are provided in the brentuximab 
vedotinIB.
1.3.[ADDRESS_577605] patients diagnosed with HL  or sALCLrespond to initial chemotherapy .  However, 
20%to 40% of these patients will eventually  relapse, and approximately  10% of patients 
will have refractory  disease.  Salvagechemotherapeutic regimens and ASCT are secondary  
options for these patients, but both are associated with a significant morbidity  rate.  
Immunotherap y with an ADC represents an additional therapeutic modality with the 
potential to maintain or improve effi cacy without concomitant increase in toxicity .
Brentuximab vedotin is a novel ADC directed against the CD30 surface antigen expressed 
on hematologic malignancies including HL and sALCLtumor cells.  Preclinical studies of 
brentuximab vedotin demonstrated a ntitumor activity  in both in vitro and in vivo models.  
This study  is the first clinical use of brentuximab vedotin exclusively  in pediatric patients 
with relapsed or refractory CD30+ malignancies, the majority  of which are expected to be 
HL and sALCL.  The safety, pharmacokinetics (PK), immunogenicit y, and antitumor 
activity of brentuximab vedotin will be evaluated in eligible patients.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 36As the goal of phase1 of thisstudy is to establish safet y and define the MTD and/or 
recommended phase 2 doseof brentuximab vedotin in pediatric hematological malignancies 
with high expression of CD30, patients with relapsed or refractory  CD30+ malignancies 
(including HL and sALCL) are planned for inclusion in the phase 1 study population .
The phase2 portion of the study  will enroll patients into 2 separate arms based on diagnosis 
ofrelapsedor refractory  sALCL,or relapsed or refractory  HL; patients will receive 
brentuximab vedotin at the MTD and/or recommended phase 2 dose (RP2D)determined in 
the phase [ADDRESS_577606] overall response rate (CR +PR) and DORwill be 
evaluated.
Conducting the phase [ADDRESS_577607] the trial to obtain treatment with other investigational products.
1.4   Potential Risk s and Benefits
This trial will be conducted in compliance with the protocol, good clinical practice (GCP), 
applicable regulatory requirements, and International Conference on Harmonisation (I CH) 
guidelines.
1.4.1   Benefit Analysis in Hodgkin Lymphoma
StudySG035-0003, a phase2 studyof brentuximab vedotin evaluated 1.8 mg/kg 
administered IVevery 3weeks in a relativel y homogeneous population of [ADDRESS_577608].
A 75% ORR (representing the predefined primary  endpoint of the trial) with a durability  of 
6.7months was observed .  A substantial proportion (34%) of all treated patients obtained a 
complete remission as manifested b y no evidence of ly mphoma by  [CONTACT_2085], laboratory , or 
radiographic measures .  Observed CRs were durable, with the median duration not reached 
and a lower 95% confidence interval bound of 8.[ADDRESS_577609] , and this 
potentially  curative treatment option was enabled in a meaningful fraction of patients with 
HL treated in the study .
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577610] 
recently delivered treatment .  Analysis of transplant -ineligible patients in phase 1 studies 
demonstrated clinical benefit in the pretransplant setting.
1.4.2   Benefit Analysis in Systemic Anaplastic Large Cell Lymphoma
StudySG035-0004, a phase 2 study of brentuximab vedotin 1.8 mg/kg administered IV
every 3weeks in 58patients 12 years of age or older with sAL CL, an ORR of 86% was
observed and 53% of patients obtained a CRas manifested by [CONTACT_452968] b y 
clinical, laboratory , or radiographic measures.  The ability  to attain a second CRor achieve a 
first CRafter the failure of frontline therap y enables an improved opportunity for SCT, an 
exploratory  yet potentially  curativetreatment.
As for HL, an intrapatient comparison of PFS per investigator assessment obtained with 
brentuximab vedotin versus the most recent prior therap y was conducted.  In 90% of cases , 
the most recent prior therapy  was multiagent chemotherapy , delivered with or without 
ASCT.  The median PFS duration achieved with brentuximab vedotin was approximately  
[ADDRESS_577611] recent prior therap y.
1.4.3   Potential Risks in C hildren
The recommended dose of brentuximab vedotin in a dult patients is 1.8 mg/kg administered 
IVevery 3weeks as long as the patient continues to benefit from and tolerates therapy .  At 
this dose and schedule, the most common adverse events were peripheral sensory  
neuropath y, fatigue, nausea, diarrhea, p yrexia, upper respi[INVESTIGATOR_2826], neutropenia, 
and vomiting .  These events have been primarily  mild ormoderate in severity .
The most notable adverse event associated with brentuximab vedotin is peripheral 
neuropath ythat tends to increase in severity with longer duration of therapy, consistent with 
thatobserved with other antimicrotubule agents such as vinca alky loids or taxanes.  S ensory 
events were more common than motor events, and the peripheral neuropathy  (PN)events 
typi[INVESTIGATOR_96448] a distal to proximal pattern of development, also similar to the PN seen 
with other tubulin disruptors.  
Approximately  half of patients in the phase 2 studies 
experienced treatment -emergent PN, which was primarily  mild to moderate (Grade 1 or 
Grade2).  The most fr equently occurring events were peripheral sensory  neuropathy  (44%), 
peripheral motor neuropathy  (9%),and paresthesia (4%) .  Grade3 peripheral neuropathy  
events occurred in 18 (11%) patients .  No Grade 4 PN events were reported.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577612] 1 PN Standardis ed MedDRA Query  
(SMQ) event, the median time to onset of any  PN SMQ event was 12.4 weeks.  For
â‰¥Grade3 events, there was a clear trend toward first onset in later cy cles, with the majority  
of events having first onset between C ycles9 and 16.  Overall, 15% of patients had dose 
modifications for PN SMQ events .  Dose delay s for PN SMQ events occurred in 20 patients 
(13%) and dose reductions occurred in 12 patients (8%) .  Treatment discontinuations for PN 
SMQ events occurred in 14 patients (9%) .  Neuropathy  was generall y reversible, with a 
median time from onset to resolution or improvement of 6.6 weeks (range, 0.3 to 
54.4weeks).
The majority  of peripheral neuropathy  events were Grade1 or Grade 2 and were 
manageable by [CONTACT_452969].  For new or worsening events of Grade 2 or 
Grade3 neuropathy , dosing should be held until neuropathy  improves to â‰¤Grade1 and then 
restarted at the 1.2mg/kgdoselevel.  For Grade 4 (life-threatening )peripheral neuropathy , 
brentuximab vedotin should be discontinued .
Infusion-related reactions (I RRs) are possible with brentuximab vedotin, especially  related 
to the development of clinically  significant titers of antitherapeutic antibodies (ATAs ).  
Patients must be monitored fo r the possibility  of an acute reaction during brentuximab 
vedotin administration.  If IRR symptoms develop, the infusion should be interrupted and 
appropriate medical management instituted.  Further information on the management of 
IRRs is provided in Sect ion6.1.
Progressive multifocal leukoencephalopat hy (PML)has beenreported with brentuximab 
vedotinuse.  PML is a rare demyelinating disease of the brain that is caused by  [CONTACT_452970] (JCV). It typi[INVESTIGATOR_452941]. Presenting features may  include altered mental status, motor deficits such as 
hemiparesis or ataxia, visual disturbances, or higher cortical d ysfunction such as dy sphasia 
or agnosia. Seizures have also been reported in PML  patients (approximately  20%). The 
onset of neurological deficits may  occur over weeks to months.(60)  Cognitive decline 
without accompan ying deficits in motor or sensory  function is uncommon.  Optic nerve 
involvement, fever, and spi[INVESTIGATOR_452942] P ML. In 
addition, peripheral neuropathy , which has been reported with brentuximab vedotin 
treatment, is not commonly  reported with PML . If PML is suspected, a diagnostic work -up 
should be performed , as described in Section 6.8.2.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 39Stevens-Johnson sy ndrome (SJS) , including toxic epi[INVESTIGATOR_23936],has been reported in 
patients who received brentuximab vedotin.  P atients were concurrently receiving other 
medications (naproxen and tramadol, respectively) that areknown to cause SJS and may 
have contributed to the development of SJS. Stevens-Johnson sy ndromeis considered to be 
an unacceptable stud y drug-related toxicity .  If SJS occurs, the administration of 
brentuximab vedotin must be discontinued and the approp riate medical therapy  
administered.  
Acute pancreatitis has been reported in patients treated with brentuximab vedotin and has 
contributed to fatal outcomes in some cases.  Onset ty pi[INVESTIGATOR_452943] 1 to 2 doses of 
brentuximab vedotin.  Early  symptoms included severe abdominal pain, nausea, and 
vomiting.  Some of the pancreatitis cases were complicated by  [CONTACT_452971], including cholelithiasis and alternate etiologies (eg, pancreatic ly mphoma 
progression, displacement of bile du ct stent).
Concomitant use of brentuximab vedotin and bleomy cin is contraindicated due to pulmonary  
toxicity. In a clinical trial that studied brentuximab vedotin with bleomy cin as part of a
combination regimen, the rate of noninfectious pulmonary  toxicity was higher than the 
historical incidence reported with ABVD ( adriamycin, bleomy cin, vinblastine, dacarbazine).
Patients ty pi[INVESTIGATOR_452944] d yspnea.Interstitial infiltration and/or inflammation 
were observed on radiographs and computed tomogr aphic imaging of the chest. Most 
patients responded to corticosteroids.
Hepatotoxicity , predominately  in the form of as ymptomatic mild to moderate transient 
elevations in AST and/or AL T, has been reported inpatients treated with brentuximab 
vedotin.  Patients should be monitored for elevated liver enzy mes.
Preliminary  population PK anal yses of the effects of brentuximab vedotin on renal and 
hepatic function suggest that no dose adjustments are necessary  for patients with renal or 
hepatic impairment.  Additional analy sis is planned to more fully  characterize the 
pharmacokinetics in this patient population.   
The effects of brentuximab vedotin on embry ogenesis, reproduction, and spermatogenesis in 
humans are unknown.  In addition, data about the effects of b rentuximab vedotin in pregnant 
women are unavailable .  Patients of childbearing potential are advised to use adequate and 
effective contraception during brentuximab vedotin treatment and for a 6-monthperiod 
thereafter.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO %UHQWX[LPDEYHGRWLQUHFRJQL]HVWKH&'DQWLJHQRQWXPRUFHOOVD QGQRUPDODFWLYDWHG
7FHOOV,QQRQFOLQLFDOWR[LFRORJ\VWXGLHVK\SRFHOOXODULW\RI WKHERQHPDUURZDQGO\PSKRLG
GHSOHWLRQRIWKHWK\PXVZHUHREVHUYHGLQUDWVDQGPRQNH\V,W LVSRVVLEOHWKDWELQGLQJRI
EUHQWX[LPDEYHGRWLQWRQRUPDO&'7FHOOVFRXOGUHQGHUWKHVHFH OOVLQHIIHFWLYHWKXV
OHDGLQJWRDOWHUDWLRQVLQLPPXQHIXQFWLRQ7RGDWHWKHHIIHFW RIEUHQWX[LPDEYHGRWLQRQWKH
LPPXQHV\VWHPRISHGLDWULFSDWLHQWVDQGWKHH[WHQWRUGXUDWLRQ RILPPXQHG\VIXQFWLRQ
IROORZLQJWKHFRPSOHWLRQRIEUHQWX[LPDEYHGRWLQLVXQNQRZQ$SHG LDWULFSRSXODWLRQKDVD
UDSLGO\GHYHORSLQJLPPXQHV\VWHPFKDUDFWHUL]HGE\FRQWLQXDOH[S RVXUHWRQHRDQWLJHQVDQGD
ODUJHWK\PXVZKHUH7FHOOVHOHFWLRQLVDFWLYHO\HQJDJHG&' LVH[SUHVVHGRQPHGXODU\
FHOOVRIWKHWK\PXVKRZHYHUWKHUROHRI&'LQ7FHOOVHOHFWL RQLVFRQWURYHUVLDO
3UHFOLQLFDOGDWDVXJJHVWDSRWHQWLDOLPSDFWRIEUHQWX[LPDEYHGR WLQRQWK\PLFFHOO
SRSXODWLRQV$GGLWLRQDOO\\RXQJHUSDWLHQWVDUHPRUHOLNHO\WR KDYHLPPXQHVXSSUHVVLRQ
DIWHUFRPSOHWLRQRIFKHPRWKHUDS\LQFOXGLQJWKHORVVRISURWHFW LYHVHUXPDQWLERG\
FRQFHQWUDWLRQVDJDLQVWYDFFLQHV7KHUHLVDUHGXFWLRQLQYDFFL QHDQWLJHQVSHFLILFDQWLERG\
FRQFHQWUDWLRQVDIWHUFRPSOHWLRQRIFKHPRWKHUDS\
7KHH[WHQWDQGGXUDWLRQRILPPXQHG\VIXQFWLRQIROORZLQJWKHFRP SOHWLRQRIVWDQGDUGGRVH
FKHPRWKHUDS\ZLOOGHSHQGRQWKHDQWLQHRSODVWLFDJHQWXVHGDQGL WVGRVHLQWHQVLW\DQGFDQ
WKHUHIRUHYDU\ZLGHO\7KLVPD\LQIOXHQFHLPPXQLW\WRYDFFLQH DQWLJHQVDQGUHVSRQVHVWR
YDFFLQDWLRQ7RWDO%DQG7O\PSKRF\WHVXVXDOO\UHFRYHUIXOO\ TXDQWLWDWLYHO\DQG
IXQFWLRQDOO\PRQWKVDIWHUFRPSOHWLRQRIFKHPRWKHUDS\DOWKRXJK LQVRPHFDVHVUHFRYHU\
PD\WDNHXSWR\HDU 7KHUHLVDUHGXFWLRQRILPPXQRJOREXOLQO HYHOVDIWHUFRPSOHWLRQRI
FKHPRWKHUDS\SDUWLF XODUO\RI,J*OHYHOV1RUPDOL]DWLRQRILPP XQRJOREXOLQOHYHOVFDQ
WDNHXSWR\HDUDIWHUFRPSOHWLRQRIWUHDWPHQW$UHFHQWVWXG\ ORRNLQJDWLPPXQLW\WR
YDFFLQHVDWDPHGLDQWLPHRIPRQWKVDIWHUFRPSOHWLRQRIWUHDW PHQWIRUDFXWHOHXNHPLDLQ
%ULWLVKFKLOGUHQGHPRQVWUDWHGSURWHFWLYHDQWLERG\FRQFHQWUDWLRQ VIRUDOOSDWLHQWVWRWHWDQXV
WR+LEWRPHDVOHVWR 1HLVVHULDPHQLQJLWLGLV JURXS&PHQLQJRFRFFXV&
DQGWRDOOSROLRYLUXVVHURW \SHV7KHUHIRUHLQRUGHUWRD VVHVVWKHHIIHFWRI
EUHQWX[LPDEYHGRWLQRQSHGLDWULFLPPXQHIXQFWLRQWKHGXUDWLRQR IDQ\FKDQJHVWRWKHOHYHOV
RI 
ZLOOEHH[DPLQHGDWEDVHOLQHDQG
DQGPRQWKVÂ“PRQWKDIWHUWUHDWPHQWLVFRPSOHWHG
7RDGGUHVVVDIHW\FRQFHUQVUHJDUGLQJJURZWKDQGGHYHORSPHQWLQ FKLOGUHQWUHDWHGZLWK
EUHQWX[LPDEYHGRWLQ&HQWHUVIRU'LVHDVH&RQWURO&'&UHFRPPHQG HG:RUOG+HDOWKCCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 41Organization ( WHO)international growth charts for children aged ï€¼24 months (available at 
cdc.gov/growthcharts) and CDC growth charts in persons aged 2 to 19 years will be used.  
Clinical charts are available for boy s and for girls at 
cdc.gov/growthcharts/clinical_charts.htm .  A sexual maturity  scale such as the one 
developed b y Tanner is used to assess the ph ysical developmental stage of a patient .  This 
scale assigns a Tanne r stage of 1 (prepubertal) to 5 (adult) to girls based on breasts and 
pubic hair and to bo ys based on genitalia and pubic hair.
The multiagent chemotherap y regimens often employed as salvage therap y in patients with 
relapsed or refractory  HL or sAL CL carrysignificant toxicities .  Given the benefit observed 
with brentuximab vedotin monotherap y in thispopulation with aggressive disease, the 
manageable adverse event profile is notable.
2.   STUDY OBJECTIVES
2.1   Phase1 Primary Objectives
The primary  objectives in phase 1 are:
ï‚·To assess the safet y profile and determine the pediatric maximum tolerated dose 
and/or recommended phase 2 dose of brentuximab vedotin
ï‚·Toassess the pharmacokinetics of brentuximab vedotin
2.2   Phase1 Secondary Objectives
The secondary  objective s in phase 1 are:
ï‚·To determine the immunogenicity  of brentuximab vedotin
ï‚·To determine best overall response rate (complete remission, partial remission) with 
brentuximab vedotin
ï‚·To determine the time to progression, time to response, duration of response, and 
event-free, progression- free, and overall survival with brentuximab vedotin
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO  3KDVH([SORUDWRU\2EMHFWLYHV
7KHH[SORUDWRU\REMHFWLYHLQSKDVHLV
 3KDVH3ULPDU\2EMHFWLYHV
7KHSULPDU\REMHFWLYHLQSKDVHLV
 3KDVH6HFRQGDU\2EMHFWLYHV
7KHVHFRQGDU\REMHFWLYHVLQSKDVHDUH
ï‚·7RGHWHUPLQHWKHWLPHWRSURJUHVVLRQWLPHWRUHVSRQVHGXUDWLRQ RIUHVSRQVHDQG
HYHQWIUHHSURJUHVVLRQIUHHDQGRYHUDOOVXUYLYDOZLWKEUHQWX[ LPDEYHGRWLQ
ï‚·7RDVVHVVWKHSKDUPDFRNLQHWLFVDQGVDIHW\SURILOHRIEUHQWX[LPDE YHGRWLQ
ï‚·7RGHWHUPLQHWKHLPPXQRJHQLFLW\RIEUHQWX[LPDEYHGRWLQ
 3KDVH([SORUDWRU\2EMHFWLYHV
7KHH[SORUDWRU\REMHFWLYHLQSKDVHLV
 678'<(1'32,176
 3KDVH3ULPDU\(QGSRLQWV
7KHSULPDU\HQGSRLQWVLQSKDVHDUH
ï‚·$GYHUVHHYHQWV$(VVHULRXVDGYHUVHHYHQWV6$(VDVVHVVPHQW VRIFOLQLFDO
ODERUDWRU\YDOXHVDQGYLWDOVLJQVPHDVXUHPHQWV
ï‚·3ODVPDFRQFHQWUDWLRQVRIEUHQWX[LPDEYHGRWLQWRWDOWKHUDSHXWLF DQWLERG\DQG
00$(CCI
CCI
CCI
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO  3KDVH6HFRQGDU\(QGSRLQWV
7KHVHFRQGDU\HQGSRLQWVLQSKDVHDUH
ï‚·$QWLWKHUDSHXWLFDQWLERG\$7$WLWHUDQGQHXWUDOL]LQJ$7$WLWHU
ï‚·%HVWRYHUDOOUHVSRQVHUDWH&535DVGHWHUPLQHGE\DQLQGHSHQ GHQWUHYLHZIDFLOLW\
,5)XVLQJSRVLWURQHPLVVLRQWRPRJUDSK\3(7FRPSXWHGWRPRJUD SK\&7
PDJQHWLFUHVRQDQFHLPDJLQJ05,DQGFOLQLFDODVVHVVPHQWDFFRU GLQJWR
,QWHUQDWLRQDO:RUNLQJ*URXS,:*UHYLVHGUHVSRQVHFULWHULD
ï‚·7LPHWRSURJUHVVLRQ
ï‚·7LPHWRUHVSRQVH
ï‚·'XUDWLRQRIUHVSRQVH
ï‚·(YHQWIUHHVXUYLYDO
ï‚·3URJUHVVLRQIUHHVXUYLYDO
ï‚·2YHUDOOVXUYLYDO
 3KDVH([SORUDWRU\(QGSRLQWV
7KHH[SORUDWRU\HQGSRLQWVLQSKDVHDUH
 3KDVH3ULPDU\(QGSRLQWV
7KHSULPDU\HQGSRLQWLQSKDVHLV
ï‚·%HVWRYHUDOOUHVSRQVHUDWH&535DVGHWHUPLQHGE\DQ,5)XVLQ J3(7&705,
DQGFOLQLFDODVVHVVPHQWDFFRUGLQJWR,:*UHYLVHGUHVSRQVHFULWHU LDCCI
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO  3KDVH6HFRQGDU\(QGSRLQWV
7KHVHFRQGDU\HQGSRLQWVLQSKDVHDUH
ï‚·7LPHWRSURJUHVVLRQ
ï‚·7LPHWRUHVSRQVH
ï‚·'XUDWLRQRIUHVSRQVH
ï‚·(YHQWIUHHVXUYLYDO
ï‚·3URJUHVVLRQIUHHVXUYLYDO
ï‚·2YHUDOOVXUYLYDO
ï‚·$GYHUVHHYHQWVVHULRXVDGYHUVHHYHQWVDVVHVVPHQWVRIFOLQLFDO ODERUDWRU\YDOXHV
DQGYLWDOVLJQVPHDVXUHPHQWV
ï‚·3ODVPDFRQFHQWUDWLRQVRIEUHQWX[LPDEYHGRWLQWRWDOWKHUDSHXWLF DQWLERG\DQG
00$(
ï‚·$QWLWKHUDSHXWLFDQWLERG\$7$WLWHUDQGQHXWUDOL]LQJ$7$WLWHU
 3KDVH([SORUDWRU\(QGSRLQWV
7KHH[SORUDWRU\HQGSRLQWLQSKDVHLV
 678'<'(6,*1
 2YHUYLHZRI6WXG\'HVLJQ
7KLVLVDSKDVHRSHQODEHOVLQJOHDJHQWPXOWLFHQWHUGRVHH VFDODWLRQVWXG\RI
EUHQWX[LPDEYHGRWLQLQSHGLDWULFSDWLHQWVZLWKUHODSVHGRUUHIU DFWRU\V$/&/RU+/IRU
ZKLFKVWDQGDUGFXUDWLYHOLIHSURORQJLQJRUSDOOLDWLYHWUHDWP HQWGRHVQRWH[LVWRULVQRCCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 45longer effective .  The primary  objectives of the study  are to assessthe safety  and 
pharmacokinetics ,determine thepediatricMTDand/or RP2Dof brentuximab vedotin in 
pediatric patients , andevaluatethe antitumor activity  of brentuximab vedotin in eligible 
patients.
Approximately 42evaluable patients will be enrolled in this study .  In the phase 1 portion of 
the study, at least12patients with relapsed or refractory  CD30+ malignancies (including HL 
and sALCL) will be enrolled in 2 planned dose cohorts (3 to 6 patients per cohort) according 
to the standard 3 +3 dose escalation scheme .
Once the MTD and/or RP2D havebeen reached, patients will be enrolled by [CONTACT_452972] 2 study arms: relapsedor refractory  sALCL,or relapsedor refractory  HL.  A 
sufficient number of patients will be enrolled in the phase2 portion of the study to have at 
least 15evaluable patients with sAL CL (including patients treated at the RP2D during 
phase1), of whom at least 10patients are in first relapse, and at least 15evaluable patients 
with HL (including patients treated at RP2D during phase 1).
Brentuximab vedotin will be administered b y IVinfusion once every  21days.  Each 21-day 
treatment cy cle is composed of 1 day of study drug treatment, followed b y a monitoring
period of 20 days.  The starting dose in phase 1 will be 1.4mg/kg ,and escalation will 
proceed using a traditional 3 +3 design to a maximum dose of 1.8 mg/kg.
Overall response will be evaluated beginning after 2cycles of therapy .  Objective response 
over the course of the study  willbe assessed b y an IRFaccording to the IWGRevised 
Response Criteria for Malignant Ly mphoma.(1)  Patients, including those who achieve a CR, 
a PR, or stable disease ( SD), may receive brentuximab vedotin for up to 16cycles.  
Treatment with brentuximab vedotin beyond 16cyclesmay be permitted at the joint 
discretion of the spons or andthe investigator for those patients experiencing continued 
clinical benefit .  Following administration of the final dose of brentuximab vedotin , patients
will be monitored for adverse events for a minimum of 30days.  Patients will be followed 
for PFS and OSevery [ADDRESS_577613] patient.   Patients whoremain on treatme nt 
after Cycle16 will be followed according to the above schedule or until study  closure.
Study drug will be discontinued due to occurrence of unacceptable AE, progressive disease, 
patient withdrawal, or study  termination.  Patients may  discontinue therap y at any time.  
Additionally , those patients who experience a CR and are candidates for hematopo ieticstem 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577614] discontinue brentuximab vedotin prior to chemotherap y and 
transplant; these patients will be followed for survival anal ysesuntil study  closure.
AEs will be assessed, and laboratory  values, vital signs, and electrocardiograms (ECGs) will 
be obtained to evaluate the safet y and tolerability  of brentuximab vedotin .
Serial blood samples for determination of the plasma concentratio n of brentuximab vedotin , 
total therapeutic antibod y,and MMAE will be obtained during Cy cle1 and subsequent 
cycles at prespecified time points as described in the Schedule of Events (SOE) and in 
Section7.4.14.
Radiological evaluations , (CT scanormagnetic resonance imaging [MRI ], and PET as 
clinically indicated ),will be employ ed to assess the status of the patientâ€™s underly ing 
disease.  An evaluation of disease re sponse will be assessed by  [CONTACT_452973](1)evaluated at C ycles2, 4, 7, 10, 13, 
and [ADDRESS_577615] 
30evaluable patients (15 with sALCL and 15with HL) at RP2D, including the patients from 
the phase [ADDRESS_577616] dose of study  drug.
Patients who are withdrawn from treatment during C ycle1 for reasons other than dose 
limiting toxicities ( DLTs)will be replaced ; additional patients may be enrolled to ensure up 
to12evaluable patients in phase1.
4.3   Duration of Study
Patients who achieve a CR,a PR, or SD may receive brentuximab vedotin for up to 
16cycles, until they  experience disease progression.  Extended brentuximab vedotin
therapy, beyond 16cycles, may  be permitted at the joint discretion of the sponsor and 
investigator for those patien ts experiencing continued clinical benefit .
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577617] meet all of the following inclusion criteria for study  enrollment:
1.Male or female patients aged 2 to < 18years (5 to < 18years for patients with HL) .
2.Have a diagnosis of systemic anaplastic large -cell lymphoma,or Hodgkin ly mphoma
for which standard, curative, life -prolonging, or palliative treatment does not exist or 
is no longer effective .  (Patients diagnosed with any  relapsed or refractory  CD30+ 
hematological malignancy [eg, primary mediastinal B -cell lymphoma] may be 
included in phase 1 of the study .)
3.Patients with sALCLmust have documented anaplast ic lymphoma kinase (ALK) 
status.
4.Patients with HL  must be in their second or later relapse or have failed s ystemic 
chemotherap y either as induction therap y for advanced stage disease or salvage 
therapy, and beineligible for, refused, or previously received a stem cell transplant .
5.Patients with relapsed or refractory  sALCL must be bey ond first remission or 
refractory  to front-line chemotherap y.
6.Performance score â‰¥60 from L ansky Play Performance Scale if â‰¤16 years
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 487.Female patients who:
ï‚·Are surgically  sterile, OR
ï‚·If they are of childbearing potential, agree to practice 2effective methods of 
contraception, at the same time, from the time o f signing the informed consent 
through [ADDRESS_577618] dose of study drug, or
ï‚·Agree to practice true abstinence, when this is in line with the preferred and usual 
lifestyle of the subject. ( Periodic abstinence [eg, calendar, ovulation, 
symptothermal, postovulation methods ]and withdrawal ar e not acceptable 
methods of contraception. )
8.Male patients, even if surgically  sterilized (ie, status postvasectomy ), who:
ï‚·Agree to practice effective barrier contraception during the entire stud y treatment  
period and through 6monthsafter the last dose o f study drug, or
ï‚·Agree to practice true abstinence, when this is in line with the preferred and usual 
lifestyle of the subject. ( Periodic abstinence [eg, calendar, ovulation, 
symptothermal, postovulation methods for the female partner] and withdrawal 
are not acceptable methods of contraception.)
9.Voluntary  written consent (and institution- specific assent as appropriate based upon 
patient comprehension) must be given before performance of an y study-related 
procedure not part of standard medical care, with th e understanding that 
consent/assent may  be withdrawn b y the patient or patient guardian at an y time 
without prejudice to future medical care.
10.Suitable venous access for the study -required procedures.
11.Clinical laboratory  values as specified below within [ADDRESS_577619] dose of 
study drug:
ï‚·Absolute neutrophil count greaterthan or equal to 1,500/Î¼L .
ï‚·Platelet count greaterthan or equal to 75,000/Î¼L .
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 49ï‚·Serum bilirubin level less than or equal to 1.5 ï‚´upper limits of normal (ULN) or 
less than or equal to 3 ï‚´ULN for patients with an indirect hy perbilirubinemia 
due to Gilbertâ€™s disease.
ï‚·Serum creatinine less than or equal to 1.5 ï‚´ULN.
ï‚·Alanine aminotransferase (ALT or SGPT) and aspartate aminotransferase (AST 
or SGOT) less than or equal to 2.5 ï‚´ULN.  AST and AL T levels may be 
elevated up to 5 ï‚´ULN if their elevation can be reasonably  ascribed to the 
presence of metastatic disease in the liver.
12.Patients must have a radiographicall y or clinically evaluable tumor per the IWG
criteria.(1)
5.[ADDRESS_577620] fully  recovered from the acute toxic effects of all prior chemotherapy , 
immunotherapy , or radiotherapy  prior to entering this study .  Patients meeting an y of the 
following exclusion criteria are not to be enrolled in the study .  If a patient is positive for 
ANY of the exclusion criteria, the patient will not be eligible for the stud y.
1.Current diagnosis of primary  cutaneous AL CL (those with sAL CL are eligible).
2.Received an al logeneic stem cell transplant < 3monthsprior to first dose of study  
medication, or presence of poly merase chain reaction ( PCR)-detectable CMV in any  
post-allogeneic transplant patient . (Prior PCR positivity  that was successfully  treated 
is acceptable provided the baseline PCR result is negative prior to first dose of study  
drug.)
3.Receiving immunosuppressive therap y.
4.Receiving s ystemic therapy  for chronic graft -versus-host disease (topi[INVESTIGATOR_52201] y is 
allowed).
5. Previous treatment with any anti- CD30 antibody .
6.Therapeutic monoclonal antibody  use within the longer of 6 weeks or 5 plasma 
half-lives.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577621] 3 years. (The 
following are exempt from the 3- year limit:nonmelanoma skin cancer and cervical 
carcinoma in situ on biopsy  or a squamous intraepi[INVESTIGATOR_385779] .)
9.Known active cerebral/meningeal disease , including signs or s ymptoms of 
progressive multifocal leukoencephalopath y (PML)or any history of PML.
10.History of cirrhosis .
11.Active sy stemic viral, bacterial, or fungal infection requiring antimic robial, antiviral 
therapy or antifungal therapy within [ADDRESS_577622] dose of study  drug (routine 
antimicrobial proph ylaxis is acceptable) .
12.Concurrent therap y with other anti -neoplastic or experimental agents .
13.Systemic corticosteroid therap y <7days prior to first dose of study  medication .
14.Any serious underl ying medical condition that, in the opi[INVESTIGATOR_452945] , would impair the patientâ€™s abilityto receive or tolerate the planned 
treatment .
15.Known hy persensitivity  to recombinant proteins, murine proteins, or an y excipi[INVESTIGATOR_378228] .
16. Received nitrogen mustard agents, melphalan, or BCNU therap y within [ADDRESS_577623] study  dose.
17.Prior autologous hem atopoietic stem cell infusion ï€¼ 4weeks prior to first study  dose.
18.Grade2 or greaterunresolved toxicity  from prior antineoplastic therapy .
19.Received a nystrong or listed moderate inhibitor of CYP3A4 ï€¼ 2weeks prior to first 
study dose.  (Please refer to the Study  Manual for an example list of prohibi ted 
CYP3A4 inhibitors.)
20.Grade2 or greater peripheral neuropathy .
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577624] dose of study  drug.
22.Received local palliative radiation therap y ï€¼14days prior to the first dose of study  
medication.
23.Received radiation therapy to more than 25% of the bone marrow -containing spaces 
<84days prior to first dose of study  medication.
6.   STUDY DRUG
6.1   Study Drug Administration
Study drug will be administered only  to eligible patients under the supervision of the 
investigator or identified subinvestigator(s).
Infusion-related reactions may  occur during the infusion of brentuxi mab vedotin.  The 
infusion should be administered at a site properl y equipped and staffed to manage 
anaphylaxis should it occur.  The patient should be observed for [ADDRESS_577625] 1hour to allow 
administration of IV drugs if necessary.  All supportive measures consistent with optimal 
patient care will be given throughout the stud y according to institution alstandards. 
Medications for infusion- related reactions, such as epi[INVESTIGATOR_238], antihistamines, and 
corticosteroids, should be available for immediate use.
Patients who experience a Grade 1 or Grade 2 infusion -related reaction may receive 
subsequent brentuximab infusions with premedication consisting of acetaminophen (650 mg 
orally) and diphenhy dramine (25 â€“50 mg orally  or 10â€“25 mg IV) or according to institutional 
standards, administered 30 to 60minutes prior to each 30-minute brentuximab vedotin 
infusion. Premedication may  include acetaminop hen, an antihistamine, and a corticosteroid.
If a Grade3 or greater infusion-related reaction consistent with anaphy laxis occurs, 
immediately  and permanently  discontinue administration of brentuximab vedotin and 
administer appropriate medical therap yper institutional guidelines.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577626] be calculated in order to achieve a 30 -minute infusion period.  Study treatment will be 
administered through a dedicated IV line and cannot be mixed with other medications.
In the phase 1portion of the stu dy, the starting dose will be 1.4 mg/kg and escalation will 
proceed using a traditional 3 +3 design to a maximum dose of 1.8 mg/kg.  Dosing is based 
on patientsâ€™ weight according to the institutional standard; however, doses will be adjusted 
for patients who experience a â‰¥ 10% change in weight from the most recent dose 
calculation .  Actual weight will be used except for patients weighing greater than 100 kg; 
dose will be calculated based on [ADDRESS_577627] whole number of milligrams.
The dose for the phase 2 portion of the study will be the MTD and/or RP2D , as determined 
duringphase1.  Each 21-day treatment cy cle is composed of [ADDRESS_577628] discontinue brentuximab vedotin prior to initiating a conditioning regimen; 
these patients will be followed for survival anal yses until study closure.  Following 
administration of the final dose of brentuximab vedotin , patients will be followed for safety 
for a minimum of 30 days.
6.2   Definitions of Dose -Limiting Toxicity
Toxicity will be evaluated according to the National Cancer InstituteCommon Terminology  
Criteria for Adverse Events (NCICTCAE)version4.03, effective 14 June2010.(64)  These 
criteria are provided in the Study  Manual.  DLT will be defined as discussed in 
Sections6.2.2and 6.2.3.
6.2.[ADDRESS_577629] clinician will discuss and document the overall toxicity profile 
in detail before deciding whether to initiate cohort expansion, dose escalation, dose 
modification,and/or future proph ylaxis with colony -stimulating factors (CSFs) .
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 536.2.2   Nonhematologic Toxicity
For nonhematologic toxicities, DL T will be defined as any  CTCAE v. 4.03 Grade3 or 
greater toxicity except for:
ï‚·Grade3 fatigue
ï‚·Grade3 or 4 nausea and vomiting lasting less than 24 hours
ï‚·Grade3 nonhematologic laboratory  abnormalities that resolve to Grade 1 or 
baseline (if the patient entered the stud y with existing toxicity ) within 14 days
6.2.3   Hematologic Toxicity
DLT for hematologic toxicity  will be def ined as:
ï‚·Grade4 neutropenia lasting long er than 7days
ï‚·Grade3 febrile neutropenia requiring antibiotics
ï‚·Grade4 febrile neutropenia
ï‚·Grade4 platelet count (<25,000/ ÂµL) at any time
6.2.4   Phase1: Dose Modification for an Individual P atient Who Experiences DLT
Any patient experiencing DL T lasting 14 days or longer will be discontinued from the study.  
Dose modification for further treatments with brentuximab vedotin will only occur for 
individual patients who experience a protocol defined DLT of less than 14 daysâ€™duration, 
yet whom the site investigator and project clinician believe can safely  receive additional 
treatment .  Subsequent doses should be decr eased to the previous dose levelor to 0.9mg/kg 
for patients in the 1.4 -mg/kg cohort .
The DLT experience d by [CONTACT_452974]1 or baseline 
at the time of the next scheduled dose .  If toxicity  does not return to less than or equal to 
Grade1 or baseline within 14 days, the patient should be taken off stud y; every effort should 
be made to ensure thatearly termination procedures are followed.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 546.2.5   Phase1: Dose Elimination/Holding/Reduction for Patients Who Have Not 
Experienced a DLT
A scheduled dose of brentuximab vedotin may be held up to [ADDRESS_577630] not y et recovered from an adverse event (AE) before the 
next scheduled dose administration .  For patients withAEs that have returnedto baseline or 
Grade1 values, a held dose may  be administered up to [ADDRESS_577631] Grade 1.  If the dose is eliminated, and/or the tox icities have not re solved within 
14days,the patient should be taken off study ; every effort should be made to ensure that 
early termination procedures are followed.
6.2.6   Maximum Tolerated Dos e or Recommended Phase 2 Dose
ThepediatricMTD and/or RP2D will be the highest dose at which no more than [ADDRESS_577632] treatment cy cle.  The MTD 
and/or RP2D will be established without the use of colony stimulating factors ( CSFs)in 
Cycle 1.
6.3   Dose Escalation Rules
The dose intervals will follow the 3+3 traditional escalation rules, starting with the 
treatment of 3 patients at the 1.4-mg/kgdose:
ï‚·If 0 of 3patients experiences DLT, dose escalation will proceed to the 1.8 -mg/kg 
dose at which 3 patients will be enrolled.
ï‚·If 1 of 3patients experiences DLT, 3 additional patients will be enrolled at the 
1.4-mg/kg dose level.
ï‚·If no more than 1 of 6 patients experiences DLT, escalation will continue to the 
1.8-mg/kg dose level.
ï‚·If 0 or 1patient experiences DLT, 3additional patients will be enro lled at the 
1.8mg/kg dose level.
ï‚·If 2or more patients in either dose level experience DLT, dosing will s top, and the 
previous dose levelwill be considered the MTD.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 55oIf 2 or more DLTs are experienced at the 1.4 -mg/kg dose, the dose will be 
reduced to 0.9 mg/kg.
oIf 2 or more DLTs are experienced at the 1.8 -mg/kg dose, the previous dose
level (1.4 mg) is considered the MTD and RP2D.
Figure6-1is a diagrammatical representation of these rules.
Figure6-1   Dose Escalation Algorithm
Enter 3 additional
patients at
1.4 mg/kg dose
> 1 DLT in
6 patients1 DLT in
6 pat ientsEnter 3 patients
SGN -35 1.4 mg/kg
Enter 3 pat ients
1.8 mg/kg
Reduce dose
to 0.9 mg/kg
0 or 1 DLT
Enter 3 additional
patients at
1.8 mg/kg dose
0 or 1 DLT in 6 patients
MTD/RP2D=
1.8 mg/kg>1 DLT
MTD/RP2D =
1.4 mg/kg0 DLT 1 DLT 2-3 DLTs
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 56Table6-1   Planned Dose Levels
Dose Level Dose (mg/kg)
1 1.4
2 1.8
More conservative dose escal ation, evaluation of intermediate doses, and expansion of an existing dose level 
are all permissible following discussions between the sponsor and the investigators, if such measures are 
needed for patient safety or for a better understanding of the dose -related toxicity, exposure, or 
pharmacodynamics of brentuximab vedotin .
The starting dose of brentuximab vedotin will be approximately  80% of the adult MTD, 
equal to 1.4 mg/kg, given on Day 1 of a 21-day cycle.  Patients not receiving all doses of
brentuximab vedotin in Cycle1 for reasons other than DLTs ,will be replaced within the 
cohort;additional patients may  be enrolled to ensure up to12evaluable patients in phase 1.
6.4   Phase2Dose-Modification Guidelines
6.4.1   Criteria for Dose Modification*
The start of the next cy cle may be delayed for up to [ADDRESS_577633] 1 dose level (or 
to 0.9mg/kgif the patient is receiving the 1.4- mg/kgdose) if the patient has any  of the 
following:
ï‚·Brentuximab vedotin- related toxicity  that results in a delay  of more than 14 daysin 
the start of a subsequent cy cle of treatment because of lack of recovery  to the 
specified re -treatment criteria
ï‚·Grade4 thrombocytopenia (platelet count ï€¼25,000/ÂµL ) lasting more than 
7consecutive day s.
ï‚·Grade3 or greater nonhematologic toxicity attributed to brentuximab vedotin except 
for the following , whichdo not require dose reduction:
oGrade3 or greaternausea and/or emesis in the absence of optimal anti- emetic 
prophylaxis(Optimal anti emetic prophylaxis is defined as an anti emetic 
regimen that emplo ys both a 5-HT3 antagonist and a corticosteroid given in 
standard doses and according to standard schedules.)
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 57oGrade3 or greaterdiarrhea that occurs in the absence of optimal supportive 
therapy
oGrade3 fatigue
Brentuximab vedotin- related neuropathy  should be ma naged with a combination of dose 
delay and reduction to 1.2mg/kg(or to 0.9mg/kgif the patient is receiving the 1.4-mg/kg
dose).  For new or worsening Grade 2 or 3 neuropathy , dosing should be held for up to
21days until neuropathy  improves to â‰¤Grade1 and then restarted at 1.2mg/kg(or to 
0.9mg/kgif the patient is receiving the 1.4-mg/kgdose).  For Grade 4 peripheral 
neuropath y, brentuximab vedotin should be discontinued.
When a dose reduction of brentuximab vedotin is required, no re -escalation of dose will be 
permitted.*
6.4.[ADDRESS_577634] meet the following criteri a:
ï‚·ANC must be â‰¥1,000/ ÂµL
ï‚·Platelet count must be â‰¥75,000/ ÂµL
ï‚·For therap y to resume, toxicity  considered to be related to treatment with 
brentuximab vedotin must have resolved to ï‚£Grade1, to the patientâ€™s baseline 
values, or to a level considered acceptable b y the physician (eg, hy pophosphatemia 
that can be managed b y oral replacement) .
For the phase [ADDRESS_577635] been met.  Should the start of the next cy cle during phase 1 need to be 
delayed for more than 14daysbecause of incomplete recovery  from treatment-related 
toxicity, this will be considered a DLT and the patient should be discontinued from study .  If 
apatient recovered from a DLT in less than 14 days, the patient may  receive additional 
                                                
*The phase [ADDRESS_577636] 
received the RP2D in phase 1 of the study.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 58treatment with brentuximab vedotin ;the dose will be reduced by  [CONTACT_2669] 1 dose level (or to 
0.9 mg/kg for patients receiving the 1.4 -mg/kg dose) when treatment resumes.
6.4.[ADDRESS_577637] discontinue brentuximab vedotin prior to chemotherapy a nd transplant ; 
these patients will be followed for overall survival until study  closure.
Grade4 nonhematologic toxicities will in general require that treatment with brentuximab 
vedotinbe permanently  discontinued .  If, in the opi[INVESTIGATOR_452946], it is in the patientâ€™s best interest to continue treatment with brentuximab vedotin , 
then the dose of brentuximab vedotin should be reduced b y at least 1 dose level (or to 
0.9mg/kgif the patient is receiving the 1.4-mg/kg dose)after recovery  of the toxicity  or 
toxicities in question to Grade 1 or to baseline values.
A patientâ€™s treatment with study  drug may  also be discontinued for an y of the following 
reasons:
ï‚·Patient withdrawal .
ï‚·Stable disease or better and completed 16 treatment cycles (brentuximab vedotin ).
ï‚·The investigator or patient deems it in the patientâ€™s best interest to discontinue , 
including patients who experience a CR and are candidates for hematopo ietic stem 
cell transplantation .  The reason justify ing study treatment withdrawal must be 
documented in the CRF.
Patients will attend the end-oftreatment-visit 30days (ï‚±7days)after receiving their last 
dose of study  drug.
A patient may  be discontinued from the study  (during treatment cy cle or follow -up) for an y 
of the following reasons:
ï‚·Death
ï‚·Patient withdraws consent for further follow -up
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 59ï‚·Lost to follow -up
ï‚·Study termination by  [CONTACT_20555] (If the sponsor and/or the investigator should 
discover conditions arising during the stud y that indicate it should be terminated, an 
appropriate schedule for termination will be instituted.)
Patients who discontinue from study  treatment will remain on study  and followed for a 
minimum of 30days for safety unless they  withdraw consent .  All patients who receive at 
least 1dose of stud y drug will be followed PFS and OS every 12weeks for 12 months after 
the EOT visit. Thereafter, assessment for OS will continue every  6 months until the sooner 
of death or stud y closure.  Patients whoremain on treatment after Cy cle16 will be followed 
according to the above schedule or until study  closure.
6.5   Excluded Concomitant Medications and Procedures
The following medications and procedures are prohibited during the stud y:
ï‚·Radiation therap y for disease under stud y
ï‚·Any investigational agent other t han brentuximab vedotin , including agents that are 
commerciall y available for indications other than sAL CL or HL that are under 
investigation for the treatment of sAL CL or HL
ï‚·Any anticancer treatment with activity  against sALCL and HL other than 
brentuxima b vedotin
ï‚·Myeloid growth factors (eg, G -CSF, GM -CSF)(Cycle1 only)
ï‚·Any strong and listed moderate CYP3A4 inhibitors ( prohibited CYP3A4 inhibitors 
are listed in the Study  Manual).
In addition, the c oncomitant use of brentuximab vedotin and bleomy cin is con traindicated 
due to pulmonary  toxicity.
6.6   Permitted Concomitant Medications and Procedures
The use of intermittent corticosteroid treatment to manage h ypersensitivity reactions is 
allowed.  The use of platelet sand/or red blood cell supportive growth fac tors or transfusions 
when applicable is allowed .  Colony-stimulating factors may  not be used for any  patient in a 
prophylactic setting during the first treatment cy cle but can be administered thereafter as per 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 60ASCO guidelines or local institutional practic e if the patient has experienced complicated 
and/or prolonged neutropenia. However, any  patient who experiences a hematological DLT 
may not continue brentuximab vedotin treatment with concomitant CSFs , and CSFs may  not 
be used to meet eligibility  criteria.
6.[ADDRESS_577638] meet 1 of the following:
ï‚·Surgically sterile, OR
ï‚·If they are of childbearing potential, agree to practice 2effective methods of 
contraception from the time of signing of the ICFthrough 6monthsafter the last 
dose of study  drug, or
ï‚·Agree to pra ctice true abstinence, when this is in line with the preferred and usual 
lifestyle of the subject.  (Periodic abstinence [eg, calendar, ovulation, 
symptothermal, postovulation methods] and withdrawal are not acceptable 
methods of contraception.)
Male patie nts, even if surgically  sterile,must agree to 1 of the following:
ï‚·Practice effective barrier contraception during the entire study  treatment period 
and through [ADDRESS_577639] dose of stud y drug, or
ï‚·Agree to practice true abstinence, when this is in line with the preferred and usual 
lifestyle of the subject.  (Periodic abstinence [eg, calendar, ovulation, 
symptothermal, postovulation methods for the female partner] and withdrawal 
are not acceptable methods of contraception.).
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577640], 
and recorded in the eCRF.  Events that are greater than Grade 1 in severitywill result in 
dose delay, reduction ,or discontinuation .  Guidelines for brentuximab vedotin dose 
modification in the event of peripheral neuropathy are shown in Section 6.4.
6.8.2   Management of Progressive Multifocal Leukoencenphalopathy
Signs and s ymptoms of progressive multifocal leukoencephalopathy  (PML) may  include 
altered mental status; motor deficits, such as hemiparesis or ataxia; visu al disturbances; or 
higher cortical dy sfunction, such as dy sphasia or agnosia. See the IBfor further details.
If PML is suspected, hold further brentuximab vedotin dosing and undertake a diagnostic 
work-up that may  include (but is not li mited to):
ï‚·Neurologic examinations, as warranted
ï‚·Brain MRI: features suggestiv e of PML  include presence of uni focal or multifocal 
lesions, mainly  of the white matter, which are t ypi[INVESTIGATOR_452947]
ï‚·Polymerase chain reaction analysis: John Cunningham virus ( JCV)DNA detectable 
in cerebrospi[INVESTIGATOR_452948] a brain biops y
ï‚·Neurology  consultation
If PML is confirmed, treatment with brentuximab vedotin should be discontinued 
permanentl y.
6.8.3   Nausea and/or V omiting
Although this study  will not initially  employ prophylactic anti -emetics, there is no 
prohibition against their use in the management of a patient who develops nausea and/or 
vomiting.  As in the prophy lactic setting, [ADDRESS_577641].
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 626.8.4   Diarrhea
Prophylactic antidiarrheals (eg, loperamide) will not be used in this protocol; however, 
patients will be instructed to take antidiarrheal medications at phy sicianâ€™s discretion until 
they are diarrhea -free for at least 12 hou rs.  Fluid intake should be maintained to avoid 
dehydration.
6.9   Blinding and Unblinding
This is an open -label study .
6.10   Description of Investigational Agents
Brentuximab vedotinfor Injection is a sterile, preservative- free, white to off -white 
lyophilized cake for reconstitution for I V administration .  Brentuximab vedotin for Injection 
is supplied in single- use, Type1 borosilicate glass vials with FluroTecÂ®-coated buty l rubber 
stoppers and aluminum seals.  Each vial of the product contains brentuximab ve dotin, 
trehalose, sodium citrate, and poly sorbate80.  The lyophilized product, after reconstitution 
with 10.5 mL sterile Water for Injection, [LOCATION_002] Pharmacopeia ( USP), yields 11mL 
of brentuximab vedotin solution (5 mg/mL).
6.[ADDRESS_577642] be reconstituted with the appropriate amount of Sterile Water for 
Injection, USP (see Pharmacy  Manual for details).  GENTLY swirl the vial until the 
contents are completel y dissolved.  The vial must not be shaken or vigorously swirled ; 
excess agitation may  cause aggregate formation .  Visually inspect the reconstituted drug 
product for an y particulate matter and discoloration.
The appropriate amount of reconstituted stud y treatment will be withdrawn from the vial(s) 
and diluted in a 50 -to 100-mL infusion bag containing 0.9% Sodium Chloride I njection, 
USP.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577643] not be shaken ; 
excess agitat ion may cause aggregate formation .  Prior to administration, the reconstituted 
and diluted drug product should be inspected visually  for any particulate matter and 
discoloration .
The formulation contains no preservative and is intended for single use only ;infusion 
solutions should be prepared and transferred using aseptic technique in a biosafet y hood.
Refer to the Directions for Use/ Pharmacy  Manual for more specific instructions on 
reconstitution and use.
6.[ADDRESS_577644] ,and the vial and carton will be labeled to meet
country-specific regulatory  requirements.
6.13   Storage, Handling, and Accountability
Vials of brentuximab vedotin for Injection are to be stored at 2ÂºC to 8ÂºC in a secure location 
(eg,locked room) accessible only  to the pharmacist, the investigator, or a duly  designated 
person.
Study treatment does not contain preservatives; therefore, opened and recons tituted vials of 
study treatment must be used on the same day  when stored under refrigeration at 2oC to 8oC.  
Reconstituted study  treatment should not be stored at room temperature.  It is recommended 
that study  treatment vials and solutions be protected from direct sunlight until the time of 
use.  Reconstituted vials must not be shaken .
Drug accountability  instructions are provided in the Pharmacy  Manual.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577645] of investigators is available in the sponsorâ€™s 
investigator database.
7.2   Arrangements for Recruitment of Patients
Recruitment and enrollment strategies for this study  may include recruitment from the
investigatorâ€™s local practice or referrals from other phy sicians.  If advertisements become 
part of the recruitment strategy , they will be reviewed by  [CONTACT_21980] 
(IRB)/independent ethics committee (IEC) .  It is not envisioned that pris oners (or other 
populations that might be subject to coercion or exploitation) will be enrolled into this study .
7.[ADDRESS_577646] 3+3 dose escalation scheme in the 
phase1 portion of the study.  Two ascending dose cohorts are planned (3 to 6 patients per 
cohort).
Once the MTD and/or RP2D has been reached, patients will be enrolled by  [CONTACT_452959]2 study armsby [CONTACT_637] :relapsedor refractory  sALCL or relapsed or 
refractory HL.
7.4   Study Procedures
Refer to the Schedule of Events for timing of assessments .  Additional details are provided 
as necessary  in the sections that follow.
7.4.1   Informed Consent
Each patient (or patientâ€™s legal guardian ) must provide written informed consent before an y 
study-required procedures are conducted, unless those procedures are performed as part of 
the patientâ€™s standard care .
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 657.4.2   Patient Demographics
The date of birth, race, ethnicity , and sex of the patient are to be recorded during screening.
7.4.3   Medical History
During the Screening period, a complete medical history  will be compi[INVESTIGATOR_194435].  
The history  will emphasize the background and progress of the patientâ€™s malignancy  and 
include a d escription of prior therapi[INVESTIGATOR_231910].  In addition, concomitant medications will be 
recorded as specified in Section 7.4.8.
7.4.4   Physical Examination
A complete ph ysical examination â€”including assessments of gener al appearance, skin, head 
(eyes, ears, nose, and throat), neck, lungs, heart, abdomen, back, l ymph nodes, extremities, 
and neurological s ystemâ€”will be completed at the times specified in the Schedule of 
Events.
7.4.5   Patient Height and Weight
Height and weight will be obtainedduring screening (within [ADDRESS_577647] dose of 
brentuximab vedotin )and on Day 1 of each 21- day cycle.
7.4.6   Vital Signs
Vital signs measurements include supi[INVESTIGATOR_050] (after 3-5 minutes in this position) and standing 
(after 3-5minutes in this position) measurements of diastolic and sy stolic blood pressure, 
heart rate, and oral temperature.   
7.4.[ADDRESS_577648] should be performed 
per institutional guidelines; any samples collected during C ycle 17 and beyond should not be 
sent to the central laboratory ,and data should not be captured in the eCRF. Additional 
pregnancy tests may  also be repeated during the study  if requested b y an IEC/IRB or if 
required b y local regulations.  
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 667.4.8   Concomitan t Medications and Procedures
Medications used by [CONTACT_452975] b y the patient will be 
recorded in the electronic case report form ( eCRF)from signing of informed consent form
through 30days after the last dose of brentux imab vedotin .  See Sections 6.5and6.6for a 
list of medications and therapi[INVESTIGATOR_452949] .
7.4.[ADDRESS_577649] dose of study  drug.
Procedures for completion of the enrollment information are described in the Study  Manual.
7.4.11   Electrocardiogram
A 12-lead electrocardiogram ( ECG)will be obtained at screening and at Cycle 1, Day1 
(baseline), and at EOT.  If the screening ECG was obtained within the [ADDRESS_577650] be collected as specified in the Schedule of Events .  
During C ycle 17 and beyond, hematology  and serum chemistry  tests should be performed 
per institutional guidelines at the local laboratory ; samples should not be sent to the central 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 67laboratory ,and data should not be captured in the eCRF, unless the laboratory  result is 
assessed to contribute to an AE.
Handling and shipment of clinical laboratory  samples will be outlined in the Study  Manual.  
Clinical laboratory  evaluations will be performed as outlined:
Clinical Chemistry and Hematology
Blood samples for anal ysis of the following clinical chemistry  and hematological parameters 
will be obtained as specified in the Schedule of Events .
Hematology
ï‚·Hemoglobin
ï‚·Hematocrit
ï‚·Platelet (count)ï‚·Total WBC count
ï‚·Differential WBC count
Machine counts are acceptable.
Serum Chemistry
ï‚·Blood urea nitrogen
ï‚·Creatinine
ï‚·Urate
ï‚·Bilirubin (total , 
direct, indirect )
ï‚·Lactate 
dehydrogenase
ï‚·Gamma glutamy l 
transferase
ï‚·Phosphorusï‚·Albumin
ï‚·Alkaline phosphatase
ï‚·Aspartate 
aminotransferase 
(AST)
ï‚·Alanine 
aminotransferase 
(ALT)
ï‚·Fasting glucose
ï‚·Sodium
ï‚·Potassiumï‚·Calcium
ï‚·Chloride
ï‚·Carbon dioxide
ï‚·Magnesium
7.4.13   Disease Assessment
[IP_ADDRESS]   Development Assessment and Tanner Scale
Development assessment and Tanner Scale areto be performed as specifi ed in the Schedule 
of Events .  The development assessment will include weight-for-age and stature -for-age 
percentiles; see Section 14.3for Tanner Scale information.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential [IP_ADDRESS]   Imaging
Patients will undergo CT with contrast as appropriate, MRI , and PETto monitor and assess 
disease progression .  CT scans will be used to eval uate the chest only ; MRI will be used to 
evaluatetheneck, abdomen, and pelvis.  PET, CT, and MRI scans will be performed as 
specified in the Schedule of Events.  Objective response over the course of the studywill be 
assessed b y an IRFaccording to the IWGRevised Response Criteria for Malignant 
Lymphoma.(1)  Contrast CT scans of the chest will be obtained at screeni ng.   Anatomical 
measurements (summed across target lesions) will be collected at baseline and each 
subsequent evaluation using an imaging modality  consistent with that used at screening .  
Objective assessments will be performed at each time point as descr ibed in the Schedule of 
Events.  When possible, the same qualified ph ysician will interpret results to reduce 
variability .  Radiographic images will be maintained at the site, and test results and 
physicianâ€™s findings will be filed in patient source documents .
[IP_ADDRESS]   B Symptom Assessments
B symptom assessments, including fever, night sweats, and weight loss, will be evaluated at 
the time points indicated in the Schedule of Events .
7.4.14   Pharmacokinetic Measurements
Blood samples for the determination of serum brentuximab vedotin concentrations will be 
collected at the following time points:
ï‚·All Cycles: Day1:  within 4 hoursbefore the start of the brentuximab vedotin 
infusion and 5 minutes (Â±1 minute)after the end of the brentuximab vedotin infusion
ï‚·Cycles 1and 8:
oDay2: 24hours (ï‚±4hours) from the start of the Day 1 brentuximab vedotin 
infusion
oDay3: 48hours (ï‚±4hours) from the start of the Day 1 brentuximab vedot in
infusion
oDay5: 96hours (ï‚±24hours) from the start of the Day 1 brentuximab vedotin
infusion
oDay14: 312hours (ï‚±48hours) from the start of the Day 1 brentuximab 
vedotininfusion
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO ï‚·&\FOH
o'D\SKDVHRQO\KRXUV ï‚±KRXUVIURPWKHVWDUWRIWKH'D\
EUHQWX[LPDEYHGRWLQLQIXVLRQ
o'D\KRXUV ï‚±KRXUVIURPWKHVWDUWRIWKH'D\EUHQWX[LPDEYHGRWLQ
LQIXVLRQ
o'D\KRXUV ï‚±KRXUVIURPWKHVWDUWRIWKH'D\EUHQWX[LPDEYHGRWLQ
LQIXVLRQ
6HUXPFRQFHQWUDWLRQVRIEUHQWX[LPDEYHGRWLQWRWDOWKHUDSHXWLF DQWLERG\DQG00$(ZLOO
EHGHWHUPLQHGXVLQJYDOLGDWHGDVVD\V
'HWDLOVUHJDUGLQJWKHKDQGOLQJSURFHVVLQJDQGVKLSSLQJRI3. VDPSOHVFDQEHIRXQGLQWKH
6WXG\0DQXDO
 3KDUPDFRG\QDPLF0HDVXUHPHQWV

 ,PPXQRJHQLFLW\
%ORRGVDPSOHVZLOOEHFROOHFWHGDVVSHFLILHGLQWKH 6FKHGXOHRI(YHQWV WRHYDOXDWHVHUXP
$7$VDQGQHXWUDOL]LQJ$7$V2QWKHGD\VRIGRVHDGPLQLVWUDWLRQ WKHEORRGVDPSOHVIRU
$7$DQGQHXWUDOL]LQJ$7$DVVHVVPHQWPXVWEHFROOHFWHGEHIRUHWK HEUHQWX[LPDEYHGRWLQCCI
CCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577651] be permanently  discontinued for patients meet ingany ofthe following 
criteria:
ï‚·Completed 16 cycles of brentuximab vedotin therapy(unless extended treatment is 
warranted due to clinical benefit) .
ï‚·The investigator or patient, or patientâ€™s legal guardian deems it is in the patientâ€™s best 
interest to discontinue .  (The reason justify ing study treatment withdrawal must be 
documented in the eCRF.)
ï‚·Progressive disease .
Treatment with study  drug may  also be discontinued for an y of the following reasons:
ï‚·Adverse event
ï‚·Protocol violation
ï‚·Initiation of hematopoietic stem cell or bone marrow transplant
ï‚·Study terminated by  [CONTACT_452976] (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 71ï‚·Withdrawal of consent by[CONTACT_452977]â€™s guardian
ï‚·Lost to follow -up
ï‚·Other.
Oncestudy drug has been discontinued, all study  procedures outlined for the EOT visit will 
be completed as specified in the Schedule of Events .  The primary  reason for study  drug 
discontinuation will be recorded on the eCRF.
Patients who are withdrawn from treatment during C ycle1 for reasons other than DLT will 
be replaced; additional patients may  be enrolled to ensure at least12 evaluable patients in
phase1.
7.8   Withdrawal of Patients F rom Study
A patient may  be withdrawn from the stud y for any of the following reasons:
ï‚·Lost to follow -up
ï‚·Study terminated by  [CONTACT_3211]
ï‚·Withdrawalof consent by [CONTACT_452978]
ï‚·Death
ï‚·Other
The consequence of study withdrawal is that no new information will be collected from the 
withdrawn patient and added to the existing data or any  database.
7.9   Study Compliance
Study drug will be administered or dispensed onl y to eligible patients under the supervision 
of the investigator or identified subinvestigator(s).  The appropriate stud y personnel will 
maintain records of study drug receipt and dispensing.
7.10   Posttreatment Follow -up Assess ments
Patients who stop treatment for an y reason other than progressive disease (PD) or the start of 
subsequent anticancer therap ywill continue to have follow -up visitsto determine time to 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577652] patient.   Patients who remain on 
treatment after Cy cle 16 will be followed according to the above schedule or until study  
closure.
Survivor information may be collected b y methods that include, but are not limited to, 
telephone, e -mail, mail, or retrieved from online or other databases (eg, social securit y 
indexes).  In addition, information pertaining to the start of another anticancer therap y will 
be collected.
See the Schedule of Events for appropriate assessments during follow-up.
NOTE:  Related SAEs must be reported to the Millennium Department of 
Pharmacovigilance or designee.  This includes deaths that the i nvestigator considers 
related to study drug that occur during the posttreatment follow -up.  Refer to Section 9
for details regarding definitions, documentation, and reporting of SAEs.
8.   STATISTICAL AND QUAN TITATIVE ANALYSES
8.1   Statistical Methods
Statistical analy ses will be primaril y descriptive and graphic al in nature .  No formal 
statistical hy pothesis testing will be performed .  A formal statistical anal ysis plan will be 
developed and finalized before database lock.
8.1.1   Determination of Sample Size
Approximately 42evaluable patients will be enrolled in th is study.  In the phase 1 portion of 
the study, at least12patients with relapsed or refractory  CD30+ malignancies will be 
enrolled in 2 planned dose cohorts (3-6 patients per cohort), according to the standard 3 +3 
dose escalation scheme.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 73Once the MTD and/or RP2D havebeen reached, patients will be enrolled by [CONTACT_452959] 2study arms:relapsedor refractory  sALCL or relapsed or refractory  HL.  A
sufficient number of patients will be enrolled in the phase2 portion of the study to have at 
least 15evaluable patients with sALCL (including patients treated at the RP2D during 
phase1), of whom at least [ADDRESS_577653] 15evaluable patients 
with HL (including patients treated at the RP2D during phase 1).
The sample size is not based on statistical consideration .  Based on the exact binomial 
confidence interval calculation, 10responses observed out of the 15 evaluable patients
(overall response rate of 66.7%) will provide 95% confidence interval (38%, 88%) .
8.1.2   Randomization and Stratification
In phase1, patients will be enrolled in successive dose cohorts .  No randomization is 
planned for either phase 1 or phase 2 of this study.
8.1.3   Populations for Analysis
The populations used for anal ysis will include the followi ng:
ï‚·Safety population:  Patients who receive at least 1 dose of study  drug will be used for 
all safety analyses , as well as efficacy analyses.
ï‚·PK population: Patients with sufficient dosing and PK data to reliabl y estimate PK 
parameters will be used for P K analyses.
ï‚·Immune reconstitution population: Patients with sufficient dosing and sufficient 
immune reconstitution blood sampling to allow for immune reconstitution evaluation 
will be included in the immune reconstitution population.
ï‚·Response -evaluable po pulation:  Patients who receive at least [ADDRESS_577654] measurable disease at baseline, and 1 postbaseline disease assessment will be 
used for analy ses of disease response and duration of response.
ï‚·The DLT- evaluable population:  P atients who ei ther experience DLT during phase1 
or receive all scheduled doses and complete all study  procedures in phase 1 without 
DLT.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO  3URFHGXUHVIRU+DQGOLQJ0LVVLQJ8QXVHGDQG6SXULRXV' DWD
$OODYDLODEOHHIILFDF\DQGVDIHW\GDWDZLOOEHLQFOXGHGLQGDWD OLVWLQJVDQGWDEXODWLRQV1R
LPSXWDWLRQRIYDOXHVIRUPLVVLQJGDWDZLOOEHSHUIRUPHG7KHU HOHYDQFHRIPLVVLQJVDPSOH
GDWDZLOOEHDVVHVVHG
'DWDWKDWDUHSRWHQWLDOO\VSXULRXVRUHUURQHRXVZLOOEHH[DPLQH GDFFRUGLQJWRVWDQGDUGGDWD
PDQDJHPHQWRSHUDWLQJSURFHGXUHV
 'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV
'HPRJUDSKLFDQGEDVHOLQHFKDUDFWHULVWLFVZLOOEHVX[COMPANY_003]UL]HGLQ FOXGLQJVH[DJHUDFH
ZHLJKWKHLJKW ERG\VXUIDFHDUHD SULPDU\GLDJQRVLVDQGRWKHUS DUDPHWHUVDVDSSURSULDWH
1RLQIHUHQWLDOVWDWLVWLFVZLOOEHFDUULHGRXW
 (IILFDF\$QDO\VLV
7KHEHVWRYHUDOOUHVSRQVHUDWH&5UDWH35UDWHWLPHWRSURJU HVVLRQWLPHWRUHVSRQVHDQG
GXUDWLRQRIUHVSRQVHZLOOEHDQDO\]HG7KHVLGHGH[DFWEL QRPLDOFRQILGHQFHLQWHUYDO
RQWKHSHUFHQWDJHRISDWLHQWVIDOOLQJLQWRHDFKUHVSRQVHFDWHJR U\ZLOOEHHVWDEOLVKHG
'XUDWLRQRIUHVSRQVH'25WLPHWRUHVSRQVHWLPHWRSURJUHVVL RQ773()63)6DQG
26ZLOOEHDQDO\]HGXVLQJWKH.DSODQ0HLHUPHWKRG7KHWKWK PHGLDQDQGWK
SHUFHQWLOHVLIHVWLPDEOHZLWKDVVRFLDWHGVLGHGFRQILGHQF HLQWHUYDOZLOOEHSURYLGHG
 3KDUPDFRNLQHWLFV3KDUPDFRG\QDPLFV
 3KDUPDFRNLQHWLFDQG,PPXQRJHQLFLW\$QDO\VLV'HVFULSWLYHVWDWLVWLFVHJQXPEHURISDWLHQWVDULWKPHWLFPHDQ JHRPHWULFPHDQVWDQGDUG
GHYLDWLRQPHGLDQSHUFHQWDJHRIFRHIILFLHQWRIYDULDWLRQPLQL PXPDQGPD[LPXPZLOOEH
XVHGWRVX[COMPANY_003]UL]H3.SDUDPHWHUVRIEUHQWX[LPDEYHGRWLQWRWDOW KHUDSHXWLFDQWLERG\DQG
00$(IRUHDFKFRKRUW,PPXQRJHQLFLW\SDUDPHWHUV$7$WLWHUDQG QHXWUDOL]LQJ$7$WLWHU
ZLOOEHVX[COMPANY_003]UL]HGXVLQJGHVFULSWLYHVWDWLVWLFV,QGLYLGXDODQ GPHDQSODVPDFRQFHQWUDWLRQ
GDWDZLOOEHSORWWHGRYHUWLPH'HVFULSWLYHVWDWLVWLFVZLOOEH SUHVHQWHGIRUVHUXP3.
SDUDPHWHUV

CCI
CCI
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO  6DIHW\$QDO\VLV
$OLVWLQJRI'/7VIRUHDFKGRVHOHYHOZLOOEHSURYLGHG6DIHW\ ZLOOEHHYDOXDWHGE\WKH
LQFLGHQFHRI$(VVHYHULW\DQGW\SHRI$(VDQGE\FKDQJHVIURP EDVHOLQHLQWKHSDWLHQWÂ¶V
YLWDOVLJQVQHXURWR[LFLW\DVVHVVPHQW(&*VDQGFOLQLFDOODERU DWRU\UHVXOWVXVLQJWKHVDIHW\
SRSXODWLRQ([SRVXUHWRVWXG\GUXJDQGUHDVRQVIRUGLVFRQWLQXD WLRQZLOOEHWDEXODWHG
7UHDWPHQWHPHUJHQW$(VWKDWRFFXUDIWHUDGPLQLVWUDWLRQRIWKHI LUVWGRVHRIVWXG\GUXJDQG
WKURXJKGD\VDIWHUWKHODVWGRVHRIVWXG\GUXJZLOOEHWDEXOD WHG$(VZLOOEHWDEXODWHG
DFFRUGLQJWRWKH0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV 0HG'5$DQGZLOOLQFOXGH
WKHIROORZLQJFDWHJRULHV
ï‚·7UHDWPHQWHPHUJHQW$(V
ï‚·6WXG\GUXJUHODWHGWUHDWPHQWHPHUJHQW$(V
ï‚·*UDGHRUKLJKHUWUHDWPHQWHPHUJHQW$(V
ï‚·*UDGHRUKLJKHU VWXG\GUXJ UHODWHGWUHDWPHQWHPHUJHQW$(V
ï‚·7KHPRVWFRPPRQO\UHSRUWHGWUHDWPHQWHPHUJHQW$(VLHWKRVHHY HQWVUHSRUWHGIRU
ï‚³RIDOOSDWLHQWV
ï‚·6$(V
$OLVWLQJRIWUHDWPHQWHPHUJHQW$(VUHVXOWLQJLQVWXG\GUXJGLV FRQWLQXDWLRQZLOOEH
SURYLGHG7KHLQGLYLGXDOSDWLHQWÂ¶VLQIRUPDWLRQRQWKH'/7VZLO ODOVREHSUHVHQWHGLQD
OLVWLQJ
'HVFULSWLYHVWDWLVWLFVIRUWKHDFWXDOYDOXHVRIFOLQLFDOODERUD WRU\SDUDPHWHUVDQGRUFKDQJH
IURPEDVHOLQHLQFOLQLFDOODERUDWRU\SDUDPHWHUVZLOOEHSUHVHQ WHGIRUDOOVFKHGXOHG
PHDVXUHPHQWVRYHUWLPH0HDQODERUDWRU\YDOXHVRYHUWLPHZLOO EHSORWWHGIRUNH\
ODERUDWRU\SDUDPHWHUV
'HVFULSWLYHVWDWLVWLFVIRUWKHDFWXDOYDOXHVDQGRUWKHFKDQJH VIURPEDVHOLQHRIYLWDOVLJQV
DQGZHLJKWRYHUWLPHZLOOEHWDEXODWHGE\VFKHGXOHGWLPHSRLQWCCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577655] postbaseline values, may  be used 
to understand the brentuximab vedotin safety profile.
All concomitant medications collected from screening through the stud y period will be 
classified to preferred terms according to the World Health Organization (WHO) drug 
dictionary .
Additional safet y analyses may be performed to most clearl y enumerate rates of toxicities 
and to further define the safet y profile of brentuximab vedotin .
8.1.9   Electrocardiogram Analysis
ECG intervals (QT and corrected QT intervals [QTcF], PR, QRS, and ventricular rate) will 
be summarized at each scheduled time point, along with mean change from baseline to 
posttreatment time point.
8.1.[ADDRESS_577656] who has 
signed informed consent to participate in a stud y but before administration of an y study 
medication; it does not necessarily  have to have a causal relationship with study  
participation.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 779.1.2   Adverse Event Definition
Adverse event (AE) means any  untoward medical occurrence in a patient or subject 
administered a pharmaceutical product; the untoward medical occurrence does not 
necessarily  have a causal relationship with this treatment.  An AE can therefore be an y 
unfavorable and unintended sign (including an abnormal laboratory  finding), sy mptom, or 
disease temporall y associated with the use of a medicinal (investigational) product whether 
or not it is related to the medicinal product .  This includes any  newly occurring event, or a 
previous condition that has increased in severity  or frequency  since the administration of 
study drug.
An abnormal laboratory  value will not be assessed as an AE u nless that value leads to 
discontinuation or delay  in treatment, dose modification, therapeutic intervention, or is 
considered b y the investigator to be a clinically significant change from baseline .
9.1.3   Serious Adverse Event Definition
Serious AE (SAE) me ans any untoward medical occurrence that at any  dose:
ï‚·Results in death.
ï‚·Is life-threatening (refers to an AE in which the patient was at risk of death at the 
time of the event .  It does not refer to an event which hypotheticall y might have 
caused death if it were more severe).
ï‚·Requires inpatient hospi[INVESTIGATOR_1324]
(see clarification in the following paragraph on planned hospi[INVESTIGATOR_602]).
ï‚·Results in persistent or significant dis ability or incapacity.  (Disability  is defined 
as a substantial disruption of a personâ€™s ability  to conduct normal life functions).
ï‚·Is a congenital anomaly/birth defect .
ï‚·Is a medically important event .  This refers to an AE that may  not result in death, 
beimmediately  life threatening, or require hospi[INVESTIGATOR_059], but may  be considered 
serious when, based on appropriate medical judgment, may  jeopardize the patient, 
require medical or surgical intervention to prevent [ADDRESS_577657] of an infectious agent .  
Examples of such medical events include allergic bronchospasm requiring intensive 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 78treatment in an emergency room or at home, blood dy scrasias or convulsions that do 
not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or 
drug abuse; an y organism, virus, or infectious particle (eg, prion protein transmitting 
transmissible spongiform encephalopath y), pathogenic or nonpathogenic, is 
considered an infectious age nt.
In this stud y, intensity for each AE, including an y lab abnormality , will be determined using 
the NCI CTCAE version4.03,effective 14 June2010.(64)  Clarification should be made 
between a nSAE and an AE that is considered to be severe (Grade 3or 4), because the terms 
serious and severe are NOT sy nonymous.  The general term severeis often used to describe 
the intensity  (severity) of a specific event; the event itself, however, may be of relatively 
minor medical significance (such as a Grade 3 headache).  This is NOT the same as serious , 
which is based on patient/event outcome or action criteria described previously , and is 
usually associated with events that pose a threat to a patientâ€™s life or ability  to function .  A 
severe AE (Grade 3 or 4) does not necessarily  need to be considered serious.  For example, a 
white blood cell count of 1000/ ÂµLto less than 2000/ ÂµLis considered Grade 3 (severe) but 
may not be considered to be an SAE .  Seriousness (not intensity ) serves as a guide for 
defining reg ulatory reporting obligations.
9.2   Procedures for Recording and Reporting Adverse Events and Serious 
AdverseEvents
All AEs spontaneously  reported by  [CONTACT_5363]/or in response to an open question from 
study personnel or revealed by  [CONTACT_4171], phy sical examination, or other diagnostic 
procedures will be recorded on the appropriate page of the eCRF (see Section 9.3for the 
period of observation) .  Any clinically  relevant deterioration in laboratory assessmen ts or 
other clinical finding is considered an AE.  When possible, signs and s ymptoms indicating a 
common underly ing pathology  should be noted as 1 comprehensive event.
Regardless of causalit y,SAEs and serious pretreatment events (as defined in Section 9.1) 
must be reported (see Section 9.3for the period of observation) b y the investigator to the 
Millennium Department of Pharmacovigilance or designee (contact [CONTACT_452979]).  This should be done by [CONTACT_51260] 24hoursafter becoming aware 
of the event .  The SAE Form, created specificall y by [CONTACT_20555], will be provided to each 
clinical study  site.  A sample of the SAE Form may  be found in t he Study Manual.  
Follow-up information on the SAE or serious pretreatment event may  be requested by  
[CONTACT_20555] .  SAE report information must be consistent with the data provided on the 
eCRF.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 6$(5HSRUWLQJ&RQWDFW,QIRUPDWLRQ
$OO2WKHU&RXQWULHV5HVWRI:RUOG
3ODQQHGKRVSLWDODGPLVVLRQVRUVXUJLFDOSURFHGXUHVIRUDQLOOQH VVRUGLVHDVHWKDWH[LVWHG
EHIRUHWKHSDWLHQWZDVHQUROOHGLQWKHWULDODUHQRWWREHFRQV LGHUHG$(VXQOHVVWKHFRQGLWLRQ
GHWHULRUDWHGLQDQXQH[SHFWHGPDQQHUGXULQJWKHWULDOHJVXUJ HU\ZDVSHUIRUPHGHDUOLHURU
ODWHUWKDQSODQQHG
)RUERWKVHULRXVDQGQRQVHULRXV$(VWKHLQYHVWLJDWRUPXVWGHWH UPLQHERWKWKHLQWHQVLW\RI
WKHHYHQWDQGWKHUHODWLRQVKLSRIWKHHYHQWWRVWXG\GUXJDGPLQ LVWUDWLRQ)RUVHULRXV
SUHWUHDWPHQWHYHQWVWKHLQYHVWLJDWRUPXVWGHWHUPLQHERWKWKHL QWHQVLW\RIWKHHYHQWDQGWKH
UHODWLRQVKLSRIWKHHY HQWWRVWXG\SURFHGXUHV
,QWHQVLW\IRUHDFK$(LQFOXGLQJDQ\ODEDEQRUPDOLW\ZLOOEHG HWHUPLQHGXVLQJWKH
1&,&7&$(YHUVLRQ HIIHFWLYH-XQH 7KHFULWHULDDUHSURYLGHGLQWKH6WXG\
0DQXDO
5HODWLRQVKLS WRVWXG\GUXJDGPLQLVWUDWLRQZLOOEHGHWHUPLQHGE\WKHLQYHVWLJD WRUUHVSRQGLQJ
\HVRUQRWRWKLVTXHVWLRQ,VWKHUHDUHDVRQDEOHSRVVLELOLW\ WKDWWKH$(LVDVVRFLDWHGZLWKWKH
VWXG\GUXJ"
 0RQLWRULQJRI$GYHUVH(YHQWVDQG3HULRGRI2EVHUYDWLRQ
$(VERWKQRQVHULRXVDQGVHULRXVZLOOEHPRQLWRUHGWKURXJKRXW WKHVWXG\DVIROORZV
ï‚·$(VZLOOEHUHSRUWHGIURPWKHILUVWGRVHRIVWXG\GUXJWKURXJK GD\VDIWHU
DGPLQLVWUDWLRQRIWKHODVWGRVHRIVWXG\GUXJDQGUHFRUGHGLQW KHH&5)V$OOHYHQWV
UHODWLQJWRSHULSKHUDOQHXURSDWK\UHJDUGOHVVRIVHULRXVQHVVZLO OEHIROORZHGIRUDOO
FKDQJHVLQVHYHULW\XQWLOUHVROXWLRQWREDVHOLQHRUVWXG\FORVX UHZKLFKHYHURFFXUV
ILUVWDQGUHFRUGHGLQWKHH&5)[COMPANY_003]
[COMPANY_003]
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 80ï‚·Serious pretreatment events will be reported to the Millennium Department of 
Pharmacovigilance or d esignee from the time of the signing of the ICF up to first 
dose of study  drug, but will not be recorded in the eCRF.
ï‚·Related and unrelated SAEs will be reported to the Millennium Department of 
Pharmacovigilance or designee from the first dose of study  drug through 
30days 
after administration of the last dose of stud y drug and recorded in the eCRF .  After 
this period, only  related SAEs must be reported to the Millennium Department of 
Pharmacovigilance or designee.  SAEs should be monitored until they  are resolved 
or are clearly  determined to be due to a patientâ€™s stable or chronic condition or 
intercurrent illness(es) .
9.[ADDRESS_577658] also be contact[CONTACT_88815] y by [CONTACT_29658] a 
completed Pregnancy  Form to the Millennium Department of P harmacovigilance or 
designee(see Section 9.2).  The pregnancy  must be followed for the final pregnancy  
outcome.
If a female partner of a male patient becomes pregnant during the male patientâ€™s 
participation in this study , the sponsor must also be contact[CONTACT_51262] a 
completed Pregnancy  Form to the Millennium Department of Pharmacovigilance or 
designee(see Section 9.2).  Every effort should be made to fo llow the pregnancy  for the 
final pregnancy  outcome.
10.   ADMINISTRATIVE REQUI REMENTS
10.1   Good Clinical Practice
The study  will be conducted in accordance with the I CH-GCP and the appropriate regulatory  
requirement(s) .  The investigator will be thoroughly  familiar with the appropriate use of the 
study drug as described in the protocol and the Investigator Brochure .
10.[ADDRESS_577659] all obser vations and other data pertinent to the study  for each study  
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 81patient.  Study data will be entered into an eCRF by  [CONTACT_781] a secure, validated, 
web-based electronic data capture (EDC) application .  Millennium will have access to all 
data upon e ntry in the EDC application .
The study monitorwill discuss instances of missing or uninterpretable data with the 
investigator for resolution.  Any  changes to study  data will be made to the eCRF and 
documented via an electronic audit trail associated with the affected eCRF.
10.[ADDRESS_577660] information in the 
eCRFs fo r the patients for whom they  are responsible.
eCRFs will be completed for each stud y patient.  It is the investigatorâ€™s responsibility  to 
ensure the accuracy , completeness, clarit y, and timeliness of the data reported in the 
patientâ€™s eCRF.
The investigato r, or designated representative, should complete the eCRF as soon as 
possible after information is collected.
The investigator must provide through the EDC application formal approval of all the 
information in the eCRFs and changes to the eCRFs to endorse the final submitted data for 
the patients for which he or she is responsible.  The audit trail entry  will show the userâ€™s 
identification information and the date and time of the correction.
Millennium, or a designee, will retain the eCRF data and correspon ding audit trails .  A copy 
of the final archival eCRF in the form of a compact disk (CD) or other electronic media will 
be placed in the investigatorâ€™s study  file.
10.[ADDRESS_577661] be consistent with the patientâ€™s 
source documentation .  During the course of the study , the study  monitor will make study  
site visits to review protoc ol compliance, verify  eCRFs against source documentation, assess 
drug accountability , and ensure that the stud y is being conducted according to pertinent 
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 82regulatory  requirements.  The review of medical records will be performed in a manner that 
ensures tha t patient confidentiality  is maintained.
10.5   Ethical Considerations
The study  will be conducted in accordance with applicable regulatory  requirement(s) and 
will adhere to GCP standards .  The IRB/IEC will review all appropriate study  
documentation to safegu ard the rights, safety , and well -being of the patients.  The study  will 
be conducted onl y at sites where IRB/IEC approval has been obtained.  The protocol, IB, 
ICF, advertisements (if applicable), written information given to the patients (including 
diary cards), safet y updates, annual progress reports, and an y revisions to these documents 
will be provided to the IRB/IEC by  [CONTACT_8893], as allowed by  [CONTACT_13125].
10.6   Patient Information and Informed Consent
After the stud y has been fully explained, written informed consent will be obtained from 
either the patient or his/her guardian or legal representative before study  participation .  The 
method of obtaining and documenting the informed consent and the contents of the consent 
must comply with the I CH-GCP and all applicable regulatory  requirements.
10.7   Patient Confidentiality
To maintain patient privacy , all eCRFs, study  drug accountabilit y records, study reports, and 
communications will identify  the patient b y initials where permitte dand/or by  [CONTACT_51266] .  The patientâ€™s confidentialit y will be maintained and will not be made 
publicly available to the extent permitted by  [CONTACT_4913].
10.[ADDRESS_577662] thetrial in compliance with the protocol provided by  
[CONTACT_51268]/favorable opi[INVESTIGATOR_1686]/IEC and the appropriate 
regulatory  authority(ies).  Modifications to the protocol are not to be made without 
agreement of both the investigator an d Millennium .  Changes to the protocol will require 
written IRB/IEC approval/favorable opi[INVESTIGATOR_151580], except when the 
modification is needed to eliminate an immediate hazard or hazards to patients .  Millennium, 
or a designee, will submit al l protocol modifications to the appropriate regulatory  
authority(ies) in accordance with the governing regulations.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO :KHQLPPHGLDWHGHYLDWLRQIURPWKHSURWRFROLVUHTXLUHGWRHOLPL QDWHDQLPPHGLDWHKD]DUG
RUKD]DUGVWRSDWLHQWVWKHLQYHVWLJDWRUZLOOFRQWDFW0LOOHQQLX PRUDGHVLJQHHLI
FLUFXPVWDQFHVSHUPLWWRGLVFXVVWKHSODQQHGFRXUVHRIDFWLRQ $Q\GHSDUWXUHVIURPWKH
SURWRFROPXVWEHGRFXPHQWHG
 2QVLWH$XGLWV
5HJXODWRU\DXWKRULWLHVWKH,(&,5%DQGRU0LOOHQQLXPPD\UHTX HVWDFFHVVWRDOOVRXUFH
GRFXPHQWVH&5)VDQGRWKHUVWXG\GRFXPHQWDWLRQIRURQVLWHDXG LWRULQVSHFWLRQ'LUHFW
DFFHVVWRWKHVHGRFXPHQWVPXVWEHJXDUDQWHHGE\WKHLQYHVWLJDWR UZKRPXVWSURYLGHVXSSRUW
DWDOOWLPHVIRUWKHVHDFWLYLWLHV
 ,QYHVWLJDWRUDQG6LWH5HVSRQVLELOLW\IRU'UXJ$FFRXQWDE LOLW\
$FFRXQWDELOLW\IRUWKHVWXG\GUXJDWWKHWULDOVLWHLVWKHUHVS RQVLELOLW\RIWKHLQYHVWLJDWRU
'UXJDFFRXQWDELOLW\UHFRUGVLQGLFDWLQJWKHGUXJÂ¶VGHOLYHU\GDWH WRWKHVLWHLQYHQWRU\DWWKH
VLWHXVHE\HDFKSDWLHQWDQGDPRXQWUHWXUQHGWR0LOOHQQLXPR UDGHVLJQHHRUGLVSRVDORI
WKHGUXJLIDSSURYHGE\0LOOHQQLXPZLOOEHPDLQWDLQHGE\WKH FOLQLFDOVLWH0LOOHQQLXPRU
LWVGHVLJQHHZLOOUHYLHZGUXJDFFRXQWDELOLW\DWWKHVLWHRQDQ RQJRLQJEDVLV
$OOPDWHULDOFRQWDLQLQJVWXG\GUXJZLOOEHWUHDWHGDQGGLVSRVHG RILQDFFRUGDQFHZLWK
JRYHUQLQJUHJXODWLRQV
 3URGXFW&RPSODLQWVDQG0HGLFDWLRQ(UURUV
$SURGXFWFRPSODLQWLVDYHUEDOZULWWHQRUHOHFWURQLFH[SUHVV LRQWKDWLPSOLHVGLVVDWLVIDFWLRQ
UHJDUGLQJWKHLGHQWLW\VWUHQJWKSXULW\TXDOLW\RUVWDELOLW\ RIDGUXJSURGXFW,QGLYLGXDOV
ZKRLGHQWLI\DSRWHQWLDOSURGXFWFRPSODLQWVLWXDWLRQVKRXOGLPP HGLDWHO\FRQWDFW 
VHHWKHQH[WSDUDJUDSKDQGUHSRUWWKHHYHQW:KHQHYHUSRVVLE OHWKHDVVRFLDWHG
SURGXFWVKRXOGEHPDLQWDLQHGLQDFFRUGDQFHZLWKWKHODEHOLQVWU XFWLRQVSHQGLQJIXUWKHU
JXLGDQFHIURPD0LOOHQQLXPTXDOLW\UHSUHVHQWDWLYH
$PHGLFDWLRQHUURULVDSUHYHQWDEOHHYHQWWKDWLQYROYHVDQLGHQ WLILDEOHSDWLHQWDQGWKDWOHDGV
WRLQDSSURSULDWHPHGLFDWLRQXVHZKLFKPD\UHVXOWLQSDWLHQWKD UP:KLOHRYHUGRVHVDQG
XQGHUGRVHVFRQVWLWXWHPHGLFDWLRQHUURUVGRVHVPLVVHGLQDGYHUWH QWO\E\DSDWLHQWGRQRW
,QGLYLGXDOVZKRLGHQWLI\DSRWHQWLDOPHGLFDWLRQHUURUVLWXDWLRQ VKRXOGLPPHGLDWHO\FRQWDFW
VHHEHORZDQGUHSRUWWKHHYHQW[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO )RU3URGXFW&RPSODLQWVRU0HGLFDWLRQ(UURUV
FDOO
3URGXFWFRPSODLQWVDQGPHGLFDWLRQHUURUVLQDQGRIWKHPVHOYHVD UHQRW$(V,IDSURGXFW
FRPSODLQWRUPHGLFDWLRQHUURUUHVXOWVLQDQ6$(DQ6$(IRUPVK RXOGEHFRPSOHWHGDQGVHQW
WRWKH0LOOHQQLXP'HSDUWPHQWRI3KDUPDFRYLJLODQFHRUGHVLJQHHU HIHUWR6HFWLRQ 
 &ORVXUHRIWKH6WXG\
:LWKLQGD\VRIWKHHQGRIWKHVWXG\WKHVSRQVRUZLOOQRWLI\ WKHFRPSHWHQWDXWKRULWLHVDQG
WKH,(&VLQDOOPHPEHUVWDWHVZKHUHWKHVWXG\LVEHLQJFDUULHG RXWWKDWWKHVWXG\KDVHQGHG
:LWKLQ\HDURIWKHHQGRIWKHVWXG\DVX[COMPANY_003]U\RIWKHFOLQLFD OWULDOUHVXOWVZLOOEH
VXEPLWWHGWRWKHFRPSHWHQWDXWKRULWLHVDQG,(&VLQDOOPHPEHUV WDWHVLQYROYHGLQWKHVWXG\
6WXG\SDUWLFLSDWLRQE\ LQGLYLGXDOVLWHVRUWKHHQWLUHVWXG\ PD\EHSUHPDWXUHO\WHUPLQDWHGLI
LQWKHRSLQLRQRIWKHLQYHVWLJDWRURU0LOOHQQLXPWKHUHLVVXII LFLHQWUHDVRQDEOHFDXVH
:ULWWHQQRWLILFDWLRQGRFXPHQWLQJWKHUHDVRQIRUVWXG\WHUPLQDWL RQZLOOEHSURYLGHGWRWKH
LQYHVWLJDWRURU0LOOHQQLXPE\WKHWHUPLQDWLQJSDUW\
&LUFXPVWDQFHVWKDWPD\ZDUUDQWWHUPLQDWLRQLQFOXGHEXWDUHQRW OLPLWHGWR
ï‚·'HWHUPLQDWLRQRIXQH[SHFWHGVLJQLILFDQWRUXQDFFHSWDEOHULVNW RSDWLHQWV
ï‚·)DLOXUHWRHQWHUSDWLHQWVDWDQDFFHSWDEOHUDWH
ï‚·,QVXIILFLHQWDGKHUHQFHWRSURWRFROUHTXLUHPHQWV
ï‚·,QVXIILFLHQWLQFRPSOHWHDQGRUXQHYDOXDEOHGDWD
ï‚·'HWHUPLQDWLRQRIHIILFDF\EDVHGRQLQWHULPDQDO\VLV
ï‚·3ODQVWRPRGLI\VXVSHQGRUGLVFRQWLQXHWKHGHYHORSPHQWRIWKH VWXG\GUXJ
6KRXOGWKHVWXG\EHFORVHGSUHPDWXUHO\WKHVLWHZLOOQRORQJHU EHDEOHWRDFFHVVWKH('&
DSSOLFDWLRQZLOOQRWKDYHDULJKWWRXVHWKH('&DSSOLFDWLRQ DQGZLOOFHDVHXVLQJWKH
SDVVZRUGRUDFFHVVPDWHULDOVRQFHWKHLUSDUWLFLSDWLRQLQWKHVW XG\KDVFRQFOXGHG,QWKH[COMPANY_003]
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577663] been provided, these will be 
returned to Millennium once the siteâ€™s participation in the study  has concluded.
Within [ADDRESS_577664] Retention
The investigator will maintain all study  records according to the ICH-GCP and applicable 
regulatory  requirement(s) .  Records will be retained for at least [ADDRESS_577665] or according to applicable regulatory  
requirement(s) .  If the investigator withdraws from the responsibility  of keepi[INVESTIGATOR_51179], custody  must be transferred to a person willing to accept the responsibility  and 
Millennium notified.
11.   USE OF INFORMATION
All information regarding brentuximab vedotin supplied by  [CONTACT_452980] .  The investigator agrees to use this information to 
accomplish the study and will not use it for other pu rposes without consent from 
Millennium .  It is understood that there is an obligation to provide Millennium with 
complete data obtained during the stud y.  The information obtained from the clinical study  
will be used toward the development of brentuximab vedotin and may be disclosed to 
regulatory  authority(ies), other investigators, corporate partners, or consultants as required.
Upon completion of the clinical study  and evaluation of results by  [CONTACT_20555], the hospi[INVESTIGATOR_452950]/or investigator may publish or disclose the clinical trial results pursuant to 
the terms contained in the applicable Clinical Trial Agreement.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577666] read Protocol C25002 Amendment 4:  A Phase1/2 Study  of brentuximab v edotin 
(SGN-35)in Pediatric Patients With Relapsed or Refractory  Systemic Anaplastic Large -Cell 
Lymphoma or Hodgkin Ly mphoma
I agree to conduct the study  as detailed herein and in compliance with International 
Conference on Harmonisation Guidelines for Good Clinical Practice and app licable 
regulatory  requirements and to inform all who assist me in the conduct of this study  of their 
responsibilities and obligations.
Principal investigator [INVESTIGATOR_452951] (printed)
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577667], Specht L, Horning SJ, et al. 
Revised response criteria for malignant ly mphoma. Journal of Clinical Oncology  
2007;25(5):579 -86.
2.Cartwright RA, Watkins G. Epi[INVESTIGATOR_452952]'s disease: a review. 
Hematological Oncology 2004;22(1):11-26.
3.Belgaumi A, Al -Kofide A, Joseph N, Jamil -Malik R, Khafaga Y, Sabbah R. Hodgkin 
lymphoma in very  young children: Clinical characteristic s and outcome of treatment. 
Leukemia & Ly mphoma 2008;49(5):910 -6.
4. Punnett A, Tsang RW, Hodgson DC. Hodgkin l ymphoma across the age spectrum: 
epi[INVESTIGATOR_623] , therapy, and late effects. Seminars in Radiation Oncology  
2010;20(1):30 -44.
5.Voute P, Barrett A, Stevens M, Caron H. Cancer in Children, Clinical Management, 
Fifth Edition. [LOCATION_001], NY: Oxford University  Press; 2005.
6.Yung L, Linch D. Hodgkin's l ymphoma. Lancet 2003;361(9361):943 -51.
7.Pi[INVESTIGATOR_12348] S, Ascani S, L eoncini L , Sabattini E, Zinzani P, Pi[INVESTIGATOR_452953] P, et al. Hodgkin's 
lymphoma: the pathologist's viewpoint. J Clin Pathol 2002;55(3):[ADDRESS_577668] J, Weston CL , Machin D, et al. Long -term 
outcome in children with Hodgkin's l ymphoma: the [LOCATION_008] Children's 
Cancer Stud y Group HD82 trial. European Journal of Cancer 2007;43(7):1171 -9.
9.Duggan DB, Petroni GR, Johnson JL , Glick JH, Fisher RI, Connors JM, et al. 
Randomized comparison of ABVD and MOPP/ABV h ybrid for the treatment of 
advanced Hodgkin's disease: rep ort of an intergroup trial. Journal of Clinical 
Oncology  2003;21(4):607 -14.
10.Connors JM. State -of-the-art therapeutics: Hodgkin's l ymphoma. Journal of Clinical 
Oncology  2005;23(26):6400-8.
11.Hodgson DC, Hudson MM, Constine L S. Pediatric hodgkin l ymphoma: maximizing 
efficacy and minimizing toxicity . Semin Radiat Oncol 2007;17(3):230-42.
12.Herbertson R, Hancock BW. Hodgkin Lymphoma in adolescents. Cancer Treatment 
Reviews 2005;31(5):339 -60.
13.Thomson AB, Wallace WH. Treatment of paediatric Hodgkin's disease. a balance of 
risks. European Journal of Cancer 2002;38(4):468-77.
14. Olson MR, Donaldson SS. Treatment of pediatric hodgkin l ymphoma. Current 
Treatment Options in Oncology  2008;9(1):81 -94.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 8815.Hutchinson RJ, Fry er CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT, et al. 
MOPP or radiation in addition to ABVD in the treatment of pathologicall y staged 
advanced Hodgkin's disease in children: results of the Children's Cancer Group 
Phase III Trial. Journal of Clinical Oncology  1998;16(3):897 -906.
16.Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low -dose involved -field 
radiotherap y in pediatric Hodgkin's disease: the Stanford experience. Journal of 
Clinical Oncology  1994;12(10):2160-6.
17.Smith RS, Chen Q, Hudson MM, L ink MP, Kun L, Weinstein H, et al. Prognostic 
factors for children with Hodgkin's disease treated with combined -modality therap y. 
Journal of Clinical Oncology  2003;21(10):2026 -33.
18.Carroll W, Finlay J. Cancer in Children and Adolescents. Sudbury , MA: Jones and 
Bartlett Publishers; 2010.
19.Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Reduced health- related quality  of 
life among Hodgkin's disease survivors: a comparative study  with general population 
norms. Annals of Oncology  1999;10(1):71 -7.
20.Das P, Ng AK, Stevenson MA, Mauch PM. Clini cal course of thoracic cancers in 
Hodgkin's disease survivors. Annals of Oncology  2005;16(5):793 -7.
21. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. 
Long-term risk of second malignancy  in survivors of Hodgkin's disease treat ed 
during adolescence or young adulthood. Journal of Clinical Oncology 
2000;18(3):487 -97.
22. Aleman BM, van den Belt- Dusebout AW, De Bruin ML , van 't Veer MB, Baaijens 
MH, de Boer JP, et al. L ate cardiotoxicity  after treatment for Hodgkin l ymphoma. 
Blood 2007;109(5):1878 -86.
23.Behringer K, Josting A, Schiller P, Eich HT, Bredenfeld H, Diehl V, et al. Solid 
tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin 
Lymphoma Study  Group. Ann Oncol 2004;15(7):1079 -85.
24.Schellong G , Dorffel W, Claviez A, Korholz D, Mann G, Scheel -Walter HG, et al. 
Salvage therap y of progressive and recurrent Hodgkin's disease: results from a 
multicenter study  of the pediatric DAL/GPOH -HD study  group. Journal of Clinical 
Oncology  2005;23(25):6181-9.
25. Ruhl U, Albrecht M, Dieckmann K, Luders H, Marciniak H, Schellenberg D, et al. 
Response -adapted radiotherap y in the treatment of pediatric Hodgkin's disease: an 
interim report at 5 years of the German GPOH -HD 95 trial. International Journal of 
Radiation Oncology , Biology, Physics 2001;51(5):1209-18.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577669] GS, Wolden SL , Thomson J, et al. 
Randomized comparison of low- dose involved -field radiotherap y and no 
radiotherap y for children with Hodgkin's disease who achieve a complete response to 
chemotherap y. Journal of Clinical Oncology  2002;20(18):3765-71.
27.Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. 
Effectiveness of high dose chemoradiotherap y and autologous stem cell 
transplantation fo r patients with biopsy -proven primary  refractory  Hodgkin's disease. 
British Journal of Haematology  2004;124(5):645 -52.
28. Horning S, Fanale M, deVos S, Borchmann P, Illidge T, Engert A, et al. Defining a 
population of Hodgkin l ymphoma patients for novel therapeutics: an international 
effort. Annals of Oncology  2008;19(Suppl 4):iv121.
29.Windsor R, Stiller C, Webb D. Peripheral T -cell lymphoma in childhood: 
population -based experience in the [LOCATION_008] over 20 years. Pediatric Blood 
& Cancer 2008;50(4) :784-7.
30.Filippa DA, Ladan yi M, Wollner N, Straus DJ, O'Brien JP, Portlock C, et al. CD30 
(Ki-1)-positive malignant ly mphomas: clinical, immunophenoty pic, histologic, and 
genetic characteristics and differences with Hodgkin's disease. Blood 
1996;87(7):[ADDRESS_577670] Vader PC, Heule F, Geerts ML , van Vloten 
WA, et al. Primary  and secondary  cutaneous CD30(+) l ymphoproliferative disorders: 
a report from the Dutch Cutaneous Lymphoma Group on the long -term follow -up 
data of 219 patients and guidelines for diagnosis and treatment. Blood 
2000;95(12):3653 -61.
32.Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapi[INVESTIGATOR_4605], Saltman DL , et 
al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non -
Hodgkin's l ymphoma.Science 1994;263(5151):1281 -4.
33. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapi[INVESTIGATOR_4605], Look AT, et al. 
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non -Hodgkin's 
lymphoma. Science 1995;267(5196):316 -7.
34.Rosolen A, Pi[INVESTIGATOR_324045] M, Garaventa A, Burnelli R, d'Amore ES, Giuliano M, et al. 
Anaplastic large cell l ymphoma treated with a leukemia -like therap y: report of the 
Italian Association of Pediatric Hematology  and Oncology  (AIEOP) LNH -92 
protocol. Cancer 2005;104(10):2133 -40.
35.Cannella S, Santoro A, Bruno G, Pi[INVESTIGATOR_324045] M, Mussolin L , Mangili G, et al. Germline 
mutations of the perforin gene are a frequent occurrence in childhood anaplastic 
large cell ly mphoma. Cancer 2007;109(12):2566 -71.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 9036.Leventaki V, Drakos E, Medeiros L J, LimMS, Elenitoba -Johnson KS, Claret FX, et 
al. NPM-ALK oncogenic kinase promotes cell- cycle progression through activation 
of JNK/cJun signaling in anaplastic large -cell lymphoma. Blood 2007;110(5):1621-
30.
37.Medeiros L J, Elenitoba -Johnson KS. Anaplastic Large Cell Ly mphoma. American 
Journal of Clinical Pathology  2007;127(5):[ADDRESS_577671] K, et al. CD30(+) 
anaplastic large cell l ymphoma: a review of its histopathologic, genetic, and clinical 
features.Blood 2000;96(12):3681 -95.
39.Brugieres L, Deley  MC, Pacquement H, Meguerian- Bedoyan Z, Terrier -Lacombe 
MJ, Robert A, et al. CD30(+) anaplastic large- cell lymphoma in children: analy sis of 
82 patients enrolled in two consecutive studies of the French Soc iety of Pediatric 
Oncology . Blood 1998;92(10):3591 -8.
40.Brugieres L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, et al. 
Relapses of childhood anaplastic large -cell lymphoma: treatment results in a series of 
41 children --a report from the French Societ y of Pediatric Oncology. Annals of 
Oncology  2000;11(1):[ADDRESS_577672] of the methotrexate administration dose on the need for intrathecal treatment 
in children and a dolescents with anaplastic large -cell lymphoma: results of a 
randomized trial of the EICNHL Group. Journal of Clinical Oncology  
2009;27(6):[ADDRESS_577673] C, et al. 
Single-drug vinblastine a s salvage treatment for refractory  or relapsed anaplastic 
large-cell lymphoma: a report from the French Society  of Pediatric Oncology . 
Journal of Clinical Oncology  2009;27(30):5056 -61.
43.Le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I , McCarthy  K, et al. 
Prognostic factors in childhood anaplastic large cell ly mphoma: results of a large 
European intergroup study. Blood 2008;111(3):1560-6.
44.Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, Yakisan E, et al. 
Successful treatment strateg y for Ki-1 anaplastic large -cell lymphoma of childhood: 
a prospective anal ysis of 62 patients enrolled in three consecutive Berlin -Frankfurt -
Munster group studies. Journal of Clinical Oncology  1994;12(5):899 -908.
45.Reiter A, Schrappe M, Parwaresch R, Hen ze G, Muller -Weihrich S, Sauter S, et al. 
Non-Hodgkin's ly mphomas of childhood and adolescence: results of a treatment 
stratified for biologic subty pes and stage --a report of the Berlin -Frankfurt -Munster 
Group. Journal of Clinical Oncology  1995;13(2):359 -72.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577674] M, Peters C, Burkhardt B, Ebell W, Klingebiel T, et al. 
Time to Failure and CD3 -Expression Are Strong Prognostic Factors in Relapsed 
Anaplastic Large Cell Lymphoma of Childhood and Adolescence. Blood (ASH 
Annual Meeting Abstract s) 2005;106(11):abstr 3327.
47. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. 
Allogeneic transplantation improves the overall and progression -free survival of 
Hodgkin l ymphoma patients relapsing after autologous transplantati on: a 
retrospective stud y based on the time of HLA typi[INVESTIGATOR_175684]. Blood 
2010;115(18):3671 -7.
48.Savage KJ, Monti S, Kutok JL , Cattoretti G, Neuberg D, De Leval L, et al. The 
molecular signature [CONTACT_452993] B -cell lymphoma differs from that of other 
diffuse large B -cell lymphomas and shares features with classical Hodgkin 
lymphoma. Blood 2003;102(12):3871-9.
49.Savage KJ. Primary  mediastinal large B -cell lymphoma. Oncologist 2006;11(5):488 -
95.
50.Boleti E, Johnson PW. Primary  mediastinal B- cell lymphoma. Hematological 
Oncology  2007;25(4):157 -63.
51.Seidemann K, Tiemann M, L auterbach I, Mann G, Simonitsch I , Stankewitz K, et al. 
Primary mediastinal large B -cell lymphoma with sclerosis in pediatric and 
adolescent patients: treatment and results from three therapeutic studies of the 
Berlin-Frankfurt -Munster Group. Journal of Clinical Oncology  2003;21(9):1782-9.
52.Gerrard M, Cairo M, Weston C, Pi[INVESTIGATOR_131907] R, Michon J, Auperin A, et al. Primary  
mediastinal large b -cell lymphoma:  Results of the FABLMB 96 study . Pediatric 
Blood & Cancer 2004;43:361; abstr O.134.
53. Patte C, Auperin A, Sebban C, Bergeron C, Gisselbrecht C, Ribrag V, et al. The 15-
20 Year Old Patients With NHL Treated in [LOCATION_009]:  Data of Childhood and Adult 
Databases. Pedi atric Blood & Cancer 2006;46(Abstract 43):848.
54.Dunleavy K, Pi[INVESTIGATOR_61818] S, Tay K, Grant N, Chen C, Shovlin M, et al. Comparative 
Clinical and Biological Features of Primary  Mediastinal B -Cell Lymphoma (PMBL) 
and Mediastinal Grey  Zone Lymphoma (MGZL). Blood (ASH Annual Meeting 
Abstracts) 2009;114(22):abstr 106.
55. Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. High- dose 
chemotherap y with autologous bone marrow rescue in children with poor -risk 
Burkitt's l ymphoma: a report from the Euro pean Lymphoma Bone Marrow 
Transplantation Registry . Blood 1997;90(8):2921 -30.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 9256.Glade Bender J L, Adamson PC, Reid JM, Xu L , Baruchel S, Shaked Y, et al. Phase I  
trial and pharmacokinetic study  of bevacizumab in pediatric patients with refractory  
solid tumors: a Children's Oncology Group Study. Journal of Clinical Oncology 
2008;26(3):[ADDRESS_577675] ory 
solid tumors: a study  of the pediatric oncology  experimental therapeutic 
investigators' consortium. Journal of Clinical Oncology  2009;27(30):5102 -8.
58. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in 
the human liver --evidence that the shift between CYP3A7 and CYP3A4 occurs 
immediately  after birth. European Journal of Biochemistry  1997;247(2):625 -34.
59.Hines RN, McCarver DG. The ontogen y of human drug -metabolizing enz ymes: 
phase I oxidative enzy mes. Journal of Pharmacolog y & Experimental Therapeutics 
2002;300(2):[ADDRESS_577676] DB, Nath A. Progressive multifocal 
leukoencephalopath y and other forms of JC virus disease. Nature Reviews 
Neuroscience 2010;6(12):[ADDRESS_577677] . Journal of I mmunology  1999;163(1):194-
205.
62.DeYoung AL, Duramad O, Winoto A. The TNF receptor family member CD30 is 
not essential for negative selection. Journal of I mmunology  2000;165(11):6170-3.
63.Zengin E, Sarper N. Humoral immunity  to diphtheria, tetanus, measles, and 
hemophilus influenzae type b in children with acute ly mphoblastic leukemia and 
response to re -vaccination. Pediatric Blood & Cancer 2009;53(6):967 -72.
64. U.S. Department of Health and Human Services, National Institutes of Health 
National Cancer Institute. Common Terminology  Criteria for Adverse Events 
(CTCAE). Version 4.03. 14 June 2010.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577678] describes child's play  during the past week, 
averaging out good day s and bad day s.
100 -Fully active, normal.
90 -Minor restrictions in phy sically strenuous activity .
80 -Active, but tires more quick ly.
70 -Both greater restriction of and less time spent in play  activity.
60 -Up and around, but minimal active play ; keeps busy  with quieter activities.
50 -Gets dressed but lies around much of the day ; no active play ; able to participate in all 
quiet playand activities.
40 -Mostly in bed; participates in quiet activities.
30 -In bed; needs assistance even for quiet play .
20 -Often sleepi[INVESTIGATOR_007]; play  entirely limited to very  passive activities.
10 -No play; does not get out of bed.
0 -Unresponsive.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 9414.2  Karnofsky Performance Scale
Karnofsky Performance Scale
100 -Normal; no complaints; no evidence of disease.
90 -Able to carry  on normal activity ; minor signs or sy mptoms of disease.
80 -Normal activity  with effort; some signs or s ymptoms of disease.
70 -Cares for self; unable to carry  on normal activity  or to do active work.
[ADDRESS_577679] of own needs.
50 -Requires considerable assistance and frequent medical care.
40 -Disabled; requires special ca re and assistance.
30 -Severely disabled; hospi[INVESTIGATOR_175691].
20 -Hospi[INVESTIGATOR_20545] ; very sick; active supportive treatment necessary .
10 -Moribund; fatal processes progressing rapi[INVESTIGATOR_375].
0 -Dead.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577680] Pubic Hair
1 (prepubertal) No palpable glandular tissue or pi[INVESTIGATOR_452954]; elevation of areola onlyNo pubic hair; short, fine vellus 
hair only
[ADDRESS_577681] 
and areola together as a small mound; areolar 
diameter increasedSparse, long, pi[INVESTIGATOR_452955]
[ADDRESS_577682] 
and areola; although more darkly pi[INVESTIGATOR_49194], areola 
still pale and immature; nipple generally at or above 
midplane of breast tissue when individual is seated 
uprightDark, coarse, curly hair, extending 
sparsely over mons
[ADDRESS_577683] Adult-type hair, abundant but 
limited to mons and labia
5 (adult) Recession of areola to contour of breast; 
development of Montgomery's glands and ducts on 
areola; further pi[INVESTIGATOR_452956]; nipple 
generally below  midplane of breast tissue when 
individual is seated upright; maturation independent 
of breast sizeAdult-type hair in quantity and 
distribution; spread to inner 
aspects of the thighs in most racial 
groups
Data from Ross GT: Disorders of the ovary and female reproductive tract.  In Wilson JD, Foster DW (eds): 
Textbook of Endocrinology, 7th ed.  Philadelphia, WB Saunders, 1985, p 206 .
Table 14-2   Pubertal Stages in Boys
Stage Pubic Hair Genital
1 Absence of pubic hair Childlike penis, testes, and scrotum (testes 2 mL)
2 Sparse, lightly pi[INVESTIGATOR_452957]; testes begin to enlarge (3 â€“5 mL)
3 Hair become s coarse, darker, and more 
curled and more extensivePenis has grown in length and diameter; testes now 8 â€“
10 mL; scrotum more rugated
[ADDRESS_577684] of thighsPenis further enlarged with development of the glans; 
scrotum and testes (10 â€“13 mL) further enlarged
5 Hair is adult and extends to thighs Penis and scrotum fully adult; testes 15 mL and 
greater
Modified from Marshall WA, Tanner JM: Variation in pattern of pubertal changes in boys.  Arch Di s Child 
1970;45:13 â€“23.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 9614.4   Amendment 1 Rationale and Purposes
Rationale for Amendment 1
This amendment seeks to promote patient safet y by [CONTACT_452981]-drug interactions, using an objective definition of dose -limiting toxici ty (DLT), and 
specifying administration equipment that ensures drug compatibility .
Purposes for Amendment1
ï‚·Exclude those patients receiving strong inhibitors of CYP3A4 and institute a [ADDRESS_577685] 
received strong inhibitors of CYP3A4
ï‚·Prohibit concomitant administration of strong inhibitors of CYP3A4 during the 
brentuximab vedotin treatment period
ï‚·Remove investigator attributions from the definitions of dose- limiting toxicities 
(DLTs)
ï‚·Prohibit the use of poly ethylene IV bags for the administration of brentuximab vedotin 
in this trial
ï‚·Correct typographical errors, punctuation, grammar, and formatting
14.5   Amendment 2 Rationale and Purposes ([LOCATION_009] -Specific Amendment)
Rationale for Am endment 2
One case of progressive multifocal leukoencephalopathy  (PML) was reported in a 
48-year-old male patient with Hodgkin l ymphoma (HL) who developed progressive disease 
after undergoing an autologous bone marrow transplant.  He subsequentl y received both 
local radiation therap y and [ADDRESS_577686] 
of 3doses of brentuximab vedotin.  Two months after his initial dose, he presented with 
focal neurologic sy mptoms and was later diagnosed with PML .  As HL and
immunosuppressive therapi[INVESTIGATOR_452958] , it is unclear what role 
brentuximab vedotin play ed in the development of PML , although a contributory  role cannot 
be excluded. Therefore, the protocol now excludes patients with signs or sy mptoms of PML  
and contains instructions for the suggested management of suspected PML that include 
immediate brentuximab vedotin discontinuation.
Purposes for Amendment2
ï‚·Revise exclusion criteria to exclude patients with signs or s ymptoms of PML
ï‚·Add instructio ns for the management of suspected PML
ï‚·Add PML  and John Cunningham virus (JCV) to the L ist of Abbreviations
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 9714.6   Amendment 3 Rationale and Purposes
Rationale for Amendment 3
Events of progressive multifocal leukoencephalopathy  (PML) have been reported in p atients 
who received brentuximab vedotin.  The protocol now excludes patients with signs or 
symptoms of PML  and contains instructions for the suggested management of suspected 
PML that include brentuximab vedotin discontinuation.
Infusion-related reactions (IRRs) have been reported in previous studies with brentuximab 
vedotin.  I nformation has been added on the management of infusion -related reactions, 
including instructions to immediately  and permanently  discontinue administration of 
brentuximab vedotin for Grade3 or higher infusion -related reactions consistent with 
anaphylaxis.
Events of pulmonary  toxicity were reported in a study  with brentuximab vedotin given with 
bleomycin as part of a combination regimen.  The protocol now includes information on the 
occurrence of pulmonary toxicity  and specifies that the concomitant use of bleomy cin with 
brentuximab vedotin is contraindicated.
Peripheral neuropath y has been a frequentl y reported adverse event in previous studies with 
brentuximab vedotin.  Cumulative d osing with brentuximab vedotin has been associated 
with an increased incidence of peripheral neuropathy .  The original protocol states that the 
brentuximab vedotin dose should be held in the case of n ew or worsening events of Grade [ADDRESS_577687] 14 days is required for patients who received local palliative 
radiation therap y; a washout per iod of at least 84 days is required for patients who receive 
radiation therap y to more than 25% of bone marrow-containing spaces.  Exclusion criteria 
have been added to specify  these restrictions on receiving radiation therapy prior to the first 
dose of st udy drug.
Planned imaging assessments have been revised in order to minimize radiation exposure in 
this pediatric population.  Magnetic resonance imaging (MRI) will be performed for neck, 
abdomen, and pelvis evaluations; computed tomograph y (CT) scans will be used for chest 
evaluations only .
Patient enrollment was defined as at the time of informed consent in the original version of 
the protocol.  To conform to Millennium protocol standards, the definition of enrollment has 
been changed to at the time of fi rst dose of stud y drug.
The contact [CONTACT_452982] (SAEs) and events of pregn ancy has been 
revised.  Section 14.[ADDRESS_577688] 
information by  [CONTACT_452983].
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 98Purposes for Amendment3
The purposes of this amendment are to:
ï‚·Add information on the occurrence and management of progressive multi focal 
leukoencephalopath y (PML).
ï‚·Add information on the occurrence and management of infusion -related reactions.
ï‚·Add information on the risk of pulmonary  toxicity with brentuximab vedotin when given 
in combination with bleomy cin.
ï‚·Add exclusion criterion for patients with signs or sy mptoms of PML .
ï‚·Add exclusion criterion for patients with Grade2 or higher peripheral ne uropathy.
ï‚·Add exclusion criterion for patients who are pregnant or both lactating and 
breastfeeding.
ï‚·Add exclusion criterion for patients who received local palliative radiation therap y 
within [ADDRESS_577689] dose of study  drug.
ï‚·Add exclusion criter ion for patients who received radiation therap y to more than 25% of 
bone marrow -containing spaces within [ADDRESS_577690] dose of study  drug.
ï‚·Revise planned imaging assessments to include MRI .
ï‚·Change the definition of enrollment to at the time of fir st dose of study  drug.
ï‚·Add section in the appendix containing updated SAE and pregnancy  reporting contact 
[CONTACT_3031].
ï‚·Add development assessment and Tanner Scale and B symptom assessments to study  
procedures section.
ï‚·Revise inclusion criterion for pregnan cy.
ï‚·Revise dose modification section for clarity .
ï‚·Revise time frame for reporting SAEs to the sponsor.
ï‚·Revise time frames for prior alloSCT and autologous hematopoietic stem cell 
transplant ationfor study eligibility .
ï‚·Revise exclusion criteria for corticos teroid therap y.
ï‚·Revise assessment times for pregnancy  tests.
ï‚·Specify that patients must have recovered from any  toxic effects of prior radiotherapy , 
chemotherap y, or immunotherap y prior to enrollment.
ï‚·Specify that direct and indirect bilirubin assessments will be performed.
ï‚·Specify that weight and height screening assessments must be performed within [ADDRESS_577691] dose of study  drug.
ï‚·Clarify that an independent review facility  (IRF) will assess objective response over the 
course of the stud y, per International Working Group (I WG) criteria.
ï‚·Clarify that concomitant medications will be monitored starting at the time of signed 
informed consent form.
ï‚·Clarify that a 10% or greater change in patient weight (increase or decrease) will require 
brentuxim ab vedotin dose adjustment.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 99ï‚·Clarify that patients who are withdrawn from treatment during C ycle1 for reasons other 
than dose -limiting toxicities (DLTs) will be replaced.
ï‚·Clarify the use of concomitant colony -stimulating factors (CSFs).
ï‚·Clarify that the ce ntral laboratory  will be used for c linical chemistry , hematology , and 
immune reconstitution evaluations, and that local labs may  be used for dosing decisions 
only.
ï‚·Clarify that medical history  is not obtained on Day 1, Cycle1.
ï‚·Clarify timing of hematology and serum chemistry  samples.
ï‚·Clarify that patients who respond may  receive up to 16 cycles of brentuximab until 
disease progression.
ï‚·Remove Eastern Cooperative Oncology  Group (ECOG) Performance Status from 
appendices.
ï‚·Rename [CONTACT_452994]/Biomarker s Analysissection to Immune Reconstitution 
Analysis.
ï‚·Correct typographical errors, punctuation, grammar, and formatting .
For specific examples of changes in text and where the changes are located, see 
Section14.7.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential [ZIP_CODE].7   Amendment 4 Detailed Summary of Changes
THE PRIMARY SECTIONS OF THE PROTOCOL  AFFECTED BY [CONTACT_452984] 4 ARE INDICATED.  THE CORRESPONDI NG TEXT HAS BEEN 
REVISED THROUGHOUT THE PROTOCOL.
Purpose:   Revise the length of the follow -up period to align with the PI P
The primary change occurs in Section 4.1,Overview of Study  Design:
Formerly 
read:Patients will be followed for [ADDRESS_577692] dose of 
brentuximab vedotin to assess overall survival .
Now 
reads:Patients will be followed for PFS and OS every [ADDRESS_577693] patient.   Patients who remain on 
treatment after Cycle 16 will be followed according to the above schedule 
or until study closure .
Sections that also contain this change are:
ï‚·PROTOCOL  SUMMARY
ï‚·Schedule of Events
ï‚·Section 4.3,Duration of Study
ï‚·Section 6.4.3,Criteria for Discontinuation of Brentuximab v edotin
ï‚·Section 7.10,Posttreatment Follow- up Assess ments
Purpose:   Clarify that the primary  endpoint of the phase 2 study is bestORR
The primary change occurs in Section 2.4,Phase2 Primary  Objectives:
Formerly 
read:The primary  objectives in phase2 include:
ï‚·To determine the overall response rate (complete remission, partial 
remission) with brentuximab vedotin at the recommended pha se2 dose
Now 
reads:The primaryobjective in phase 2 is:
ï‚·To determine the bestoverall response rate (complete remission, partial 
remission) with brentuximab vedotin at the recommended phase 2 dose
Sections that also contain this change are:
ï‚·PROTOCOL  SUMMARY
ï‚·Section 1.3.1, Study Rationale
ï‚·Section2.2, Phase1 Secondary  Objectives
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 101ï‚·Section3.2, Phase1 Secondary  Endpoints
ï‚·Section3.4, Phase2 Primary  Endpoints
ï‚·Section8.1.6, Efficacy Analysis  
Purpose:   Addsafety language regarding the potential risk of SJS
The primary  change occurs in Section 1.4.3, Potential Risks in C hildren:
Added 
text:Stevens-Johnson syndrome (SJS) ,including toxic epi[INVESTIGATOR_194],
has been reported in patients who received brentuximab vedotin.  
Patients were concurrently receiving other medications (naproxe n and 
tramadol, respectively) that are known to cause SJS and may have 
contributed to the development of SJS.  Stevens-Johnson syndrome is 
considered to be an unacceptable study drug- related toxicity.   If SJS 
occurs, the administration of brentuximab vedotin must be discontinued 
and the appropriate medical therapy administered.
Purpose:   Add safety  language regarding the potential risk of pancreatitis
The primary  change occurs in Section 1.4.3, Potential Risks in C hildren:
Added 
text:Acute pancreatitis has been reported in patients treated with 
brentuximab vedotin and has contributed to fatal outcomes in some 
cases.  Onset typi[INVESTIGATOR_452943] 1 to 2 doses of brent uximab 
vedotin.  Early symptoms included severe abdominal pain, nausea, and 
vomiting.  Some of the pancreatitis cases were complicated by [CONTACT_452985], including cholelithiasis and alternate 
etiologies (eg, pancreatic lymphoma progre ssion, displacement of bile 
duct stent).
Purpose:   Add safety  language regarding the potential risk of hepatotoxicity
The primary  change occurs in Section 1.4.3, Potential Risks in C hildren:
Added 
text:Hepatotoxicity, predominately in the form of asymptomatic mild to 
moderate transient elevations in AST and/or ALT, has been reported in
patients treated with brentuximab vedotin.  Patients should be monitored 
for elevat ed liver enzymes.
Purpose:   Revisethetotal bilirubin inclusion criterion to include patients with abnormal 
values due to indirect h yperbilirubinemia due to Gilbertâ€™s disease
The primary  change occurs in Section 5.1,Inclusion Criteria , criterion 11 :  
Formerly 
read:ï‚·Serum bilirubin level less than or equal to 1.5 Ã—upper limits of normal 
(ULN).
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 102Now 
reads:ï‚·Serum bilirubin level less than or equal to 1.5 Ã—upper limits of normal 
(ULN) or less than or equal to 3 Ã— ULN for patients with an indirect 
hyperbilirubinemia due to Gilbertâ€™s disease .
Purpose:   Revise study  eligibility  criterionregarding elevated ALT and AST values due 
to the presence of metastatic disease in the liver
The primary  change occ urs in Section 5.1,Inclusion Criteria , criterion 11 :  
Formerly 
read:ï‚·Alanine aminotransferase (ALT or SGPT) and aspartate 
aminotransferase (AST or SGOT) less than or equal to 2.5 Ã—ULN.  
Now 
reads:ï‚·Alanine aminotransferase (ALT or SGPT) and aspartate 
aminotransferase (AST or SGOT) less than or equal to 2.5 Ã—ULN.  AST 
and ALT levels may be elevated up to 5 Ã— ULN if their elevation can 
be reasonably ascribed to the presence of metastatic disease in the 
liver.
Purpose:   Revise the washout period for s ystemic corticosteroid treatment in the 
exclusion criteria
The primary  change occurs in Section 5.2,Exclusion Criteria , criterion 13 :  
Formerly 
read:13.Systemic corticosteroid therap y <14days prior to first dose of study  
medication.
Now 
reads:13.Systemic corticosteroid therapy <7days prior to first dose of study  
medication.
Purpose:   Revise the required minimum time between previous alloge neic or autologous 
stem cell transplantation and the first dose of study  drug
The primary  changes occur in Section 5.2, Exclusion Criteria , criteria 2 and 17 :
Formerly
read:2.Received allogeneic stem cell transplant < 6monthsprior to first dose of 
study medication , or presence of pol ymerase chain reaction (PCR) -
detectable CMV in an y post-allogeneic transplant ationpatient. (Prior 
PCR positivity  that was successfull ytreated is acceptable provided the 
baseline PCR result is negative prior to first dose of study  drug.)
â€¦
17.Prior autologous hem atopoietic stem cell infusion < 6weeks beforefirst 
study dose.  
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 103Now 
reads:2.Received allogeneic stem cell transplant < 3monthsprior to first dose of 
study medication, or presence of pol ymerase chain reaction (PCR) -
detectable CMV in an y post-allogeneic transplant ationpatient. (Prior 
PCR positivity  that was successfull y treated is acceptable provided the 
baseline PCR result is negative prior to first dose of study  drug.)
â€¦
17.Prior autologous hematopoietic stem cell infusion < 4weeks beforefirst 
doseof the study drug.
The PROTOCOL  SUMMARY also contains this change.
Purpose:   Add to the exclusion criteria anyhistory of PML
The primary  change in Section 5.2, Exclusion Criteria , criterion 9:  
Formerly 
read:9. Known active cerebral/meningeal disease , including signs or s ymptoms of 
progressive multifocal leukoencephalopath y (PML).
Now 
reads:9.Known active cerebral/meningeal disease, including signs or s ymptoms of 
progressive multifocal leukoencephalopath y (PML) or any history of 
PML.
The PROTOCOL  SUMMARY also contains this change.
Purpose:   Revise the CYP3A4 exclusion criterion to exclude listed moderate inhibitorsof 
CYP3A4
The primary  change occurs in Section 5.2, Exclusion Criteria , criterion 19 :  
Formerly 
read:19.Received a strong inhibitor of CYP3A4 ï€¼2weeks prior to first study  
dose.  (Strong inhibitors of CYP3A4 are listed in Appendix.)
Now 
reads:19.Received any strong or listed moderate inhibitor of CYP3A4 ï€¼ 2weeks 
prior to first study  dose.  (Please refer to the Study Manual for an 
example list of prohibited CYP3A4 inhibitors .)
Section6.5, Excluded Concomitant Medications and Procedures ,also contains this 
change.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 104Purpose:   Modifythecontraception language regarding abstinence to align with company  
standards
The primary  change occurs in Section 5.1, Inclusion Criteria , criterion 7:
Formerly 
read:7. Female patients who are of childbearing potential, agree to practice 
2effective methods of contraception, at the same time, from the time o f 
signing the informed consent form (ICF) through [ADDRESS_577694] dose of study  drug, or agree to completely  abstain 
from heterosexual intercourse .
Now 
reads:7.Female patients who:
ï‚·Are surgically sterile, OR
ï‚·If theyare of childbearing potential, agree to practice [ADDRESS_577695] dose of study  drug, or
ï‚·Agree to practice true abstinence, when this is in line with the 
preferred and usual lifestyle of the subject.  ( Periodic abstinence (eg, 
calendar, ovulation, symptothermal, postovulation methods] and 
withdrawal are not acceptable methods of contraception. )
8.Male patients, even if surgically  sterilized (ie, status postvasectomy ), 
who:
ï‚·Agree to practice effective barrier contraception during the entire stud y 
treatment  period and through [ADDRESS_577696] dose of study  drug, 
or
ï‚·Agree to practicetrue abstinence, when this is in line with the 
preferred and usual lifestyle of the subject.  ( Periodic abstinence [eg, 
calendar, ovulation, symptothermal, postovulation methods for the 
female partner ]and withdrawal are not acceptable methods of 
contraception.)
Section6.7, Precautions and Restrictions , also contains this change.  
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 105Purpose:   Revise language regarding dose adjustments for a â‰¥ 10% weight change; add 
language for patients weighing more than 100 kg
The primary  change occurs in Section 6.1,Study Drug Administration :
Added 
text:Dosing is based on patientsâ€™ weight according to the institutional 
standard; however, doses will be adjusted for patients who experience a 
â‰¥10% change in weight from the most recent dose calculation.  Actual 
weight will be used except for patients weighing greater than 100 kg; 
dose will be calculated based on [ADDRESS_577697] whole number of milligrams .
The Schedule of Events , footnote s, also contains this change.
Purpose:   Correcttheunitsof measurement for platelet count, absolute neutrophil count, 
and white blood cell count
The primary  change occurs in Section 6.4.2,Criteria for Beginning or Delay ing a 
Subsequent Treatment Cy cle:
Formerly 
read:ï‚·ANC must be â‰¥1,000/mm3
ï‚·Platelet count must be â‰¥75,000/mm3
Now 
reads:ï‚·ANC must be â‰¥1,000/ÂµL
ï‚·Platelet count must be â‰¥75,000/ÂµL
The sections that also contain this change are:
ï‚·Section6.2.3,Hematologic Toxicity
ï‚·Section6.4.1,Criteria for Dose Modification*
ï‚·Section9.1.3, Serious Adverse Event Definition
Purpose:   Remove the restriction on the use of poly ethylene infusion bags for dilution of 
brentuximab vedotin, as previously  described in Administrative L etter2
The primary  change occurs in Section 6.11, Preparation, Recons titution, and 
Dispensation:
Deleted 
text:The appropriate amount of reconstituted stud y treatment will be withdrawn 
from the vial(s) and diluted in a 50 -to 100-mL infusion bag containing 0.9% 
Sodium Chloride I njection, USP .  Do not use polyethy lene infusion bags.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 106Purpose:   Update packaging and labeling instructions for brentuximab vedotin
The primary  change occurs in Section 6.12, Packaging and Labeling :
Formerly 
read:Brentuximab vedotin for Injection is supplied in 5 mL (10mg) single use, 
Type1 borosilicate glass vials.
Now 
reads:Brentuximab vedotin vials will be packaged as single -use cartons .  Each 
carton will contain [ADDRESS_577698], and the vial and 
carton will be labeled to meet country -specific regulatory requirements .
Purpose:   Revise the timing for the development assessment and Tanner Scale
The primary  change occurs in the Schedule of Events:  
Removed the Xin the Development assessment and Tanner Scale row underthe D15-21 
of Cycle column. 
Added an X in the Development assessment and Tanner Scale row in the Each 21 -Day 
Cycle:  D1 column.
Purpose:   Permit occasional changes in the timing of tests and procedures without 
permission from the project clinician
The primary  change occurs i n the Schedule of Events footnotes:  
Formerly 
read:  Tests and procedures should be performed on schedule, but occasional 
changesare allowable (Â±2 days) with permission of the medical monitor for 
holidays, vacations, and other administrative reasons.
Now 
reads:  Tests and procedures should be performed on schedule, but occasional 
changesare allowable (Â±2days) for holiday s, vacations, and other 
administrative reasons, unless otherwise indicated .
Purpose: Revise language regarding premedication for infusion -related reactions to 
allow the use of corticosteroids
The primary  change occurs in Section 6.1,Study Drug Administration :  
Formerly 
read:  Patients who experience a Grade 1 or Grade 2 infusion- related reaction may 
receive subsequent brentuximab infusions with premedication consisting of 
acetaminophen (650 mg orally ) and diphenhy dramine (25 â€“50 mg orally  or 
10â€“25 mg IV) or according to institutional standards, administered 30 to 60 
minutes prior to each 30 -minute brentuximab vedotin infusion.  The routine 
use of steroids as premedication is discouraged.
Now 
reads:  Patients who experience a Grade 1 or Grade 2 infusion- related reaction may 
receivesubsequent brentuximab infusions with premedication consisting of 
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO DFHWDPLQRSKHQPJRUDOO\DQGGLSKHQK\GUDPLQHÂ±PJRUD OO\RU
Â±PJ,9RUDFFRUGLQJWRLQVWLWXWLRQDOVWDQGDUGVDGPLQLVWH UHGWR
PLQXWHVSULRUWRHDFKPLQXWHEUHQWX[LPDEYHGRWLQLQIXVLRQ
3UHPHGLFDWLRQPD\LQFOXGHDFHWDPLQRSKHQDQDQWLKLVWDPLQHDQG D
FRUWLFRVWHURLG
3XUSRVH$GGDQDVVHVVPHQWIRULPPXQHUHFRQVWLWXWLRQDWWKH(27YLVLW DVSUHYLRXVO\
GHVFULEHGLQ$GPLQLVWUDWLYH/HWWHUDQGDGGDZLQGRZWRSHUIR UPLPPXQHUHFRQVWLWXWLRQ
7KHSULPDU\FKDQJHRFFXUVLQWKH 6FKHGXOHRI(YHQWV 
$GGHGDQ;LQWKH,PPXQHUHFRQVWLWXWLRQURZLQWKH(27(7GD \VSRVWODVWGRVH ï‚±
GD\VFROXPQ
7KHSULPDU\FKDQJHDOVRRFFXUVLQ6HFWLRQ 3KDVH([SORUDWRU\(QGSRLQWV 
$GGHG
WH[W
6HFWLRQVWKDWDOVRLQFOXGHWKLVFKDQJHLQFOXGH
ï‚·7KH6FKHGXOHRI(YHQWV IRRWQRWHZ
ï‚·6HFWLRQ3RWHQWLDO5LVNVLQ&KLOGUHQ
ï‚·6HFWLRQ3KDVH([SORUDWRU\(QGSRLQWV
3XUSRVH5HYLVHWKHVHFWLRQRQ,PPXQH5HFRQVWLWXWLRQUHYLVHWKHVHFWLRQ KHDGLQJDQG
DGGVHSDUDWHVHFWLRQVIRU,PPXQRJHQLFLW\$VVHVVPHQWDQG7XPRU6 SHFLPHQ
0HDVXUHPHQWV
7KHSULPDU\FKDQJHVRFFXULQQHZ6HFWLRQ ,PPXQH5HFRQVWLWXWLRQ QHZ
6HFWLRQ,PPXQRJHQLFLW\ DQGQHZ6HFWLRQ 7XPRU6SHFLPHQ
0HDVXUHPHQWV 
)RUPHUO\
UHDG3KDUPDFRG \QDPLF0HDVXUHPHQWV
7KHHIIHFWVRIEUHQWX[LPDEYHGRWLQRQWKHSHGLDWULFSHULSKHUDO LPPXQHV\VWHP
ZLOOEHH[DPLQHGE\PHDVXULQJSHULSKHUDOEORRGFHOOSRSXODWLRQV DQGWKH
FLUFXODWLQJ,JVXEFODVVHV3HULSKHUDOFHOOSRSXODWLRQVZLOOEH H[DPLQHGE\
GUDZLQJP/RISHULSKHUDOEORRGLQWRDKHSDULQL]HGWXEHDWWKHGH VLJQDWHGWLPH
SRLQWVLQWKH6FKHGXOHRI(YHQWV&HOOXODUSRSXODWLRQVLQFOXGLQJ 7FHOOVVXEVHWV
7KHOSHUF\WRWR[LFDQGPHPRU\FHOOV%FHOOV1.FHOOVDQG JUDQXORF\WHV
ZLOOEHPHDVXUHGXVLQJIORZF\ WRPHWU\,PPXQRJOREXOLQVXEFODVVH VZLOOEH
H[DPLQHGE\WDNLQJDSSUR[LPDWHO\P/RIVHUXPDQGH[DPLQLQJXV LQJ
VWDQGDUGFOLQLFDOODERUDWRU\SURFHGXUHVCCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 108Now 
reads:[IP_ADDRESS]  Immune Reconstitution
The effects of brentuximab vedotin on the pediatric peripheral immune sy stem 
will be examined by  [CONTACT_452986] :
Immune Reconstitution
ï‚·IgG
ï‚·IgM
ï‚·IgAï‚·Tetanus antib odies
ï‚·HiB
ï‚·Polioserotypesï‚·Total immunoglobulin
ï‚·Lymphocyte count
ï‚·Lymphocyte subsets
Peripheral cell popu lations will be examined using serum fromthe
heparinized blood specimens obtainedat the designated time points , as 
specified in the Schedule of Events.  Cellul ar populations including T cell
subsets (T helper, cy totoxic, and memory  cells), B cells, NK cells, and 
granulocy tes will be measured by  [CONTACT_452987].  Immunoglobulin
subclasses will be examined using standard clinical laboratory  procedures .  
Added 
text:7.4.[ADDRESS_577699] be c ollected before the brentuximab vedotin dose is 
administered.  Neutralizing ATA assessment will be performed for 
ATA-positive samples only.  Details regarding the preparation, handling, 
and shippi[INVESTIGATOR_51121] .
Added 
text:7.4.17  Tumor Specimen Measurements
This sample will be used to confirm CD30 expression by [CONTACT_452988].  Refer to the Schedule of Events for details regarding 
tumor specimen collection .
Purpose:   Add language regarding reporting requiremen ts for SAEs
The primary  change occurs in Section 7.10, Posttreatment Follow -up Assessments :
Added 
text:NOTE:  Related SAEs must be reported to the Millennium Departme nt 
of Pharmacovigilance or designee.  This includes deaths that the 
investigator considers related to study drug that occur during the 
posttreatment follow -up.  Refer to Section 9for details regarding 
definitions, documentation, and reporting of SAEs.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 3XUSRVH'HOHWHUHGXQGDQW6$(UHSRUWLQJODQJXDJHXSGDWHWKHSHULRGIRU UHSRUWLQJ
6$(VWR0LOOHQQLXPIURPFDOHQGDUGD\WRKRXUVDQGXSGDWH6$( UHSRUWLQJFRQWDFW
LQIRUPDWLRQ
7KHSULPDU\FKDQJHRFFXUVLQ6HFWLRQ 3URFHGXUHVIRU5HFRUGLQJDQG5HSRUWLQJ
$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV 
)RUPHUO\
UHDG$OO6$(VDQGVHULRXVSUHWUHDWPHQWHYHQWVDVGHILQHGLQ6HFWLRQ PXVWEH
UHSRUWHGVHH6HFWLRQIRUWKHSHULRGRIREVHUYDWLRQE\WKHLQ YHVWLJDWRUWR
WKH0LOOHQQLXP'HSDUWPHQWRI3KDUPDFRYLJLODQFHRUGHVLJQHHE\I D[LQJWKH
6$()RUPZLWKLQFDOHQGDUGD\DIWHUEHFRPLQJDZDUHRIWKHHYHQW $OO
6$(VDQGVHULRXVSUHWUHDWPHQWHYHQWVZKLFKLQFOXGHDOOGHDWKV PXVWEH
UHSRUWHGZKHWKHURUQRWFRQVLGHUHGFDXVDOO\UHODWHGWRWKHVWXG \GUXJRUVWXG\
SURFHGXUHV7KH6$()RUPFUHDWHGVSHFLILFDOO\E\0LOOHQQLXP ZLOOEH
SURYLGHGWRHDFKFOLQLFDOVWXG\VLWH$VDPSOHRIWKH6$()RUP PD\EHIRXQG
LQWKH6WXG\0DQXDO)ROORZXSLQIRUPDWLRQRQWKH6$(RUVHULR XV
SUHWUHDWPHQWHYHQWPD\EHUHTXHVWHGE\0LOOHQQLXP6$(UHSRUW LQIRUPDWLRQ
PXVWEHFRQVLVWHQWZLWKWKHGDWDSURYLGHGRQWKHH&5)
)RU6$(DQG3UHJQDQF\5HSRUWLQJ&RQWDFW,QIRUPDWLRQ
SOHDVHUHIHUWR$SSHQGL[
1RZ
UHDGV5HJDUGOHVVRIFDXVDOLW\ 6$(VDQGVHULRXVSUHWUHDWPHQWHYHQWVDVGHILQHGLQ
6HFWLRQPXVWEHUHSRUWHGVHH6HFWLRQIRUWKHSHULRGRIR EVHUYDWLRQ
E\WKHLQYHVWLJDWRUWRWKH0LOOHQQLXP'HSDUWPHQWRI3KDUPDFRYLJ LODQFHRU
GHVLJQHHFRQWDFWLQIRUPDWLRQSURYLGHGEHORZ7KLVVKRXOGEHGRQH E\
ID[LQJWKH6$()RUPZLWKLQ KRXUVDIWHUEHFRPLQJDZDUHRIWKHHYHQW
7KH6$()RUPFUHDWHGVSHFLILFDOO\E\0LOOHQQLXPZLOOEHSURYL GHGWRHDFK
FOLQLFDOVWXG\VLWH$VDPSOHRIWKH6$()RU[COMPANY_003]\EHIRXQGLQW KH6WXG\
0DQXDO)ROORZXSLQIRUPDWLRQRQWKH6$(RUVHULRXVSUHWUHDWPH QWHYHQW
PD\EHUHTXHVWHGE\ 0LOOHQQLXP6$(UHSRUWLQIRUPDWLRQPXVWEH FRQVLVWHQW
ZLWKWKHGDWDSURYLGHGRQWKHH&5)
6$(5HSRUWLQJ&RQWDFW,QIRUPDWLRQ
7KLVFKDQJHDOVRUHVXOWHGLQWKHUHPRYDORI6HFWLRQ6$(DQG 3UHJQDQF\5HSRUWLQJ
&RQWDFW,QIRUPDWLRQ[COMPANY_003]
[COMPANY_003]
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 3XUSRVH$GGODQJXDJHUHJDUGLQJWKHFROOHFWLRQRIHYHQWVRISHULSKHUDO QHXURSDWK\
7KHSULPDU\FKDQJHRFFXUVLQ6HFWLRQ 0DQDJHPHQWRI3HULSKHUDO1HXURSDWK\ 
$GGHG
WH[W7KHVHHYHQWVPD\LQFOXGHEXWDUHQRWOLPLWHGWRSHULSKHUDOVHQ VRU\
QHXURSDWK\SHULSKHUDOPRWRUQHXURSDWK\SDUHDHVWKHVLDK\SRDHV WKHVLD
SRO\QHXURSDWK\PXVFXODUZHDNQHVVDQGGHP\HOLQDWLQJSRO\QHXURS DWK\
6XFKHYHQWVUHJDUGOHVVRIVHULRXVQHVVZLOOEHIROORZHGIRUDO OFKDQJHVLQ
VHYHULW\XQWLOUHVROXWLRQWREDVHOLQHRUVWXG\FORVXUHZKLFKHY HURFFXUV
ILUVWDQGUHFRUGHGLQWKHH&5)
7KH6FKHGXOHRI(YHQWV DOVRFRQWDLQVWKLVFKDQJH
3XUSRVH5HGHILQHWKHSRSXODWLRQIRUDQDO\VLVRIWKHSKDVHH[SO RUDWRU\HQGSRLQWDVWKH
7KHSULPDU\FKDQJHRFFXUVLQ6HFWLRQ 3RSXODWLRQVIRU$QDO\VLV 
)RUPHUO\
UHDG
1RZ
UHDGV
3XUSRVH8SGDWH$(HYDOXDWLRQDQGDQDO\VLVODQJXDJH
7KHSULPDU\FKDQJHRFFXUVLQ6HFWLRQ 6DIHW\$QDO\VLV 
)RUPHUO\
UHDG$OLVWLQJRI'/7VIRUHDFKGRVHOHYHOZLOOEHSURYLGHG6DIHW\ ZLOOEH
HYDOXDWHGE\WKHLQFLGHQFHRIWUHDWPHQWHPHUJHQW$(VVHYHULW\D QGW\SHRI
$(VDQGE\FKDQJHVIURPEDVHOLQHLQWKHSDWLHQWÂ¶VYLWDOVLJQV QHXURWR[LFLW\
DVVHVVPHQW(&*VDQGFOLQLFDOODERUDWRU\UHVXOWVXVLQJWKHVDI HW\SRSXODWLRQ
([SRVXUHWRVWXG\GUXJDQGUHDVRQVIRUGLVFRQWLQXDWLRQZLOOEH WDEXODWHG
$(VZLOOEHWDEXODWHGDFFRUGLQJWRWKH0HGLFDO'LFWLRQDU\IRU5 HJXODWRU\
$FWLYLWLHV0HG'5$E\V\VWHPRUJDQFODVVKLJKOHYHOWHUPVDQ GSUHIHUUHG
WHUPVDQGZLOOLQFOXGHWKHIROORZLQJFDWHJRULHV
ï‚·7UHDWPHQWHPHUJHQW$(V
ï‚·'UXJUHODWHGWUHDWPHQWHPHUJHQW$(V
ï‚·*UDGHRUKLJKHUWUHDWPHQWHPHUJHQW$(V
ï‚·*UDGHRUKLJKHUGUXJUHODWHGWUHDWPHQWHPHUJHQW$(V
ï‚·7UHDWPHQWHPHUJHQW$(VUHVXOWLQJLQVWXG\GUXJGLVFRQWLQXDWLRQ
ï‚·6$(VCCI
CCICCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  [ADDRESS_577700] commonly  reported treatment- emergent AEs (ie, those events 
reported b y ï‚³10% of all patients) will be tabulated by  [CONTACT_452989].
Now 
reads:A listing of DLTs for each dose level will be provided.  Safety will be 
evaluated by [CONTACT_51253], severit y and type of AEs, and b y changes 
from baseline in the patientâ€™s vital signs, neurotoxicity  assessment, ECGs, 
and clinical laboratory  results using the safet y population.  Exposure to study 
drug and reasons for discont inuation will be tabulated.
Treatment -emergent AEs that occur after administration of the first dose 
of study drug and through [ADDRESS_577701] dose of study drug will 
be tabulated.   AEs will be tabulated according to the Medical Dictionary  for 
Regulatory Activities (MedDRA) and will include the following categories:
ï‚·Treatment -emergent AEs
ï‚·Study drug-related treatment -emergent AEs
ï‚·Grade3 or higher treatment -emergent AEs
ï‚·Grade3 or higher study drug-related treatment -emergent AEs
ï‚·The most commonly rep orted treatment -emergent AEs (ie, those 
events reported for ï‚³10% of all patients)
ï‚·SAEs
A listing of treatment -emergent AEs resulting in study drug 
discontinuation will be provided.
Purpose:   Remove text regarding the start of antineoplastic or anticancer therapy as it 
relates to follow -up of AEs
The primary  change occurs in Section 9.3, Monitoring of Adverse Events and Period of 
Observation:
Formerly 
read:AEs, both no nserious and serious (which include all deaths) , will be 
monitored throughout the study  as follows:
ï‚·AEs will be reported from the first dose of study  drug through [ADDRESS_577702], and recorded in 
the eCRFs.  That is, if a patient begins a new anticancer therap y, the AE 
reporting period for nonserious AEs ends at the time the new treatment 
is started.
â€¦
ï‚·SAEs will be reported to Millennium Pharmac ovigilance or designee 
from the first dose of study  drug through [ADDRESS_577703] dose of study  drug and recorded in the eCRF .  All SAEs should 
be monitored until they  are resolved or are clearl y determined to be due 
to a patientâ€™s stable or chronic condition or intercurrent illness(es).  Any 
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 6$(WKDWRFFXUVDWDQ\WLPHDIWHUFRPSOHWLRQRIWKHVWXG\DQGW KH
GHVLJQDWHGIROORZXSSHULRGWKDWWKHLQYHVWLJDWRUFRQVLGHUVWR EHUHODWHG
WRVWXG\GUXJPXVWEHUHSRUWHGWRWKH0LOOHQQLXP'HSDUWPHQWRI
3KDUPDFRYLJLODQFH
1RZ
UHDGV$(VERWKQRQVHULRXVDQGVHULRXVZLOOEHPRQLWRUHGWKURXJKRXW WKHVWXG\DV
IROORZV
ï‚·$(VZLOOEHUHSRUWHGIURPWKHILUVWGRVHRIVWXG\GUXJWKURXJK GD\V
DIWHUDGPLQLVWUDWLRQRIWKHODVWGRVHRIVWXG \GUXJDQGUHFRUGH GLQWKH
H&5)V$OOHYHQWVUHODWLQJWRSHULSKHUDOQHXURSDWK\UHJDUGOHVVRI
VHULRXVQHVVZLOOEHIROORZHGIRUDOOFKDQJHVLQVHYHULW\XQWLO
UHVROXWLRQWREDVHOLQHRUVWXG\FORVXUH ZKLFKHYHURFFXUVILUVWDQG
UHFRUGHGLQWKHH&5)
Â«
ï‚·5HODWHGDQGXQUHODWHG 6$(VZLOOEHUHSRUWHGWR WKH0LOOHQQLXP
'HSDUWPHQWRI 3KDUPDFRYLJLODQFHRUGHVLJQHHIURPWKHILUVWGRVHRI
VWXG\GUXJWKURXJKGD\VDIWHUDGPLQLVWUDWLRQRIWKHODVWGRVH RIVWXG\
GUXJDQGUHFRUGHGLQWKHH&5) $IWHUWKLVSHULRGRQO\UHODWHG6$(V
PXVWEHUHSRUWHGWRWKH0LOOHQQLXP'HSDUWPHQWRI
3KDUPDFRYLJLODQFHRUGHVLJQHH 6$(VVKRXOGEHPRQLWRUHGXQWLOWKH\
DUHUHVROYHGRUDUHFOHDUO\GHWHUPLQHGWREHGXHWRDSDWLHQWÂ¶V VWDEOHRU
FKURQLFFRQGLWLRQRULQWHUFXUUHQWLOOQHVVHV
6HFWLRQVWKDWDOVRFRQWDLQWKLVFKDQJHDUH
ï‚·6HFWLRQ2YHUYLHZRI6WXG\'HVLJQ
ï‚·6HFWLRQ'XUDWLRQRI6WXG\
ï‚·6HFWLRQ6WXG\'UXJ$GPLQLVWUDWLRQ
ï‚·6HFWLRQ3RVWWUHDWPHQW)ROORZXS$VVHVVPHQWV
3XUSRVH8SGDWHFRQWDFWLQIRUPDWLRQIRUUHSRUWLQJSURGXFWFRPSODLQWVD QGPHGLFDWLRQ
HUURUV
7KHSULPDU\FKDQJHRFFXUVLQ6HFWLRQ 3URGXFW&RPSODLQWVDQG0HGLFDWLRQ(UURUV 
)RUPHUO\
UHDG)RU3URGXFW&RPSODLQWVRU0HGLFDWLRQ(UURUV
1RZ
UHDGV)RU3URGXFW&RPSODLQWVRU0HGLFDWLRQ(UURUV[COMPANY_003]
[COMPANY_003]
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 113Purpose:   Clarify the sample size for the phase 1 and phase 2portionsof thestudy
The primary  change occurs in Section 4.1, Overview of Study  Design:  
Formerly 
read:Approximately  42evaluable patients will be enrolled in this study .  In the 
phase1 portion of the study, up to12patients with relapsed or refractory  
CD30+ malignancies (including HL and sALCL) will be enrolled in 
2planned dose cohorts (3 to 6 patients per cohort) accor ding to the standard 
3 +3 dose escalation scheme .
Once the MTD and/or RP2D ha vebeen reached, patients will be enrolled by  
[CONTACT_452990] 2 study arms: relapsed or refractory  sALCL, or 
relapsed or refractory  HL.  The phase 2 portion of the stud y study plans to 
enroll15evaluable patients with sAL CL (including patients treated at the 
RP2D during phase 1), of whom at least [ADDRESS_577704] relapse, and 
15evaluable HL patients (including patients treated at RP2D during phase 1).
Now 
reads:Approximately  42evaluable patients will be enrolled in this study .  In the 
phase1 portion of the study, at least 12patients with relapsed or refractory  
CD30+ malignancies (including HL and sALCL) will be enrolled in 
2planned dose cohorts (3 to 6 patients per cohort) according to the standard 
3 +3 dose escalation scheme .
Once the MTD and/or RP2D ha vebeen reached, patients will be enrolled by  
[CONTACT_452990] 2 study arms: relapsed or refractory  sALCL, or 
relapsed or refractory  HL.  A sufficient number of patientswill be enrolled 
inthe phase 2 portion of the study to haveat least15evaluable patients with
sALCL (including patients treated at the RP2D during phase 1), of whom at 
least 10patients are in first relapse, and at least15evaluable patients with
HL(including patients treated at RP2D during phase 1).
Sections that also contain this change are:
ï‚·PROTOCOL  SUMMARY
ï‚·Section4.2, Number of Patients
ï‚·Section 6.3Dose Esca lation Rules
ï‚·Section 7.7,Discontinuation of Treatment With Study Drug, and Patient 
Replacement
ï‚·Section8.1.1, Determination of Sample Size .
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 114Purpose:   Revise language in the Study  Design section of the P rotocol Summary to align 
with previous update smade in the protocol bod ytext
The primary  change occurs in the PROTOCOL  SUMMARY :
Formerly 
readThis is a phase 1/2, open -label, single -agent, multicenter, dose- escalation 
study of brentuximab vedotin in pediatric patients with relapsed or refractory  
sALCL or HL.  Patients with primary  mediastinal B cell l ymphoma will be 
eligible during phase 1.  The primary  objectives of the study  are to assess the 
safety and pharmacokinetics, and determine the pediatric maximum tolerated 
dose (MTD) and/or RP2D of brentuximab vedotin in pediatric patients.  In 
addition, the immunogenicity  and antitumor activity  of brentuximab vedotin 
will be evaluated in eligible patients.
Overall response will be evaluated beginning after 2 cy cles of therap y.  
Objective response over the course of the stud y will be assessed b y an 
independent review facility  (IRF) according to the International Working 
Group (IWG) Revised Response Criteria for Malignant Ly mphoma.(1)  
Patients who respond or experience stable disease may  receive up to 16 cycles 
of brentuximab vedotin.  
Now 
reads:Overview of Study  Design:  This is a phase 1/2, open- label, single -agent, 
multicenter, dose escalation study  of brentuximab vedotin in pediatric patients 
with relapsed or refractory sALCL or HL for which standard, curative, life -
prolonging, or palliative treatment does not exist or is no longer effective .  
Patients with primary  mediastinal B cell l ymphoma will be eligible during 
phase 1.  The primary  objectives of the study  are to assess the safety  and 
pharmacokinetics, and determine the pediatric MTD and/or RP2D of 
brentuximab vedotin in pediatric patients.  In addition, the immunogenicity 
and antitumor activity  of brentuximab vedotin will be evaluated in eligible 
patients.
Overall re sponse will be evaluated beginning after 2 cy cles of therapy .  
Objective response over the course of the stud y will be assessed b y an 
independent review facility  (IRF) according to the International Working 
Group (IWG) Revised Response Criteria for Maligna nt Lymphoma.(1)  
Patients, including those who achieve a CR, PR, or stable disease may  
receive brentuximab vedotin for up to 16 cycles .  Treatment with 
brentuximab vedotin beyond 16 cycles may be permitted at the joint 
discretion of the sponsor and the inv estigator for those patients 
experiencing continued clinical benefit.  
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 115Purpose:   Clarify the planned study  procedures for patients who remain on treatment after 
Cycle 16, as previously outlined in Administrative L etter #3
The primary  change occurs in th e Schedule of Events:
A column has been added in the Schedule of Events under the column header Cy cle17 
and Beyond (for patients who continue bey ond 16cycles) that indicates which procedures 
are to be performed after Cy cle 16.  Footnote m has also been added to the Schedule of 
Events.
Purpose:   Specify that serum or urine pregnancy  tests are acceptable at screening and 
before dosing on Day  1,and add a statement regar ding the scheduling of pregnancy tests
The primary change occurs in Section7.4.7, Pregnancy  Test:
Formerly 
read:Patients of childbearing potential will complete a se rum pregnancy  test during 
screening and at Cy cle 1 Day  1; this test must be confirmed negative prior to 
receipt of the first dose of brentuximab vedotin .  A urine pregnancy  test will 
be performed prior to dosing on Day  1 of each subsequent cy cle.
Now 
reads:Patients of childbearing potential will complete a serum or urinepregnancy  
test during screening, prior to dosing on Day [ADDRESS_577705] 
should be performed per institutional guidelines; any samples collected 
during Cycle 17 and beyond should not be sent to the central laboratory ,
and data should not be captured in the eCRF. Additional pregnancy 
tests may also be repeated during the stu dy if requested by [CONTACT_18369]/IRB 
or if required by [CONTACT_427].  
The sections that also contain this change are:
ï‚·Schedule of Events, footnote f
ï‚·Section5.2, Exclusion Criteria , criterion 21
Purpose:   Clarify that the timeframe for collecting clinical laboratory  values at screening 
is within4 days before the first dose of the study  drug
The primary  change occurs in Secti on5.1, Inclusion Criteria , criterion 11 :
Formerly 
read:11.Clinical laboratory  values as specified within 14days before the first 
dose of study  drug:
Now 
reads:11.Clinical laboratory  values as specified within 4days before the first dose 
of study drug:
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 116Purpose:   Clarify that patients should be observed for anaph ylaxis after each infusion of 
brentuximab vedotin
The primary  change occurs in Section 6.1, Study Drug Administration :
Formerly 
read:The patient should be observed for [ADDRESS_577706] infusion of 
brentuximab vedotin.
Now 
reads:The patient should be obs erved for 60 minutes after eachinfusion of 
brentuximab vedotin.
Purpose:   Clarify that Grade 4 neutropenia lasting more than 7 day s is considered a DL T
The primary  change occurs in Section 6.2.3,Hematologic Toxicity :
Formerly 
read:DLT for hematologic toxicity  will be defined as:
ï‚·Grade 4 neutropenia lasting greater than 7 day s
Now 
reads:DLT for hematologic toxicity  will be defined as:
ï‚·Grade 4 neutropenia lasting longerthan 7 day s
Purpose:   Clarify that unacceptab le study drug-related toxicity or disease progression will 
result in mandatory , permanent discontinuation of the study  drug
The primary  change occurs in Section 6.4.3, Criteria for Discontinuation of Brentuximab 
vedotin:
Formerly 
read:Study drug willbe discontinued earl yif a patient experiences unacceptable 
study drug-related toxicities .  
â€¦
A patientâ€™s treatment with study  drug may  also be discont inued for an y of the 
following reasons:
ï‚·Unacceptable AE.
ï‚·Disease progression.
ï‚·Patient withdrawal.
ï‚·Stable disease or better and completed 16 treatment cy cles (brentuximab 
vedotin).
ï‚·The investigator or patient deems it in the patientâ€™s best interest to 
discontinue, including patients who experience a CR and are candidates 
for hematopoetic stem cell transplantation.  The reason justify ing study 
treatment withdrawal must be documented in the CRF.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 117Now 
reads:Study drug mustbe discontinued if a patient experien ces progressive disease
or anunacceptable study drug -related toxicity.  
â€¦
A patientâ€™s treatment with study  drug may  also be discontinued for any  of the 
following reasons:
ï‚·Patient withdrawal.
ï‚·Stable disease or better and completed 16 treatment cy cles (brentuximab 
vedotin).
ï‚·The investigator or patient deems it in the patientâ€™s best interest to 
discontinue, including patients who experience a CR and are candidates 
for hematopoetic stem cell transplantation.  The reason justify ing study 
treatment withdrawal must be documented in the CRF.
Sections that also contain this change are:
ï‚·Section4.3,Duration of Study
ï‚·Section7.7, Discontinuation of Treatment With Study Drug, and Patient 
Replacement .
Purpose:   Clarify that initiation of hematopoietic stem cell transplantation isa reason for 
study drug discontinuation
The primary  change occurs in Section 7.7, Discontinuation of Treatment With Study 
Drug, and Patient Replacement :
Added 
text:Treatment with study  drug may  also be discontinued for an y of the following 
reasons:
â€¦
ï‚·Initiation of hematopoietic stem cell or bone marrow transplant
Section6.4.3, Criteria for Discontinuation of Brentuximab v edotin,also contains this 
change.  
Purpose:   Clarify that development assessments include weight -for-age and 
stature-for-age percentiles
The primary  change occurs in Section7.4.13.1, Development Assessment and Tanner 
Scale:  
Formerly 
read:Development a ssessment and Tanner Scale to be performed according to the 
timelines in the Schedule of Events.  The development assessment will 
include height and weight; see Section 14.3 for Tanner Scale information.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 1RZ
UHDGV'HYHORSPHQWDVVHVVPHQWDQG7DQQHU6FDOH DUHWREHSHUIRUPHG DVVSHFLILHG
LQWKH6FKHGXOHRI(YHQWV7KHGHYHORSPHQWDVVHVVPHQWZLOOLQF OXGHZHLJKW 
IRUDJHDQGVWDWXUHIRUDJHSHUFHQWLOHV VHH6HFWLRQIRU7DQQHU6FDOH
LQIRUPDWLRQ
7KH6FKHGXOHRI(YHQWV IRRWQRWHODOVRFRQWDLQVWKLVFKDQJH
3XUSRVH&ODULI\SURFHGXUHVIRUFOLQLFDOODERUDWRU\HYDOXDWLRQV
7KHSULPDU\FKDQJHRFFXUVLQ6HFWLRQ &OLQLFDO/DERUDWRU\(YDOXDWLRQV 
)RUPHUO\
UHDG&OLQLFDO
ODERUDWRU\HYDOXDWLRQVZLOOEHSHUIRUPHGFHQWUDOO\ 
WKHVWXG\)RUWUHDWPHQWGHFLVLRQVVHSDUDWHVDPSOHV 
+DQGOLQJDQG
VKLSPHQWRIFOLQLFDOODERUDWRU\VDPSOHVZLOOEHRXWOLQHGLQWKH VWXG\PDQXDO

+DQGOLQJDQGVKLSPHQWRIFOLQLFDOODERUDWRU\VDPSOHVZLOOEHRX WOLQHGLQWKH
6WXG\0DQXDO
&OLQLFDOODERUDWRU\HYDOXDWLRQVZLOOEHSHUIRUPHGDVRXWOLQHG
&OLQLFDO&KHPLVWU\+HPDWRORJ\DQG
%ORRGVDPSOHVIRUDQDO\VLVRIWKHIROORZLQJFOLQLFDOFKHPLVWU\ DQG
KHPDWRORJLFDOSDUDPHWHUVZLOOEHREWDLQHGDVVSHFLILHGLQWKH6 FKHGXOHRI
(YHQWV
+HPDWRORJ\
ï‚·+HPRJORELQ
ï‚·+HPDWRFULW
ï‚·3ODWHOHWFRXQWï‚·7RWDO:%&FRXQW
ï‚·'LIIHUHQWLDO:%&FRXQW
6HUXP&KHPLVWU\
ï‚·%ORRGXUHD
QLWURJHQ
ï‚·&UHDWLQLQH
ï‚·8UDWH
ï‚·%LOLUXELQWRWDO
GLUHFWLQGLUHFW
ï‚·/DFWDWH
GHK\GURJHQDVHï‚·$OEXPLQ
ï‚·$ONDOLQHSKRVSKDWDVH
ï‚·$VSDUWDWH
DPLQRWUDQVIHUDVH
$67
ï‚·$ODQLQH
DPLQRWUDQVIHUDVH
$/7
ï‚·*OXFRVHï‚·&DOFLXP
ï‚·&KORULGH
ï‚·&DUERQ
GLR[LGH
ï‚·0DJQHVLXPCCI
CCI
CCI
CCI
CCI
CCI
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO ï‚·*D[COMPANY_003]JOXWDP\O
WUDQVIHUDVH
ï‚·3KRVSKRUXVï‚·6RGLXP
ï‚·3RWDVVLXP
1RZ
UHDGV&OLQLFDOODERUDWRU\ HYDOXDWLRQVZLOOEHSHUIRUPHGFHQWUDOO \'HFLVLRQV
UHJDUGLQJHOLJLELOLW\DQGVWXG\GUXJGRVLQJPD\EHPDGHE\XVLQJ ORFDO
ODERUDWRU\UHVXOWV,IORFDOFOLQLFDOODERUDWRU\YDOXHVDUHXV HGIRUHLWKHU
HOLJLELOLW\RUVWXG\GRVLQJGHFLVLRQV WKHORFDOODERUDWRU\UHVXOWVGRQRW
UHSODFHFHQWUDOODERUDWRU\WHVWLQJDQGVDPSOHVIRUFHQWUDOODER UDWRU\
FRQILUPDWLRQPXVWEHFROOHFWHGDVVSHFLILHGLQWKH6FKHGXOHRI( YHQWV
'XULQJ&\FOHDQGEH\RQGKHPDWRORJ\DQGVHUXPFKHPLVWU\WHVWV 
VKRXOGEHSHUIRUPHGSHULQVWLWXWLRQDOJXLGHOLQHVDWWKHORFDOO DERUDWRU\
VDPSOHVVKRXOGQRWEHVHQWWRWKHFHQWUDOODERUDWRU\DQGGDWDV KRXOGQRW
EHFDSWXUHGLQWKHH&5)XQOHVVWKHODERUDWRU\UHVXOWLVDVVHVV HGWR
FRQWULEXWHWRDQ$(
+DQGOLQJDQGVKLSPHQWRIFOLQLFDOODERUDWRU\VDPSOHVZLOOEHRX WOLQHGLQWKH
6WXG\0DQXDO
&OLQLFDOODERUDWRU\HYDOXDWLRQVZLOOEHSHUIRUPHGDVRXWOLQHG
&OLQLFDO&KHPLVWU\ DQG+HPDWRORJ\
%ORRGVDPSOHVIRUDQDO\VLVRIWKHIROORZLQJFOLQLFDOFKHPLVWU\ DQG
KHPDWRORJLFDOSDUDPHWHUVZLOOEHREWDLQHGDVVSHFLILHGLQWKH6 FKHGXOHRI
(YHQWV
+HPDWRORJ\
ï‚·+HPRJORELQ
ï‚·+HPDWRFULW
ï‚·3ODWHOHWFRXQWï‚·7RWDO:%&FRXQW
ï‚·'LIIHUHQWLDO:%&FRXQW
0DFKLQHFRXQWVDUHDFFHSWDEOH
6HUXP&KHPLVWU\
ï‚·%ORRGXUHD
QLWURJHQï‚·$OEXPLQ
ï‚·$ONDOLQHSKRVSKDWDVHï‚·&DOFLXP
ï‚·&KORULGHCCI
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 120ï‚·Creatinine
ï‚·Urate
ï‚·Bilirubin (total, 
direct, indirect)
ï‚·Lactate 
dehydrogenase
ï‚·Gamma glutamy l 
transferase
ï‚·Phosphorusï‚·Aspartate 
aminotransferase 
(AST)
ï‚·Alanine 
aminotransferase 
(ALT)
ï‚·Fastingglucose
ï‚·Sodium
ï‚·Potassiumï‚·Carbon 
dioxide
ï‚·Magnesium
The Schedule of Events , footnote j, also contains this change.
Purpose:   Clarify the timing for collection of blood samples for PK assessm ents and 
removereference to total blood volumes to be collected for these assessments
The primary change occurs in Section 7.4.14, Pharmacokinetic Measurements :
Formerly 
read:Blood samples for the determination of serum brentuximab vedotin
concentrations will be collected at the following time points:
ï‚·All Cycles:Day1 immediatel y before and 5 minutes after the 
brentuximab vedotin infusion
ï‚·Cycle1:Days 2, 3, 5, 14
ï‚·Cycle2:  Days 2 (phase 1 only ), 3, 5
ï‚·Cycle8:Days 2, 3, 5, 14
Postdose PK samples on Day 1 should be obtained at 5 (Â±1)minutes after the 
end of the brentuximab vedotin infusion.  The total amount of blood drawn 
for obtaining serum or plasma from each patient for PK mea surements will be 
approximately  172mL (43specimens Ã—4mL blood per specimen) over 
16cycles of treatment.
Now 
reads:Blood samples for the determination of serum brentuximab vedotin 
concentrations will be collected at the following time points:
ï‚·All Cycles:  Day 1:within 4hoursbefore the start of the 
brentuximab vedotin infusion and 5 minutes (Â±1 minute) after the 
end of the brentuximab vedotin infusion
ï‚·Cycles1 and 8:  
oDay2: 24hours (ï‚±4hours) from the start of the Day 1 
brentuximab vedotin infusion
oDay3: 48hours (ï‚±4hours) from the start of the Day 1 
brentuximab vedotin infusion
oDay5: 96hours (ï‚±24 hours) from the start of the Day 1 
brentuximab vedotin infusion
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 121oDay14: 312hours (ï‚±48hours) from the start of the Day 1 
brentuximab vedotin infusion
ï‚·Cycle2:  
oDay2 (phase 1 only):24hours (ï‚±4hours) from the start of 
the Day1 brentuximab vedotin infusion 
oDay3: 48hours (ï‚±4hours) from the start of the Day 1 
brentuximab vedotin infusion 
oDay5: 96hours (ï‚±24hours) from the start of the Day1 
brentuximab vedotin infusion.
The Schedule of Events , footnote u, also contains this change.
Purpose:   Clarify the descriptions of Completion of Treatment and Completion of Study ,
and clarify  language f or posttreatment assessments
The primary  changes occurin Section 7.5, Completion of Treatment and Section7.6, 
Completion of Study :
Deleted 
text:Section7.[ADDRESS_577707] patient starts study  treatment.
Patients will be followed for overall survival and disease status every 12 
weeks until 12 months after the end of treatment (EOT) visit.  I nformation 
regarding the initiation of an alternative form of treatment for l ymphoma will 
also be collected.  For patients who have progressive disease, survival/disease 
status and informa tion regarding the initiation of an alternative l ymphoma 
treatment may  be obtained by  [CONTACT_25600].
Section7.[ADDRESS_577708] completed the study  if they complete up to
16cycles of treatment with brentuximab vedotin or experience progressive 
diseaseor unacceptable toxicity , and complete 30 days of safety  follow-up.
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 122Purpose:   Clarify efficacy anal ysis language to specify  thattheKaplan-Meier method will 
be used to anal yze efficacy  parameters and specify  the percentiles to be provided
The primary  change occurs in Section 8.1.6,Efficacy Analysis:  
Formerly 
read:  Duration of response (DOR), time to response, time to progression (TTP), 
EFS, PFS, and OS will be analyzed using standard survival anal ysis 
techniques based on Kaplan-Meier life testmethod.  Time to event data will 
be summarized by  25th, 50th (median), and 75th percentiles with associated 
2-sided 95% confidence interval , as well as the percentage o f censored 
observations .
Now 
reads:  Duration of response (DOR), time to response, time to progression (TTP), 
EFS, PFS, and OS will be anal yzed using theKaplan-Meier method.  The
25th, 50th (median), and 75th percentiles (if estimable) with associated 2 -
sided 95% confidence interval will be provided .
Purpose:   Clarify that assessments to be performed for the EOT visit are listed in the 
Schedule of Events
The primary  change occurs in Section 7.7, Discontinuation of Treatment With Study 
Drug, and Patient Replacement :
Formerly 
read:At the time of study drug discontinuation , all study procedures outlined for 
the end of treatm entvisit will be completed.
Now 
reads:Oncestudy drug has been discontinued , all study  procedures outlined for the 
EOTvisit will be completed as specified in the Schedule of Events .
Purpose:   Clarify that the frequency  of radiological evaluations for patients who receive 
treatment past Cy cle 16 is outlined in the Schedule of Events
The primary  change occurs in Section 4.1,Overview of Study  Design:
Added 
text:An evaluation of disease response will be assessed by  [CONTACT_452991](1) evaluated at 
Cycles 2, 4, 7, 10, 13, and [ADDRESS_577709] Cycle 16 is outlined in 
the Schedule of Events.   Additional evaluations may  be necessary  when 
clinically indicated..
Brentuximab vedotin (SGN -35)
Clinical Study Protocol C25002 Amendment 4, EudraCT:  2011 -001240-29
Confidential 123Purpose:   Clarify reasons for study  withdrawal.
The primary  change occurs in Section 7.8,Withdrawal of Patients From Study :
Formerly 
read:A patient may  be withdrawn from the stud y for any of the following reasons:
ï‚·Completed study  
ï‚·Lost to follow -up 
ï‚·Study terminated by  [CONTACT_3211]
ï‚·Withdrawal of consent by  [CONTACT_452992]
ï‚·Death
ï‚·Other
Now 
reads:A patient may  be withdrawn from the stud y for any of the following reasons:
ï‚·Lost to follow -up 
ï‚·Study terminated by  [CONTACT_3211]
ï‚·Withdrawal of consent by  [CONTACT_452978]
ï‚·Death
ï‚·Other
Purpose:   Remove Secti on 14.4,Strong Cy tochrome P450 3A4 (CYP3A4) I nhibitors (the 
list of prohibited CYP3A4 inhibitors is located in the Study  Manual)
The primary  change occurs in deleted Section 14.4, Strong Cy tochrome P450 3A4 
(CYP3A4) Inhibitors:
Deleted 
text:Section14.4, Strong Cytochrome P450 3A (CYP3A) Inhibitors
The following are considered to be strong inhibitors of CYP3A:
ï‚·atazanavir
ï‚·clarithrom ycin
ï‚·indinavir
ï‚·itraconazole
ï‚·ketoconazole
ï‚·nefazodone
ï‚·nelfinavir
ï‚·posaconazole
ï‚·ritonavir
ï‚·saquinavir
ï‚·telithromy cin
ï‚·voriconazole.
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 3XUSRVH5HSODFHUHIHUHQFHVWR33',ZLWK0LOOHQQLXP'HSDUWPHQWRI
3KDUPDFRYLJLODQFHRUGHVLJQHH
7KHSULPDU\FKDQJHRFFXUVLQ6HFWLRQ 3URGXFW&RPSODLQWVDQG0HGLFDWLRQ(UURUV 
)RUPHUO\
UHDG3URGXFWFRPSODLQWVDQGPHGLFDWLRQHUURUVLQDQGRIWKHPVHOYHVD UHQRW$(V
,IDSURGXFWFRPSODLQWRUPHGLFDWLRQHUURUUHVXOWVLQDQ6$(D Q6$(IRUP
VKRXOGEHFRPSOHWHGDQGVHQWWR33',UHIHUWR6HFWLRQ
1RZ
UHDGV3URGXFWFRPSODLQWVDQGPHGLFDWLRQHUURUVLQDQGRIWKHPVHOYHVD UHQRW$(V
,IDSURGXFWFRPSODLQWRUPHGLFDWLRQHUURUUHVXOWVLQDQ6$(D Q6$(IRUP
VKRXOGEHFRPSOHWHGDQGVHQWWR WKH0LOOHQQLXP'HSDUWPHQWRI
3KDUPDFRYLJLODQFHRUGHVLJQHH UHIHUWR6HFWLRQ
3XUSRVH$GGDEEUHYLDWLRQVWRWDEOHIRRWQRWHVLQWKH 6FKHGXOHRI(YHQWV
7KHSULPDU\FKDQJHRFFXUVLQWKH 6FKHGXOHRI(YHQWV 
)RUPHUO\
UHDG$EEUHYLDWLRQV$( DGYHUVHHYHQW&7 FRPSXWHGWRPRJUDSK\
(&* HOHFWURFDUGLRJUDP(27 HQGRIWUHDWPHQW3(7 SRVLWURQHPLVV LRQ
WRPRJUDSK\3. SKDUPDFRNLQHWLFV3' SKDUPDFRG\QDPLFV
1RZ
UHDGV$EEUHYLDWLRQV$( DGYHUVHHYHQW %0 ERQHPDUURZ%0$ ERQH
PDUURZDVSLUDWH &7 FRPSXWHGWRPRJUDSK\ ' GD\(&* 
HOHFWURFDUGLRJUDP(27 HQGRIWUHDWPHQW 05, PDJQHWLFUHVRQDQFH
LPDJLQJ26)83 2YHUDOOVXUYLYDO)ROORZXS 3(7 SRVLWURQHPLVVLRQ
WRPRJUDSK\ 3)6)83 3URJUHVVLRQIUHHVXUYLYDO)ROORZXS 3. 
SKDUPDFRNLQHWLFV3' SKDUPDFRG\QDPLFV T HYHU\ 
3XUSRVH$GGERQHPDUURZ%0DQG8QLWHG6WDWHV3KDUPDFRSHLD863WR WKH/LVWRI
$EEUHYLDWLRQVDQG*ORVVDU\RI7HUPV
7KHSULPDU\FKDQJHRFFXUVLQWKH /,672)$%%5(9,$7,216$1'*/266$5<2)
7(506
$GGHG
WH[W%0 ERQHPDUURZ
863 8QLWHG6WDWHV3KDUPDFRSHLD
3XUSRVH8SGDWHWKHQDPHRIWKH*URXS+HDGRQWKH WLWOHSDJH
7KHSULPDU\FKDQJHRFFXUVRQWKH WLWOHSDJH
)RUPHUO\
UHDG[COMPANY_003]
%UHQWX[LPDEYHGRWLQ6*1
&OLQLFDO6WXG\3URWRFRO&$PHQGPHQW(XGUD&7 
&RQILGHQWLDO 1RZ
UHDGV
3XUSRVH5HSODFHUHIHUHQFHVWRPHGLFDOPRQLWRURUVWXG\PRQLWRUZLWKS URMHFWFOLQLFLDQ
7KHSULPDU\FKDQJHRFFXUVLQ6HFWLRQ 7R[LFLW\
)RUPHUO\
UHDG7KHLQYHVWLJDWRUVDQGPHGLFDOPRQLWRUZLOOGLVFXVVDQGGRFXPHQW WKHRYHUDOO
WR[LFLW\SURILOHLQGHWDLOEHIRUHGHFLGLQJZKHWKHUWRLQLWLDWH FRKRUWH[SDQVLRQ
GRVHHVFDODWLRQGRVHPRGLILFDWLRQDQGRUIXWXUHSURSK\OD[LVZ LWKFRORQ\
VWLPXODWLQJIDFWRUV&6)V
1RZ
UHDGV7KHLQYHVWLJDWRUVDQG SURMHFWFOLQLFLDQ ZLOOGLVFXVVDQGGRFXPHQWWKHRYHUDOO
WR[LFLW\SURILOHLQGHWDLOEHIRUHGHFLGLQJZKHWKHUWRLQLWLDWH FRKRUWH[SDQVLRQ
GRVHHVFDODWLRQGRVHPRGLILFDWLRQDQGRUIXWXUHSURSK\OD[LVZ LWKFRORQ\
VWLPXODWLQJIDFWRUV&6)V
6HFWLRQVWKDWDOVRFRQWDLQWKLVFKDQJHDUH
ï‚·6FKHGXOHRI(YHQWV
ï‚·6HFWLRQ([FOXVLRQ&ULWHULD FULWHULDDQG
ï‚·6HFWLRQ3KDVH'RVH0RGLILFDWLRQIRUDQ,QGLYLGXDO3DWLHQW:KR
([SHULHQFHV'/7
ï‚·6HFWLRQ&ULWHULDIRU'LVFRQWLQXDWLRQRI%UHQWX[LPDEYHGRWLQ
ï‚·6HFWLRQ6WXG\3HUVRQQHODQG2UJDQL]DWLRQV
3XUSRVH&RUUHFWW\SRJUDSKLFDOHUURUVSXQFWXDWLRQJUD[COMPANY_003]UDQGIRUPD WWLQJ
7KHVHFKDQJHVDUHQRWOLVWHGLQGLYLGXDOO\[COMPANY_003]
äŽƒ
äŽƒ
äŽƒ
äŽƒ
äŽƒ
äŽƒäŽƒ
äŽƒ
(/(&7521,& 6,*1$785(6 

6LJQHGE\ 0HDQLQJRI6LJQDWXUH6HUYHU'DWH
GG000\\\\++PP















äŽ¤äŽƒäŽ³ä‹ä„ä–äˆäŽƒäŽ”äŽ’äŽ•äŽƒäŽ¶ä—ä˜ä‡äœäŽƒä’ä‰äŽƒä…ä•äˆä‘ä—ä˜ä›äŒää„ä…äŽƒä™äˆä‡ä’ä—äŒä‘äŽƒäŽ‹äŽ¶äŽªäŽ±äŽäŽ–äŽ˜äŽŒäŽƒäŒä‘äŽƒäŽ³äˆä‡äŒä„ä—ä•äŒä†äŽƒ äŽ³ä„ä—äŒäˆä‘ä—ä–äŽƒäŽºäŒä—ä‹äŽƒäŽµäˆää„ä“ä–äˆä‡äŽƒä’ä•
äŽµäˆä‰ä•ä„ä†ä—ä’ä•äœäŽƒäŽ¶äœä–ä—äˆääŒä†äŽƒäŽ¤ä‘ä„ä“ää„ä–ä—äŒä†äŽƒäŽ¯ä„ä•äŠäˆäŽäŽ¦äˆäääŽƒäŽ¯äœää“ä‹ä’ää„äŽƒä’ä•äŽƒäŽ«ä’ä‡äŠäŽäŒä‘äŽƒäŽ¯ äœää“ä‹ä’ää„
&OLQLFDO$SSURYDO -XQ
&OLQLFDO6FLHQFH$SSURYDO -XQ[COMPANY_003]